BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, Abdalla EK, Fleming JB, Vauthey JN, Rashid A, Evans DB. One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26:3063-3072. [PMID: 18565894 DOI: 10.1200/jco.2007.15.4377] [Cited by in Crossref: 2588] [Cited by in F6Publishing: 1164] [Article Influence: 199.1] [Reference Citation Analysis]
Number Citing Articles
1 Özdirik B, Amthauer H, Schatka I, Goretzki PE, Mogl MT, Fehrenbach U, Tacke F, Jann H, Roderburg C. A rare case of a patient with a high grade neuroendocrine tumor developing neutropenic sepsis after receiving PRRT combined with Capecitabine or Temozolomide: A case report. Mol Clin Oncol 2021;14:20. [PMID: 33363730 DOI: 10.3892/mco.2020.2182] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
2 Onyemkpa C, Davis A, McLeod M, Oyasiji T. Typical carcinoids, goblet cell carcinoids, mixed adenoneuroendocrine carcinomas, neuroendocrine carcinomas and adenocarcinomas of the appendix: a comparative analysis of survival profile and predictors. J Gastrointest Oncol 2019;10:300-6. [PMID: 31032098 DOI: 10.21037/jgo.2018.11.08] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
3 Alese OB, Jiang R, Shaib W, Wu C, Akce M, Behera M, El-Rayes BF. High-Grade Gastrointestinal Neuroendocrine Carcinoma Management and Outcomes: A National Cancer Database Study. Oncologist. 2019;24:911-920. [PMID: 30482824 DOI: 10.1634/theoncologist.2018-0382] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
4 Cusumano G, Fournel L, Strano S, Damotte D, Charpentier MC, Galia A, Terminella A, Nicolosi M, Regnard JF, Alifano M. Surgical Resection for Pulmonary Carcinoid: Long-Term Results of Multicentric Study-The Importance of Pathological N Status, More Than We Thought. Lung 2017;195:789-98. [PMID: 29022070 DOI: 10.1007/s00408-017-0056-8] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.8] [Reference Citation Analysis]
5 Sana L, Saber M. Incidental neuroendocrine tumor of the appendiceal base less than20 mm in diameter: is appendectomy enough? Pan Afr Med J 2015;22:102. [PMID: 26848349 DOI: 10.11604/pamj.2015.22.102.6548] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
6 Oba A, Kudo A, Akahoshi K, Kishino M, Akashi T, Katsuta E, Iwao Y, Ono H, Mitsunori Y, Ban D, Tanaka S, Eishi Y, Tateishi U, Tanabe M. A simple morphological classification to estimate the malignant potential of pancreatic neuroendocrine tumors. J Gastroenterol 2017;52:1140-6. [PMID: 28488114 DOI: 10.1007/s00535-017-1349-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
7 Sato Y. Clinical features and management of type I gastric carcinoids. Clin J Gastroenterol 2014;7:381-6. [PMID: 26184015 DOI: 10.1007/s12328-014-0528-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
8 Song L, Zhai X, Yu S, Ma Y, Wang F, Yu X, Tao S, Lian Y, Yang M, Tao W, Fan Q. Clinical analysis of 547 patients with neuroendocrine tumors in a Chinese population: A single-center study. Cancer Med 2019;8:3729-37. [PMID: 31127690 DOI: 10.1002/cam4.2259] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
9 Schimmack S, Yang Y, Felix K, Herbst M, Li Y, Schenk M, Bergmann F, Hackert T, Strobel O. C-reactive protein (CRP) promotes malignant properties in pancreatic neuroendocrine neoplasms. Endocr Connect 2019;8:1007-19. [PMID: 31234146 DOI: 10.1530/EC-19-0132] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
10 Horton TM, Sundaram V, Lee CH, Hornbacker K, Van Vleck A, Benjamin KN, Zemek A, Longacre TA, Kunz PL, Annes JP. PAM staining intensity of primary neuroendocrine neoplasms is a potential prognostic biomarker. Sci Rep 2020;10:10943. [PMID: 32616904 DOI: 10.1038/s41598-020-68071-6] [Reference Citation Analysis]
11 Kidambi TD, Pedley C, Blanco A, Bergsland EK, Terdiman JP. Lower gastrointestinal neuroendocrine neoplasms associated with hereditary cancer syndromes: a case series. Fam Cancer 2017;16:537-43. [PMID: 28283864 DOI: 10.1007/s10689-017-9979-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
12 Khay K, Arous S, Bentaoune T, Drighil A, Habbal R. Carcinoid heart disease revealed by cyanosis with both right and left valvular involvement: a case report. J Med Case Rep 2018;12:23. [PMID: 29386066 DOI: 10.1186/s13256-018-1574-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
13 Estrella JS, Ma LT, Milton DR, Yao JC, Wang H, Rashid A, Broaddus RR. Expression of estrogen-induced genes and estrogen receptor β in pancreatic neuroendocrine tumors: implications for targeted therapy. Pancreas 2014;43:996-1002. [PMID: 25058880 DOI: 10.1097/MPA.0000000000000203] [Cited by in Crossref: 12] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
14 黄颖秋. 消化系统神经内分泌肿瘤的诊断和治疗现状. 世界华人消化杂志 2016; 24(17): 2625-2636 [DOI: 10.11569/wcjd.v24.i17.2625] [Cited by in CrossRef: 1] [Article Influence: 0.2] [Reference Citation Analysis]
15 Bongiovanni A, Maiorano BA, Azzali I, Liverani C, Bocchini M, Fausti V, Di Menna G, Grassi I, Sansovini M, Riva N, Ibrahim T. Activity and Safety of Immune Checkpoint Inhibitors in Neuroendocrine Neoplasms: A Systematic Review and Meta-Analysis. Pharmaceuticals (Basel) 2021;14:476. [PMID: 34067837 DOI: 10.3390/ph14050476] [Reference Citation Analysis]
16 Spetz J, Langen B, Rudqvist N, Parris TZ, Helou K, Nilsson O, Forssell-Aronsson E. Hedgehog inhibitor sonidegib potentiates 177Lu-octreotate therapy of GOT1 human small intestine neuroendocrine tumors in nude mice. BMC Cancer 2017;17:528. [PMID: 28789624 DOI: 10.1186/s12885-017-3524-x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 4.0] [Reference Citation Analysis]
17 Landry JP, Schertz KL, Chiang YJ, Bhalla AD, Yi M, Keung EZ, Scally CP, Feig BW, Hunt KK, Roland CL, Guadagnolo A, Bishop AJ, Lazar AJ, Slopis JM, McCutcheon IE, Torres KE. Comparison of Cancer Prevalence in Patients With Neurofibromatosis Type 1 at an Academic Cancer Center vs in the General Population From 1985 to 2020. JAMA Netw Open 2021;4:e210945. [PMID: 33734413 DOI: 10.1001/jamanetworkopen.2021.0945] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
18 Imaoka H, Sasaki M, Takahashi H, Hashimoto Y, Ohno I, Mitsunaga S, Watanabe K, Umemoto K, Kimura G, Suzuki Y, Kan M, Ikeda M. Alternate Endpoints for Phase II Trials in Advanced Neuroendocrine Tumors. Oncologist 2019;24:47-53. [PMID: 30072388 DOI: 10.1634/theoncologist.2017-0651] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
19 Kulke MH, Siu LL, Tepper JE, Fisher G, Jaffe D, Haller DG, Ellis LM, Benedetti JK, Bergsland EK, Hobday TJ, Van Cutsem E, Pingpank J, Oberg K, Cohen SJ, Posner MC, Yao JC. Future directions in the treatment of neuroendocrine tumors: consensus report of the National Cancer Institute Neuroendocrine Tumor clinical trials planning meeting. J Clin Oncol. 2011;29:934-943. [PMID: 21263089 DOI: 10.1200/jco.2010.33.2056] [Cited by in Crossref: 208] [Cited by in F6Publishing: 97] [Article Influence: 20.8] [Reference Citation Analysis]
20 Del Prete M, Fiore F, Modica R, Marotta V, Marciello F, Ramundo V, Di Sarno A, Carratù A, di Roseto Cde L, Tafuto S, Tatangelo F, Baldelli R, Colao A, Faggiano A; Multidisciplinary Group for NeuroEndocrine Tumors of Naples. Hepatic arterial embolization in patients with neuroendocrine tumors. J Exp Clin Cancer Res 2014;33:43. [PMID: 24887262 DOI: 10.1186/1756-9966-33-43] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 4.4] [Reference Citation Analysis]
21 Hamiditabar M, Ali M, Roys J, Wolin EM, OʼDorisio TM, Ranganathan D, Tworowska I, Strosberg JR, Delpassand ES. Peptide Receptor Radionuclide Therapy With 177Lu-Octreotate in Patients With Somatostatin Receptor Expressing Neuroendocrine Tumors: Six Years' Assessment. Clin Nucl Med 2017;42:436-43. [PMID: 28263217 DOI: 10.1097/RLU.0000000000001629] [Cited by in Crossref: 29] [Cited by in F6Publishing: 13] [Article Influence: 7.3] [Reference Citation Analysis]
22 Bordin-Wosk T, Patel SP, Horman SF. GABABR-Mediated Paraneoplastic Limbic Encephalitis Due To Thymic Small Cell Carcinoma. J Gen Intern Med 2019;34:1658-61. [PMID: 31062226 DOI: 10.1007/s11606-019-05040-4] [Reference Citation Analysis]
23 Aristizabal Prada ET, Spöttl G, Maurer J, Lauseker M, Koziolek EJ, Schrader J, Grossman A, Pacak K, Beuschlein F, Auernhammer CJ, Nölting S. The role of GSK3 and its reversal with GSK3 antagonism in everolimus resistance. Endocr Relat Cancer 2018;25:893-908. [PMID: 29895527 DOI: 10.1530/ERC-18-0159] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
24 Meng Y, McCarthy G, Berthon A, Dinet J. Patient-reported health state utilities in metastatic gastroenteropancreatic neuroendocrine tumours - an analysis based on the CLARINET study. Health Qual Life Outcomes. 2017;15:131. [PMID: 28662673 DOI: 10.1186/s12955-017-0711-z] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
25 Hashim YM, Trinkaus KM, Linehan DC, Strasberg SS, Fields RC, Cao D, Hawkins WG. Regional lymphadenectomy is indicated in the surgical treatment of pancreatic neuroendocrine tumors (PNETs). Ann Surg. 2014;259:197-203. [PMID: 24253141 DOI: 10.1097/sla.0000000000000348] [Cited by in Crossref: 140] [Cited by in F6Publishing: 50] [Article Influence: 20.0] [Reference Citation Analysis]
26 Phan AT, Dave B. The pivotal role of mammalian target of rapamycin inhibition in the treatment of patients with neuroendocrine tumors. Cancer Med 2016;5:2953-64. [PMID: 27539383 DOI: 10.1002/cam4.742] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
27 Wolin E, Mita A, Mahipal A, Meyer T, Bendell J, Nemunaitis J, Munster PN, Paz-Ares L, Filvaroff EH, Li S, Hege K, de Haan H, Mita M. A phase 2 study of an oral mTORC1/mTORC2 kinase inhibitor (CC-223) for non-pancreatic neuroendocrine tumors with or without carcinoid symptoms. PLoS One 2019;14:e0221994. [PMID: 31527867 DOI: 10.1371/journal.pone.0221994] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
28 Yoon SE, Kim JH, Lee SJ, Lee J, Park SH, Park JO, Lim HY, Kang WK, Park YS, Kim ST. The impact of primary tumor site on outcomes of treatment with etoposide and cisplatin in grade 3 gastroenteropancreatic neuroendocrine carcinoma. J Cancer 2019;10:3140-4. [PMID: 31289584 DOI: 10.7150/jca.30355] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
29 Peri M, Fazio N. Clinical Evaluation of Everolimus in the Treatment of Neuroendocrine Tumors of the Lung: Patient Selection and Special Considerations. A Systematic and Critical Review of the Literature. Lung Cancer (Auckl) 2020;11:41-52. [PMID: 32753993 DOI: 10.2147/LCTT.S249928] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
30 Lakhtakia S. Therapy of Pancreatic Neuroendocrine Tumors: Fine Needle Intervention including Ethanol and Radiofrequency Ablation. Clin Endosc 2017;50:546-51. [PMID: 29207860 DOI: 10.5946/ce.2017.167] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 2.8] [Reference Citation Analysis]
31 Cai W, Ge W, Hu H, Mao J. Rectal NETs and rectosigmoid junction NETs may need to be treated differently. Cancer Med 2020;9:971-9. [PMID: 31840409 DOI: 10.1002/cam4.2779] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
32 Singhi AD, Liu TC, Roncaioli JL, Cao D, Zeh HJ, Zureikat AH, Tsung A, Marsh JW, Lee KK, Hogg ME. Alternative Lengthening of Telomeres and Loss of DAXX/ATRX Expression Predicts Metastatic Disease and Poor Survival in Patients with Pancreatic Neuroendocrine Tumors. Clin Cancer Res. 2017;23:600-609. [PMID: 27407094 DOI: 10.1158/1078-0432.ccr-16-1113] [Cited by in Crossref: 99] [Cited by in F6Publishing: 59] [Article Influence: 19.8] [Reference Citation Analysis]
33 Miller HC, Drymousis P, Flora R, Goldin R, Spalding D, Frilling A. Role of Ki-67 proliferation index in the assessment of patients with neuroendocrine neoplasias regarding the stage of disease. World J Surg. 2014;38:1353-1361. [PMID: 24493070 DOI: 10.1007/s00268-014-2451-0] [Cited by in Crossref: 48] [Cited by in F6Publishing: 45] [Article Influence: 8.0] [Reference Citation Analysis]
34 Kim BS, Park YS, Yook JH, Kim BS. Comparison of the prognostic values of the 2010 WHO classification, AJCC 7th edition, and ENETS classification of gastric neuroendocrine tumors. Medicine (Baltimore) 2016;95:e3977. [PMID: 27472674 DOI: 10.1097/MD.0000000000003977] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 3.8] [Reference Citation Analysis]
35 Kim MK, Ye F, Wang D, Cui M, Ward SC, Warner RR, Roayaie S, Shafir M, Schwartz M, Zhang D, Itzkowitz S. Differential Protein Expression in Small Intestinal Neuroendocrine Tumors and Liver Metastases. Pancreas 2016;45:528-32. [PMID: 26474427 DOI: 10.1097/MPA.0000000000000459] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
36 Araujo PB, Cheng S, Mete O, Serra S, Morin E, Asa SL, Ezzat S. Evaluation of the WHO 2010 grading and AJCC/UICC staging systems in prognostic behavior of intestinal neuroendocrine tumors. PLoS One 2013;8:e61538. [PMID: 23620762 DOI: 10.1371/journal.pone.0061538] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 2.4] [Reference Citation Analysis]
37 Lo Russo G, Pusceddu S, Prinzi N, Imbimbo M, Proto C, Signorelli D, Vitali M, Ganzinelli M, Maccauro M, Buzzoni R, Seregni E, de Braud F, Garassino MC. Peptide receptor radionuclide therapy: focus on bronchial neuroendocrine tumors. Tumour Biol 2016;37:12991-3003. [PMID: 27460087 DOI: 10.1007/s13277-016-5258-9] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
38 Kim J, Zimmerman MA, Hong JC. Liver transplantation in the treatment of unresectable hepatic metastasis from neuroendocrine tumors. J Gastrointest Oncol. 2020;11:601-608. [PMID: 32655939 DOI: 10.21037/jgo.2019.11.03] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
39 Pinto MP, Muñoz Medel M, Carrillo D, Retamal IN, Bravo ML, Valenzuela Y, Nervi B, Sánchez C, Galindo H, Ibañez C, Peña J, Balmaceda C, Madrid J, Briones J, Torres J, Nilo F, Guarda FJ, Quintana JC, Orellana P, Mondaca S, Acevedo F, Vicentini D, Cordova-Delgado M, Owen GI, Garrido M. Chilean Registry for Neuroendocrine Tumors: A Latin American Perspective. Horm Cancer 2019;10:3-10. [PMID: 30465145 DOI: 10.1007/s12672-018-0354-5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
40 Zhang M, Zhao P, Shi X, Zhao A, Zhang L, Zhou L. Clinicopathological features and prognosis of gastroenteropancreatic neuroendocrine neoplasms in a Chinese population: a large, retrospective single-centre study. BMC Endocr Disord. 2017;17:39. [PMID: 28705205 DOI: 10.1186/s12902-017-0190-6] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
41 Bongiovanni A, Recine F, Foca F, Fausti V, Riva N, Fabbri G, Severi S, Liverani C, De Vita A, Spadazzi C, Miserocchi G, Mercatali L, Amadori D, Ibrahim T. Metastatic neuroendocrine neoplasia treatments in patients over 70 years of age. Endocr Connect 2018;7:1535-41. [PMID: 30530877 DOI: 10.1530/EC-18-0478] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
42 杨建荣, 刘锦涛. 胃、大肠多发类癌1例. 世界华人消化杂志 2010; 18(21): 2282-2283 [DOI: 10.11569/wcjd.v18.i21.2282] [Reference Citation Analysis]
43 Zhu L, Shen-Tu Y, Zhang J, Fan X. [Pathological characteristic and clinical management of pulmonary carcinoid]. Zhongguo Fei Ai Za Zhi 2013;16:246-51. [PMID: 23676981 DOI: 10.3779/j.issn.1009-3419.2013.05.06] [Reference Citation Analysis]
44 Lee MS, O'Neil BH. Summary of emerging personalized medicine in neuroendocrine tumors: are we on track? J Gastrointest Oncol 2016;7:804-18. [PMID: 27747094 DOI: 10.21037/jgo.2016.08.05] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.4] [Reference Citation Analysis]
45 Trikalinos NA, Chatterjee D, Lee J, Liu J, Williams G, Hawkins W, Hammill C. Accuracy of Grading in Pancreatic Neuroendocrine Neoplasms and Effect on Survival Estimates: An Institutional Experience. Ann Surg Oncol 2020;27:3542-50. [PMID: 32206954 DOI: 10.1245/s10434-020-08377-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
46 Kawamoto T, Hishima T, Kimura K. Calcified liver metastases from a non-functioning pancreatic neuroendocrine tumor. Clin J Gastroenterol 2014;7:460-4. [PMID: 26184029 DOI: 10.1007/s12328-014-0525-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
47 Lee L, Ito T, Jensen RT. Prognostic and predictive factors on overall survival and surgical outcomes in pancreatic neuroendocrine tumors: recent advances and controversies. Expert Rev Anticancer Ther. 2019;19:1029-1050. [PMID: 31738624 DOI: 10.1080/14737140.2019.1693893] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 6.5] [Reference Citation Analysis]
48 Volante M, Righi L, Berruti A, Rindi G, Papotti M. The pathological diagnosis of neuroendocrine tumors: common questions and tentative answers. Virchows Arch 2011;458:393-402. [PMID: 21344263 DOI: 10.1007/s00428-011-1060-7] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
49 Berruti A, Fazio N, Ferrero A, Brizzi MP, Volante M, Nobili E, Tozzi L, Bodei L, Torta M, D'Avolio A, Priola AM, Birocco N, Amoroso V, Biasco G, Papotti M, Dogliotti L. Bevacizumab plus octreotide and metronomic capecitabine in patients with metastatic well-to-moderately differentiated neuroendocrine tumors: the XELBEVOCT study. BMC Cancer. 2014;14:184. [PMID: 24628963 DOI: 10.1186/1471-2407-14-184] [Cited by in Crossref: 55] [Cited by in F6Publishing: 49] [Article Influence: 7.9] [Reference Citation Analysis]
50 Srirajaskanthan R, Ahmed A, Prachialias A, Srinivasan P, Heaton N, Jervis N, Quaglia A, Vivian G, Ramage JK. ENETS TNM staging predicts prognosis in small bowel neuroendocrine tumours. ISRN Oncol. 2013;2013:420795. [PMID: 23533809 DOI: 10.1155/2013/420795] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
51 Zhang Z, Wang M. [Advanced research of mTOR and lung carcinoid tumors]. Zhongguo Fei Ai Za Zhi 2013;16:43-7. [PMID: 23327873 DOI: 10.3779/j.issn.1009-3419.2013.01.08] [Reference Citation Analysis]
52 Alexandraki KI, Karapanagioti A, Karoumpalis I, Boutzios G, Kaltsas GA. Advances and Current Concepts in the Medical Management of Gastroenteropancreatic Neuroendocrine Neoplasms. Biomed Res Int 2017;2017:9856140. [PMID: 29349087 DOI: 10.1155/2017/9856140] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.8] [Reference Citation Analysis]
53 Modlin IM, Kidd M, Filosso PL, Roffinella M, Lewczuk A, Cwikla J, Bodei L, Kolasinska-Cwikla A, Chung KM, Tesselaar ME, Drozdov IA. Molecular strategies in the management of bronchopulmonary and thymic neuroendocrine neoplasms. J Thorac Dis 2017;9:S1458-73. [PMID: 29201449 DOI: 10.21037/jtd.2017.03.82] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
54 Kim MK, Warner RR, Ward SC, Harpaz N, Roayaie S, Schwartz ME, Itzkowitz S, Wisnivesky J. Prognostic significance of lymph node metastases in small intestinal neuroendocrine tumors. Neuroendocrinology 2015;101:58-65. [PMID: 25572143 DOI: 10.1159/000371807] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 3.7] [Reference Citation Analysis]
55 Pettersson OJ, Fröss-Baron K, Crona J, Sundin A. Tumor growth rate in pancreatic neuroendocrine tumor patients undergoing PRRT with 177Lu-DOTATATE. Endocr Connect 2021;10:422-31. [PMID: 33875614 DOI: 10.1530/EC-21-0027] [Reference Citation Analysis]
56 Gu D, Hu Y, Ding H, Wei J, Chen K, Liu H, Zeng M, Tian J. CT radiomics may predict the grade of pancreatic neuroendocrine tumors: a multicenter study. Eur Radiol. 2019;29:6880-6890. [PMID: 31227882 DOI: 10.1007/s00330-019-06176-x] [Cited by in Crossref: 36] [Cited by in F6Publishing: 39] [Article Influence: 18.0] [Reference Citation Analysis]
57 Cloyd JM, Poultsides GA. Non-functional neuroendocrine tumors of the pancreas: Advances in diagnosis and management. World J Gastroenterol 2015; 21(32): 9512-9525 [PMID: 26327759 DOI: 10.3748/wjg.v21.i32.9512] [Cited by in CrossRef: 63] [Cited by in F6Publishing: 56] [Article Influence: 10.5] [Reference Citation Analysis]
58 Alexandraki K, Angelousi A, Boutzios G, Kyriakopoulos G, Rontogianni D, Kaltsas G. Management of neuroendocrine tumors of unknown primary. Rev Endocr Metab Disord 2017;18:423-31. [PMID: 29199361 DOI: 10.1007/s11154-017-9437-9] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 5.7] [Reference Citation Analysis]
59 Berzaczy D, Giraudo C, Haug AR, Raderer M, Senn D, Karanikas G, Weber M, Mayerhoefer ME. Whole-Body 68Ga-DOTANOC PET/MRI Versus 68Ga-DOTANOC PET/CT in Patients With Neuroendocrine Tumors: A Prospective Study in 28 Patients. Clin Nucl Med 2017;42:669-74. [PMID: 28682844 DOI: 10.1097/RLU.0000000000001753] [Cited by in Crossref: 31] [Cited by in F6Publishing: 11] [Article Influence: 10.3] [Reference Citation Analysis]
60 Wißt T, Jehn CF, Vierbuchen M, Starekova J. Solitary neuroendocrine carcinoma of the heart: a case report. Eur Heart J Case Rep 2018;2:yty096. [PMID: 31020173 DOI: 10.1093/ehjcr/yty096] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
61 Curran T, Pockaj BA, Gray RJ, Halfdanarson TR, Wasif N. Importance of lymph node involvement in pancreatic neuroendocrine tumors: impact on survival and implications for surgical resection. J Gastrointest Surg. 2015;19:152-160; discussion 160. [PMID: 25118642 DOI: 10.1007/s11605-014-2624-z] [Cited by in Crossref: 53] [Cited by in F6Publishing: 47] [Article Influence: 7.6] [Reference Citation Analysis]
62 Sei Y, Zhao X, Forbes J, Szymczak S, Li Q, Trivedi A, Voellinger M, Joy G, Feng J, Whatley M, Jones MS, Harper UL, Marx SJ, Venkatesan AM, Chandrasekharappa SC, Raffeld M, Quezado MM, Louie A, Chen CC, Lim RM, Agarwala R, Schäffer AA, Hughes MS, Bailey-Wilson JE, Wank SA. A Hereditary Form of Small Intestinal Carcinoid Associated With a Germline Mutation in Inositol Polyphosphate Multikinase. Gastroenterology 2015;149:67-78. [PMID: 25865046 DOI: 10.1053/j.gastro.2015.04.008] [Cited by in Crossref: 63] [Cited by in F6Publishing: 51] [Article Influence: 10.5] [Reference Citation Analysis]
63 Gut P, Czarnywojtek A, Bączyk M, Ziemnicka K, Fischbach J, Wrotkowska E, Ruchała M. Clinical features of gastroenteropancreatic tumours. Prz Gastroenterol 2015;10:127-34. [PMID: 26516377 DOI: 10.5114/pg.2015.52346] [Reference Citation Analysis]
64 Ter-Minassian M, Chan JA, Hooshmand SM, Brais LK, Daskalova A, Heafield R, Buchanan L, Qian ZR, Fuchs CS, Lin X. Clinical presentation, recurrence, and survival in patients with neuroendocrine tumors: results from a prospective institutional database. Endocr Relat Cancer. 2013;20:187-196. [PMID: 23319495 DOI: 10.1530/erc-12-0340] [Cited by in Crossref: 65] [Cited by in F6Publishing: 35] [Article Influence: 8.1] [Reference Citation Analysis]
65 Jensen RT. Cancer: a roadmap for the land of small tumors. Nat Rev Endocrinol 2011;7:319-21. [PMID: 21556022 DOI: 10.1038/nrendo.2011.73] [Reference Citation Analysis]
66 Tsilimigras DI, Brodt P, Clavien PA, Muschel RJ, D'Angelica MI, Endo I, Parks RW, Doyle M, de Santibañes E, Pawlik TM. Liver metastases. Nat Rev Dis Primers 2021;7:27. [PMID: 33859205 DOI: 10.1038/s41572-021-00261-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
67 Xiao Y, Jaskula-Sztul R, Javadi A, Xu W, Eide J, Dammalapati A, Kunnimalaiyaan M, Chen H, Gong S. Co-delivery of doxorubicin and siRNA using octreotide-conjugated gold nanorods for targeted neuroendocrine cancer therapy. Nanoscale 2012;4:7185-93. [PMID: 23070403 DOI: 10.1039/c2nr31853a] [Cited by in Crossref: 83] [Cited by in F6Publishing: 82] [Article Influence: 10.4] [Reference Citation Analysis]
68 Duan X, Zhao M, Zhang S, Xu Z, Mi L, Shi J, Ma X, Liu Y, Li N, Yin X, Han X, Han G, Wang J, Xu J, Yin F. Effects of tumor distance from anal verge on survival outcomes for rectal NENs and lymphatic metastasis risk score for colorectal NENs. Int J Colorectal Dis 2020;35:1255-64. [PMID: 32314191 DOI: 10.1007/s00384-020-03596-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
69 Yang M, Ke NW, Zhang Y, Tan CL, Tian BL, Liu XB, Huang W, Nunes Q, Sutton R. Functional and non-functional pancreatic neuroendocrine tumours: ENETS or AJCC TNM staging system? Oncotarget 2017;8:82784-95. [PMID: 29137302 DOI: 10.18632/oncotarget.20007] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
70 Yoo C, Oh CR, Kim ST, Bae WK, Choi HJ, Oh DY, Lee MA, Ryoo BY. Systemic Treatment of Advanced Gastroenteropancreatic Neuroendocrine Tumors in Korea: Literature Review and Expert Opinion. Cancer Res Treat 2021;53:291-300. [PMID: 33421978 DOI: 10.4143/crt.2020.1233] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
71 Genc CG, Klümpen HJ, van Oijen MGH, van Eijck CHJ, Nieveen van Dijkum EJM. A Nationwide Population-Based Study on the Survival of Patients with Pancreatic Neuroendocrine Tumors in The Netherlands. World J Surg 2018;42:490-7. [PMID: 29018912 DOI: 10.1007/s00268-017-4278-y] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 6.7] [Reference Citation Analysis]
72 Mota JM, Sousa LG, Riechelmann RP. Complications from carcinoid syndrome: review of the current evidence. Ecancermedicalscience. 2016;10:662. [PMID: 27594907 DOI: 10.3332/ecancer.2016.662] [Cited by in Crossref: 27] [Cited by in F6Publishing: 32] [Article Influence: 5.4] [Reference Citation Analysis]
73 Si Y, Kim S, Ou J, Lu Y, Ernst P, Chen K, Whitt J, Carter AM, Markert JM, Bibb JA, Chen H, Zhou L, Jaskula-Sztul R, Liu XM. Anti-SSTR2 antibody-drug conjugate for neuroendocrine tumor therapy. Cancer Gene Ther 2021;28:799-812. [PMID: 32684623 DOI: 10.1038/s41417-020-0196-5] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 10.0] [Reference Citation Analysis]
74 Ito T, Okusaka T, Nishida T, Yamao K, Igarashi H, Morizane C, Kondo S, Mizuno N, Hara K, Sawaki A, Hashigaki S, Kimura N, Murakami M, Ohki E, Chao RC, Imamura M. Phase II study of sunitinib in Japanese patients with unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumor. Invest New Drugs 2013;31:1265-74. [PMID: 23269537 DOI: 10.1007/s10637-012-9910-y] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 3.1] [Reference Citation Analysis]
75 Yang K, Yun SP, Kim S, Shin N, Park DY, Seo HI. Clinicopathological features and surgical outcomes of neuroendocrine tumors of ampulla of Vater. BMC Gastroenterol 2017;17:70. [PMID: 28569146 DOI: 10.1186/s12876-017-0630-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
76 Faggiano A, Ferolla P, Grimaldi F, Campana D, Manzoni M, Davì MV, Bianchi A, Valcavi R, Papini E, Giuffrida D, Ferone D, Fanciulli G, Arnaldi G, Franchi GM, Francia G, Fasola G, Crinò L, Pontecorvi A, Tomassetti P, Colao A. Natural history of gastro-entero-pancreatic and thoracic neuroendocrine tumors. Data from a large prospective and retrospective Italian epidemiological study: the NET management study. J Endocrinol Invest 2012;35:817-23. [PMID: 22080849 DOI: 10.3275/8102] [Cited by in F6Publishing: 37] [Reference Citation Analysis]
77 Hsieh JC, Chen GY, Jhou DD, Chou WC, Yeh CN, Hwang TL, Lin HC, Chu HC, Wang HM, Yen TC, Chen JS, Wu MH. The Prognostic Value of Circulating Tumor Cells in Asian Neuroendocrine Tumors. Sci Rep 2019;9:19917. [PMID: 31882775 DOI: 10.1038/s41598-019-56539-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
78 Bison SM, Haeck JC, Bol K, Koelewijn SJ, Groen HC, Melis M, Veenland JF, Bernsen MR, de Jong M. Optimization of combined temozolomide and peptide receptor radionuclide therapy (PRRT) in mice after multimodality molecular imaging studies. EJNMMI Res 2015;5:62. [PMID: 26553049 DOI: 10.1186/s13550-015-0142-y] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
79 Li WY, Liu XD, Li WN, Dong SY, Qu XH, Gong SL, Shao MR, Zhang L. Paraneoplastic Cushing's syndrome associated with bronchopulmonary carcinoid tumor in youth: A case report and review of the literature. Oncol Lett 2016;12:69-72. [PMID: 27347101 DOI: 10.3892/ol.2016.4572] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
80 Leoncini E, Boffetta P, Shafir M, Aleksovska K, Boccia S, Rindi G. Increased incidence trend of low-grade and high-grade neuroendocrine neoplasms. Endocrine 2017;58:368-79. [PMID: 28303513 DOI: 10.1007/s12020-017-1273-x] [Cited by in Crossref: 41] [Cited by in F6Publishing: 34] [Article Influence: 10.3] [Reference Citation Analysis]
81 Crabtree JS. Clinical and Preclinical Advances in Gastroenteropancreatic Neuroendocrine Tumor Therapy. Front Endocrinol (Lausanne) 2017;8:341. [PMID: 29255447 DOI: 10.3389/fendo.2017.00341] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
82 Tran CG, Sherman SK, Howe JR. Small Bowel Neuroendocrine Tumors. Curr Probl Surg 2020;57:100823. [PMID: 33234227 DOI: 10.1016/j.cpsurg.2020.100823] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
83 Mowrey K, Northrup H, Rougeau P, Hashmi SS, Krueger DA, Ebrahimi-Fakhari D, Towbin AJ, Trout AT, Capal JK, Franz DN, Rodriguez-Buritica D. Frequency, Progression, and Current Management: Report of 16 New Cases of Nonfunctional Pancreatic Neuroendocrine Tumors in Tuberous Sclerosis Complex and Comparison With Previous Reports. Front Neurol 2021;12:627672. [PMID: 33897589 DOI: 10.3389/fneur.2021.627672] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
84 Xie JW, Lu J, Lin JX, Zheng CH, Li P, Wang JB, Chen QY, Cao LL, Lin M, Tu RH, Huang CM. Different long-term oncologic outcomes after radical surgical resection for neuroendocrine carcinoma and adenocarcinoma of the stomach. Oncotarget 2017;8:57495-504. [PMID: 28915689 DOI: 10.18632/oncotarget.15488] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
85 Roland CL, Starker LF, Kang Y, Chatterjee D, Estrella J, Rashid A, Katz MH, Aloia TA, Lee JE, Dasari A, Yao JC, Fleming JB. Loss of DPC4/SMAD4 expression in primary gastrointestinal neuroendocrine tumors is associated with cancer-related death after resection. Surgery 2017;161:753-9. [PMID: 27816207 DOI: 10.1016/j.surg.2016.09.002] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
86 Sidéris L, Dubé P, Rinke A. Antitumor effects of somatostatin analogs in neuroendocrine tumors. Oncologist. 2012;17:747-755. [PMID: 22628056 DOI: 10.1634/theoncologist.2011-0458] [Cited by in Crossref: 53] [Cited by in F6Publishing: 49] [Article Influence: 5.9] [Reference Citation Analysis]
87 Fisher GA Jr, Wolin EM, Liyanage N, Pitman Lowenthal S, Mirakhur B, Pommier RF, Shaheen M, Vinik A; ELECT Study Group. Patient-Reported Symptom Control of Diarrhea and Flushing in Patients with Neuroendocrine Tumors Treated with Lanreotide Depot/Autogel: Results from a Randomized, Placebo-Controlled, Double-Blind and 32-Week Open-Label Study. Oncologist 2018;23:16-24. [PMID: 29038234 DOI: 10.1634/theoncologist.2017-0284] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
88 Padmanabhan N, Ahmed S, Kurian A, Ravishankar P. Unusual and Aggressive Cause of Gall Bladder Mass-Neuroendocrine Tumor. J Gastrointest Cancer 2020;51:307-10. [PMID: 31037470 DOI: 10.1007/s12029-019-00245-6] [Reference Citation Analysis]
89 Franchi G, Manzoni MF. Cytological Ki-67 in pancreatic endocrine tumors: a new "must"? Gland Surg 2014;3:219-21. [PMID: 25493251 DOI: 10.3978/j.issn.2227-684X.2014.08.02] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
90 Maschmeyer G, Mügge LO, Kämpfe D, Kreibich U, Wilhelm S, Aßmann M, Schwarz M, Kahl C, Köhler S, Grobe N, Niederwieser D. A retrospective review of diagnosis and treatment modalities of neuroendocrine tumors (excluding primary lung cancer) in 10 oncological institutions of the East German Study Group of Hematology and Oncology (OSHO), 2010-2012. J Cancer Res Clin Oncol 2015;141:1639-44. [PMID: 25773126 DOI: 10.1007/s00432-015-1954-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
91 Zhu LM, Tang L, Qiao XW, Wolin E, Nissen NN, Dhall D, Chen J, Shen L, Chi Y, Yuan YZ, Ben QW, Lv B, Zhou YR, Bai CM, Chen J, Song YL, Song TT, Lu CM, Yu R, Chen YJ. Differences and Similarities in the Clinicopathological Features of Pancreatic Neuroendocrine Tumors in China and the United States: A Multicenter Study. Medicine (Baltimore) 2016;95:e2836. [PMID: 26886644 DOI: 10.1097/MD.0000000000002836] [Cited by in Crossref: 17] [Cited by in F6Publishing: 6] [Article Influence: 3.4] [Reference Citation Analysis]
92 Chen YY, Li SQ, Liu HS, Qin YZ, Li L, Huang C, Bi YL, Meng YX, He J, Zhou XY, Ma DJ. Ectopic adrenocorticotropic hormone syndrome caused by neuroendocrine tumors of the thymus: 30-year experience with 16 patients at a single institute in the People's Republic of China. Onco Targets Ther 2016;9:2193-201. [PMID: 27217765 DOI: 10.2147/OTT.S100585] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
93 Liu P, Zhu X, Li J, Lu M, Leng J, Li Y, Yu J. Retrospective analysis of interventional treatment of hepatic metastasis from gastroenteropancreatic neuroendocrine tumors. Chin J Cancer Res 2017;29:581-6. [PMID: 29353981 DOI: 10.21147/j.issn.1000-9604.2017.06.13] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
94 Alawad M, Gupta R, Haseeb MA, Brunicardi FC. Clinicopathologic and Molecular Features of Mixed Neuroendocrine Non-Neuroendocrine Neoplasms of the Gallbladder. Gastroenterology Res 2020;13:269-78. [PMID: 33447306 DOI: 10.14740/gr1323] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
95 Isenberg-Grzeda E, MacGregor M, Matsoukas K, Chow N, Reidy-Lagunes D, Alici Y. Must antidepressants be avoided in patients with neuroendocrine tumors? Results of a systematic review. Palliat Support Care 2020;18:602-8. [PMID: 32036806 DOI: 10.1017/S147895152000005X] [Reference Citation Analysis]
96 Ribeiro MJM, Alonso T, Gajate P, Molina J, Barquin A, Perna C, Grande E. Huge recurrent gastric neuroendocrine tumor: a second-line chemotherapeutic dilemma. Autops Case Rep 2018;8:e2018005. [PMID: 29515980 DOI: 10.4322/acr.2018.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
97 Kitade H, Ohtsubo K, Hokkoku K, Mori M, Osamura RY, Sakuma H, Nakai M, Yano S. A case of advanced pancreatic neuroendocrine tumor in which octreotide long-acting repeatable was effective after failure of everolimus and sunitinib. Int Cancer Conf J 2019;8:24-8. [PMID: 31149542 DOI: 10.1007/s13691-018-0348-8] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
98 Amair-Pinedo F, Matos I, Saurí T, Hernando J, Capdevila J. The Treatment Landscape and New Opportunities of Molecular Targeted Therapies in Gastroenteropancreatic Neuroendocrine Tumors. Target Oncol 2017;12:757-74. [PMID: 29143176 DOI: 10.1007/s11523-017-0532-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
99 Sibeoni J, Khannoussi W, Manolios E, Rebours V, Revah-Levy A, Ruszniewski P. Perspectives of patients and physicians about neuroendocrine tumors. A qualitative study. Oncotarget 2018;9:14138-47. [PMID: 29581833 DOI: 10.18632/oncotarget.24347] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
100 Jo H, Park Y, Kim J, Kwon H, Kim T, Lee J, Pyun JC, Lee M, Yun M. Elevated miR-16-5p induces somatostatin receptor 2 expression in neuroendocrine tumor cells. PLoS One 2020;15:e0240107. [PMID: 33045023 DOI: 10.1371/journal.pone.0240107] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
101 Medley L, Morel AN, Farrugia D, Reed N, Hayward N, Davies JM, Kirichek O, Thakker RV, Talbot DC. Phase II study of single agent capecitabine in the treatment of metastatic non-pancreatic neuroendocrine tumours. Br J Cancer 2011;104:1067-70. [PMID: 21386841 DOI: 10.1038/bjc.2011.76] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 1.7] [Reference Citation Analysis]
102 Dima SO, Dumitrascu T, Pechianu C, Grigorie RT, Brasoveanu V, Sorop A, Lupescu I, Purnichescu-Purtan R, Croitoru A, Bacalbasa N, Tanase A, Tomescu DR, Herlea V, Popescu I. PROGNOSTIC FACTORS IN PATIENTS WITH SURGICAL RESECTION OF PANCREATIC NEUROENDOCRINE TUMOURS. Acta Endocrinol (Buchar) 2018;14:389-93. [PMID: 31149288 DOI: 10.4183/aeb.2018.389] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
103 Wang YH, Lin Y, Xue L, Wang JH, Chen MH, Chen J. Relationship between clinical characteristics and survival of gastroenteropancreatic neuroendocrine neoplasms: A single-institution analysis (1995-2012) in South China. BMC Endocr Disord. 2012;12:30. [PMID: 23194346 DOI: 10.1186/1472 -6823-12-30] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
104 Liu Q, Polydorides AD. Diagnosis and prognostic significance of extramural venous invasion in neuroendocrine tumors of the small intestine. Mod Pathol 2020;33:2318-29. [PMID: 32514164 DOI: 10.1038/s41379-020-0585-1] [Reference Citation Analysis]
105 Wulfert S, Kratochwil C, Choyke PL, Afshar-Oromieh A, Mier W, Kauczor HU, Schenk JP, Haberkorn U, Giesel FL. Multimodal imaging for early functional response assessment of (90)Y-/ (177)Lu-DOTATOC peptide receptor targeted radiotherapy with DW-MRI and (68)Ga-DOTATOC-PET/CT. Mol Imaging Biol 2014;16:586-94. [PMID: 24526358 DOI: 10.1007/s11307-014-0722-7] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 3.7] [Reference Citation Analysis]
106 Tsuruta N, Takayoshi K, Arita S, Aikawa T, Ariyama H, Kusaba H, Ohuchida K, Nagai E, Kohashi K, Hirahashi M, Inadomi K, Tanaka M, Sagara K, Okumura Y, Nio K, Nakano M, Nakamura M, Oda Y, Akashi K, Baba E. Systemic chemotherapy with pronounced efficacy and neutropenia in a granulocyte-colony stimulating factor-producing advanced gastric neuroendocrine carcinoma. Oncol Lett 2017;14:1500-4. [PMID: 28789371 DOI: 10.3892/ol.2017.6299] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
107 Sherman SK, Maxwell JE, Carr JC, Wang D, O'Dorisio MS, O'Dorisio TM, Howe JR. GIPR expression in gastric and duodenal neuroendocrine tumors. J Surg Res 2014;190:587-93. [PMID: 24565507 DOI: 10.1016/j.jss.2014.01.044] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
108 Hendifar AE, Ramirez RA, Anthony LB, Liu E. Current Practices and Novel Techniques in the Diagnosis and Management of Neuroendocrine Tumors of Unknown Primary. Pancreas 2019;48:1111-8. [PMID: 31609931 DOI: 10.1097/MPA.0000000000001391] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
109 Magalhães D, Sampaio IL, Ferreira G, Bogalho P, Martins-Branco D, Santos R, Duarte H. Peptide receptor radionuclide therapy with 177Lu-DOTA-TATE as a promising treatment of malignant insulinoma: a series of case reports and literature review. J Endocrinol Invest 2019;42:249-60. [PMID: 29949120 DOI: 10.1007/s40618-018-0911-3] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 4.7] [Reference Citation Analysis]
110 Strosberg JR, Benson AB, Huynh L, Duh MS, Goldman J, Sahai V, Rademaker AW, Kulke MH. Clinical benefits of above-standard dose of octreotide LAR in patients with neuroendocrine tumors for control of carcinoid syndrome symptoms: a multicenter retrospective chart review study. Oncologist. 2014;19:930-936. [PMID: 25096997 DOI: 10.1634/theoncologist.2014-0120] [Cited by in Crossref: 63] [Cited by in F6Publishing: 62] [Article Influence: 9.0] [Reference Citation Analysis]
111 Lamarca A, Nonaka D, Breitwieser W, Ashton G, Barriuso J, McNamara MG, Moghadam S, Rogan J, Mansoor W, Hubner RA, Clark C, Chakrabarty B, Valle JW. PD-L1 expression and presence of TILs in small intestinal neuroendocrine tumours. Oncotarget 2018;9:14922-38. [PMID: 29599916 DOI: 10.18632/oncotarget.24464] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 5.7] [Reference Citation Analysis]
112 Fujino M, Aishima S, Shindo K, Oda Y, Morimatsu K, Tsutsumi K, Otsuka T, Tanaka M, Oda Y. Expression of glucose transporter-1 is correlated with hypoxia-inducible factor 1α and malignant potential in pancreatic neuroendocrine tumors. Oncol Lett 2016;12:3337-43. [PMID: 27900001 DOI: 10.3892/ol.2016.5092] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
113 Krug S, Mordhorst JP, Moser F, Theuerkorn K, Ruffert C, Egidi M, Rinke A, Gress TM, Michl P. Interaction between somatostatin analogues and targeted therapies in neuroendocrine tumor cells. PLoS One 2019;14:e0218953. [PMID: 31237925 DOI: 10.1371/journal.pone.0218953] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 2.5] [Reference Citation Analysis]
114 Murai K, Imai K, Hotta K, Ito S, Yamaguchi Y, Ono H. A 10-year History of a Diminutive Rectal Neuroendocrine Tumor. Intern Med 2018;57:677-9. [PMID: 29151521 DOI: 10.2169/internalmedicine.9366-17] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
115 Wikberg E, van Essen M, Rydén T, Svensson J, Gjertsson P, Bernhardt P. Evaluation of the Spatial Resolution In monte Carlo-Based Spect/Ct Reconstruction Of 111In-Octreotide Images. Radiat Prot Dosimetry 2021:ncab055. [PMID: 33885133 DOI: 10.1093/rpd/ncab055] [Reference Citation Analysis]
116 Mirallas O, Saoudi N, Gómez-Puerto D, Riveiro-Barciela M, Merino X, Auger C, Landolfi S, Blanco L, Garcia-Burillo A, Molero X, Salcedo-Allende MT, Capdevila J. Acquired hepatocerebral degeneration in a metastatic neuroendocrine tumor long-term survivor — an update on neuroendocrine neoplasm’s treatment: A case report. World J Hepatol 2021; 13(5): 611-619 [PMID: 34131474 DOI: 10.4254/wjh.v13.i5.611] [Reference Citation Analysis]
117 Wu L, Fu J, Wan L, Pan J, Lai S, Zhong J, Chung DC, Wang L. Survival outcomes and surgical intervention of small intestinal neuroendocrine tumors: a population based retrospective study. Oncotarget. 2017;8:4935-4947. [PMID: 27903960 DOI: 10.18632/oncotarget.13632] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 5.3] [Reference Citation Analysis]
118 Jiang M, Tan Y, Li X, Fu J, Hu H, Ye X, Cao Y, Xu J, Yuan Y. Clinicopathological Features and Prognostic Factors of Colorectal Neuroendocrine Neoplasms. Gastroenterol Res Pract 2017;2017:4206172. [PMID: 28194176 DOI: 10.1155/2017/4206172] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
119 Grandhi MS, Lafaro KJ, Pawlik TM. Role of Locoregional and Systemic Approaches for the Treatment of Patients with Metastatic Neuroendocrine Tumors. J Gastrointest Surg. 2015;19:2273-2282. [PMID: 26341823 DOI: 10.1007/s11605-015-2931-z] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
120 Muscogiuri G, Altieri B, Albertelli M, Dotto A, Modica R, Barrea L, Fanciulli G, Feola T, Baldelli R, Ruggeri RM, Gallo M, Guarnotta V, Malandrino P, Messina E, Venneri MA, Giannetta E, Ferone D, Colao A, Faggiano A; NIKE group. Epidemiology of pancreatic neuroendocrine neoplasms: a gender perspective. Endocrine 2020;69:441-50. [PMID: 32468269 DOI: 10.1007/s12020-020-02331-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
121 Sakamaki Y, Tanaka R, Ishida D, Tsuji H, Mike A, Yasuoka H. Pigmented spindle cell variant of a thymic atypical carcinoid in an octogenarian. Surg Case Rep 2021;7:12. [PMID: 33409736 DOI: 10.1186/s40792-020-01094-3] [Reference Citation Analysis]
122 Masciale V, Grisendi G, Banchelli F, D'Amico R, Maiorana A, Morandi U, Dominici M, Aramini B. Cancer stem-neuroendocrine cells in an atypical carcinoid case report. Transl Lung Cancer Res. 2019;8:1157-1162. [PMID: 32010593 DOI: 10.21037/tlcr.2019.12.07] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
123 Charoenpitakchai M, Liu E, Zhao Z, Koyama T, Huh WJ, Berlin J, Hande K, Walker R, Shi C. In liver metastases from small intestinal neuroendocrine tumors, SSTR2A expression is heterogeneous. Virchows Arch 2017;470:545-52. [PMID: 28213807 DOI: 10.1007/s00428-017-2093-3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
124 Uema D, Alves C, Mesquita M, Nuñez JE, Siepmann T, Angel M, Rego JFM, Weschenfelder R, Rocha Filho DR, Costa FP, Barros M, O'Connor JM, Illigens BM, Riechelmann RP. Carcinoid Heart Disease and Decreased Overall Survival among Patients with Neuroendocrine Tumors: A Retrospective Multicenter Latin American Cohort Study. J Clin Med 2019;8:E405. [PMID: 30909590 DOI: 10.3390/jcm8030405] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
125 Ozcelik CK, Turanli S, Bozdogan N, Dibekoglu C. Clinical experience in appendiceal neuroendocrine neoplasms. Contemp Oncol (Pozn) 2015;19:410-3. [PMID: 26793027 DOI: 10.5114/wo.2015.56008] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
126 Landerholm K. Time trends in incidence and survival of small intestinal cancer in Sweden. BJS Open 2021;5:zraa044. [PMID: 33609370 DOI: 10.1093/bjsopen/zraa044] [Reference Citation Analysis]
127 Ambrosini V, Campana D, Tomassetti P, Fanti S. ⁶⁸Ga-labelled peptides for diagnosis of gastroenteropancreatic NET. Eur J Nucl Med Mol Imaging 2012;39 Suppl 1:S52-60. [PMID: 22388622 DOI: 10.1007/s00259-011-1989-4] [Cited by in Crossref: 82] [Cited by in F6Publishing: 66] [Article Influence: 9.1] [Reference Citation Analysis]
128 Lokesh KN, Anand A, Lakshmaiah KC, Babu KG, Lokanatha D, Jacob LA, Babu MCS, Rudresha AH, Rajeev LK, Saldanha SC, Giri GV, Panwar D, Koppaka D, Patidar R. Clinical profile and treatment outcomes of metastatic neuroendocrine carcinoma: A single institution experience. South Asian J Cancer 2018;7:207-9. [PMID: 30112343 DOI: 10.4103/sajc.sajc_176_17] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
129 Eads JR, Meropol NJ. A new era for the systemic therapy of neuroendocrine tumors. Oncologist 2012;17:326-38. [PMID: 22357730 DOI: 10.1634/theoncologist.2011-0356] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
130 Bollard J, Massoma P, Vercherat C, Blanc M, Lepinasse F, Gadot N, Couderc C, Poncet G, Walter T, Joly MO. The axon guidance molecule semaphorin 3F is a negative regulator of tumor progression and proliferation in ileal neuroendocrine tumors. Oncotarget. 2015;6:36731-36745. [PMID: 26447612 DOI: 10.18632/oncotarget.5481] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
131 Liu T, Liao J, Dang J, Li G. Treatments for patients with advanced neuroendocrine tumors: a network meta-analysis. Ther Adv Med Oncol 2019;11:1758835919853673. [PMID: 31191714 DOI: 10.1177/1758835919853673] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
132 Basuroy R, Srirajaskanthan R, Ramage JK. A multimodal approach to the management of neuroendocrine tumour liver metastases. Int J Hepatol 2012;2012:819193. [PMID: 22518323 DOI: 10.1155/2012/819193] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 2.0] [Reference Citation Analysis]
133 Roviello G, Zanotti L, Venturini S, Bottini A, Generali D. Role of targeted agents in neuroendocrine tumors: Results from a meta-analysis. Cancer Biol Ther 2016;17:883-8. [PMID: 27414404 DOI: 10.1080/15384047.2016.1210735] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
134 Fata CR, Gonzalez RS, Liu E, Cates JM, Shi C. Mesenteric Tumor Deposits in Midgut Small Intestinal Neuroendocrine Tumors Are a Stronger Indicator Than Lymph Node Metastasis for Liver Metastasis and Poor Prognosis. Am J Surg Pathol 2017;41:128-33. [PMID: 27684993 DOI: 10.1097/PAS.0000000000000751] [Cited by in Crossref: 16] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
135 Luo Y, Chen J, Huang K, Lin Y, Chen M, Xu L, Li ZP, Feng ST. Early evaluation of sunitinib for the treatment of advanced gastroenteropancreatic neuroendocrine neoplasms via CT imaging: RECIST 1.1 or Choi Criteria? BMC Cancer 2017;17:154. [PMID: 28231773 DOI: 10.1186/s12885-017-3150-7] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.8] [Reference Citation Analysis]
136 Fabian E, Haas B, Kump P, Lipp R, Kornprat P, Lutfi A, Talakic E, Fuchsjäger M, Spindelboeck W, Lackner C, Zollner G, Krejs GJ. Clinical-Pathological Conference Series from the Medical University of Graz : Case No 154: 32-year-old computer software engineer with nodular mass in the liver. Wien Klin Wochenschr 2016;128:277-86. [PMID: 26919853 DOI: 10.1007/s00508-016-0965-1] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
137 Siyam F, Abdullah O, Gardner M, Brietzke S, Sowers J. A Case of Carcinoid Tumor-Associated Hypercalcemia. Cardiorenal Med 2012;2:52-6. [PMID: 22493603 DOI: 10.1159/000335673] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
138 Shen C, Yin Y, Chen H, Tang S, Yin X, Zhou Z, Zhang B, Chen Z. Neuroendocrine tumors of colon and rectum: validation of clinical and prognostic values of the World Health Organization 2010 grading classifications and European Neuroendocrine Tumor Society staging systems. Oncotarget. 2017;8:22123-22134. [PMID: 27902460 DOI: 10.18632/oncotarget.13641] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
139 Miura T, Ohtsuka H, Aoki T, Aoki S, Hata T, Takadate T, Maeda S, Ariake K, Kawaguchi K, Masuda K, Ishida M, Mizuma M, Nakagawa K, Morikawa T, Fujishima F, Kamei T, Sasano H, Unno M. Increased neutrophil-lymphocyte ratio predicts recurrence in patients with well-differentiated pancreatic neuroendocrine neoplasm based on the 2017 World Health Organization classification. BMC Surg 2021;21:176. [PMID: 33789657 DOI: 10.1186/s12893-021-01178-3] [Reference Citation Analysis]
140 Yan T, Wang K, Liu J, Zeng Y, Bie F, Wang G, Du J. Wedge resection is equal to segmental resection for pulmonary typical carcinoid patients at localized stage: a population-based analysis. PeerJ 2019;7:e7519. [PMID: 31565553 DOI: 10.7717/peerj.7519] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
141 Parghane RV, Talole S, Basu S. Prevalence of hitherto unknown brain meningioma detected on 68Ga-DOTATATE positron-emission tomography/computed tomography in patients with metastatic neuroendocrine tumor and exploring potential of 177Lu-DOTATATE peptide receptor radionuclide therapy as single-shot treatment approach targeting both tumors. World J Nucl Med 2019;18:160-70. [PMID: 31040748 DOI: 10.4103/wjnm.WJNM_39_18] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
142 Diets IJ, Nagtegaal ID, Loeffen J, de Blaauw I, Waanders E, Hoogerbrugge N, Jongmans MC. Childhood neuroendocrine tumours: a descriptive study revealing clues for genetic predisposition. Br J Cancer 2017;116:163-8. [PMID: 27959889 DOI: 10.1038/bjc.2016.408] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
143 Vinayek R, Capurso G, Larghi A. Grading of EUS-FNA cytologic specimens from patients with pancreatic neuroendocrine neoplasms: it is time move to tissue core biopsy? Gland Surg. 2014;3:222-225. [PMID: 25493252 DOI: 10.3978/j.issn.2227-684x.2014.07.03] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
144 Sato Y. Endoscopic diagnosis and management of type I neuroendocrine tumors. World J Gastrointest Endosc 2015; 7(4): 346-353 [PMID: 25901213 DOI: 10.4253/wjge.v7.i4.346] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
145 Sharma J, Duque M, Saif MW. Emerging therapies and latest development in the treatment of unresectable pancreatic neuroendocrine tumors: an update for clinicians. Therap Adv Gastroenterol 2013;6:474-90. [PMID: 24179483 DOI: 10.1177/1756283X13498808] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 1.9] [Reference Citation Analysis]
146 Long HY, Huang QX, Yu YY, Zhang ZB, Yao ZW, Chen HB, Feng JW. Dehydrocostus lactone inhibits in vitro gastrinoma cancer cell growth through apoptosis induction, sub-G1 cell cycle arrest, DNA damage and loss of mitochondrial membrane potential. Arch Med Sci 2019;15:765-73. [PMID: 31110544 DOI: 10.5114/aoms.2018.73128] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
147 Folkestad O, Wasmuth HH, Mjønes P, Fougner R, Hauso Ø, Fossmark R. Survival and Disease Recurrence in Patients with Duodenal Neuroendocrine Tumours-A Single Centre Cohort. Cancers (Basel) 2021;13:3985. [PMID: 34439140 DOI: 10.3390/cancers13163985] [Reference Citation Analysis]
148 Li J, Lu M, Lu Z, Li Z, Liu Y, Yang L, Li J, Zhang X, Zhou J, Wang X, Gong J, Gao J, Li Y, Shen L. Irinotecan plus cisplatin followed by octreotide long-acting release maintenance treatment in advanced gastroenteropancreatic neuroendocrine carcinoma: IPO-NEC study. Oncotarget 2017;8:25669-78. [PMID: 27788498 DOI: 10.18632/oncotarget.12900] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
149 Chu KK, Wong KH, Chok KS. Expanding Indications for Liver Transplant: Tumor and Patient Factors. Gut Liver 2021;15:19-30. [PMID: 32102130 DOI: 10.5009/gnl19265] [Reference Citation Analysis]
150 Fang C, Wang W, Feng X, Sun J, Zhang Y, Zeng Y, Wang J, Chen H, Cai M, Lin J, Chen M, Chen Y, Li Y, Li S, Chen J, Zhou Z. Nomogram individually predicts the overall survival of patients with gastroenteropancreatic neuroendocrine neoplasms. Br J Cancer 2017;117:1544-50. [PMID: 28949958 DOI: 10.1038/bjc.2017.315] [Cited by in Crossref: 39] [Cited by in F6Publishing: 41] [Article Influence: 9.8] [Reference Citation Analysis]
151 Neklason DW, VanDerslice J, Curtin K, Cannon-Albright LA. Evidence for a heritable contribution to neuroendocrine tumors of the small intestine. Endocr Relat Cancer 2016;23:93-100. [PMID: 26604321 DOI: 10.1530/ERC-15-0442] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
152 Kurth J, Krause BJ, Schwarzenböck SM, Stegger L, Schäfers M, Rahbar K. External radiation exposure, excretion, and effective half-life in 177Lu-PSMA-targeted therapies. EJNMMI Res 2018;8:32. [PMID: 29651569 DOI: 10.1186/s13550-018-0386-4] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 4.3] [Reference Citation Analysis]
153 Lee SY, Choi YJ, Chang WJ, Shin SW, Kim YH, Kim ST. The role of chemotherapy and/or octreotide in patients with metastatic gastroenteropancreatic and hepatobiliary neuroendocrine carcinoma. J Gastrointest Oncol 2014;5:457-62. [PMID: 25436125 DOI: 10.3978/j.issn.2078-6891.2014.075] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
154 Sugimoto M, Takagi T, Hikichi T, Suzuki R, Watanabe K, Nakamura J, Kikuchi H, Konno N, Waragai Y, Asama H, Takasumi M, Watanabe H, Obara K, Ohira H. Efficacy of endoscopic ultrasonography-guided fine needle aspiration for pancreatic neuroendocrine tumor grading. World J Gastroenterol 2015; 21(26): 8118-8124 [PMID: 26185384 DOI: 10.3748/wjg.v21.i26.8118] [Cited by in CrossRef: 25] [Cited by in F6Publishing: 17] [Article Influence: 4.2] [Reference Citation Analysis]
155 Corsini EM, Mitchell KG, Sceusi EL, Mehran RJ, Rice DC, Sepesi B, Walsh GL, Swisher SG, Roth JA, Vaporciyan AA, Hofstetter WL, Antonoff MB. Multidisciplinary treatment of thymic neuroendocrine tumors: surgery remains a key component. J Thorac Dis 2019;11:3391-8. [PMID: 31559043 DOI: 10.21037/jtd.2019.08.20] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
156 Białecki M, Białecka A, Męcińska-Jundziłł K, Adamska U, Kasperska A, Czajkowski R. Imaging in a rare case of neuroendocrine tumour with skin metastases. Pol J Radiol 2018;83:e63-7. [PMID: 30038680 DOI: 10.5114/pjr.2018.73307] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
157 Chen MH, Yeh YC, Shyr YM, Jan YH, Chao Y, Li CP, Wang SE, Tzeng CH, Chang PM, Liu CY, Chen MH, Hsiao M, Huang CY. Expression of gremlin 1 correlates with increased angiogenesis and progression-free survival in patients with pancreatic neuroendocrine tumors. J Gastroenterol 2013;48:101-8. [PMID: 22706573 DOI: 10.1007/s00535-012-0614-z] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 2.1] [Reference Citation Analysis]
158 Nguyen AH, O'Leary MP, De Andrade JP, Ituarte PHG, Kessler J, Li D, Singh G, Chang S. Natural History of Renal Neuroendocrine Neoplasms: A NET by Any Other Name? Front Endocrinol (Lausanne) 2020;11:624251. [PMID: 33613455 DOI: 10.3389/fendo.2020.624251] [Reference Citation Analysis]
159 Zhang C, Wu Y, Zhuang H, Li D, Lin Y, Yin Z, Lu X, Hou B, Jian Z. Establishment and validation of an AJCC stage- and histologic grade-based nomogram for pancreatic neuroendocrine tumors after surgical resection. Cancer Manag Res 2019;11:7345-52. [PMID: 31496796 DOI: 10.2147/CMAR.S200340] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 3.5] [Reference Citation Analysis]
160 Sun W, Wu S, Han X, Yang C. Effectiveness of Endoscopic Treatment for Gastrointestinal Neuroendocrine Tumors: A Retrospective Study. Medicine (Baltimore) 2016;95:e3308. [PMID: 27082572 DOI: 10.1097/MD.0000000000003308] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
161 Santos AP, Vinagre J, Soares P, Claro I, Sanches AC, Gomes L, Fernandes I, Catarino AL, Preto J, Pereira BD, Marques AP, Rodrigues F, Amaral C, Rocha G, Mellidez JC, Simões H, Lopes JM, Bugalho MJ; On behalf of the NETs Study Group of the Portuguese Society of Endocrinology, Diabetes and Metabolism . Gastroenteropancreatic Neuroendocrine Neoplasia Characterization in Portugal: Results from the NETs Study Group of the Portuguese Society of Endocrinology, Diabetes and Metabolism. Int J Endocrinol 2019;2019:4518742. [PMID: 31467527 DOI: 10.1155/2019/4518742] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
162 Quevedo R, Spreafico A, Bruce J, Danesh A, El Ghamrasni S, Giesler A, Hanna Y, Have C, Li T, Yang SYC, Zhang T, Asa SL, Haibe-Kains B, Krzyzanowska M, Smith AC, Singh S, Siu LL, Pugh TJ. Centromeric cohesion failure invokes a conserved choreography of chromosomal mis-segregations in pancreatic neuroendocrine tumor. Genome Med 2020;12:38. [PMID: 32345369 DOI: 10.1186/s13073-020-00730-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
163 Herde RF, Kokeny KE, Reddy CB, Akerley WL, Hu N, Boltax JP, Hitchcock YJ. Primary Pulmonary Carcinoid Tumor: A Long-term Single Institution Experience. Am J Clin Oncol. 2018;41:24-29. [PMID: 26270444 DOI: 10.1097/coc.0000000000000221] [Cited by in Crossref: 16] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
164 Galetta D, Spaggiari L. Thymectomy and transpericardial nodal dissection. Thorac Cancer 2015;6:375-7. [PMID: 26273388 DOI: 10.1111/1759-7714.12194] [Reference Citation Analysis]
165 Nassereddine H, Chicaud M, Rebah K, Théou-Anton N, Sautet A, Dermer J, Couvelard A. Pathogenic ATM Variant-Harbouring Well-Differentiated Aggressive Type 1 Gastric Neuroendocrine Tumour with High-grade Features (G3 NET): a New Addition to the Clinical and Pathological Spectrum of Gastric Neuroendocrine Neoplasms. Endocr Pathol 2021. [PMID: 34019237 DOI: 10.1007/s12022-021-09681-2] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
166 Lee A, Chan DL, Wong MH, Li BT, Lumba S, Clarke SJ, Samra J, Pavlakis N. Systematic Review of the Role of Targeted Therapy in Metastatic Neuroendocrine Tumors. Neuroendocrinology 2017;104:209-22. [PMID: 27082107 DOI: 10.1159/000446115] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
167 Fisher MD, Pulgar S, Kulke MH, Mirakhur B, Miller PJ, Walker MS, Schwartzberg LS. Treatment Outcomes in Patients with Metastatic Neuroendocrine Tumors: a Retrospective Analysis of a Community Oncology Database. J Gastrointest Cancer 2019;50:816-23. [PMID: 30121904 DOI: 10.1007/s12029-018-0160-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
168 Kulkarni RS, Anand AS, Parikh SK, Panchal HP, Patel AA, Mehta DP, Patel P. Clinical and epidemiological profile of neuroendocrine tumors: An experience from a regional cancer center from Western India. South Asian J Cancer 2019;8:198-202. [PMID: 31489301 DOI: 10.4103/sajc.sajc_364_18] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
169 Zhang WH, Wang WQ, Han X, Gao HL, Xu SS, Li S, Li TJ, Xu HX, Li H, Ye LY, Lin X, Wu CT, Long J, Yu XJ, Liu L. Infiltrating pattern and prognostic value of tertiary lymphoid structures in resected non-functional pancreatic neuroendocrine tumors. J Immunother Cancer 2020;8:e001188. [PMID: 33055204 DOI: 10.1136/jitc-2020-001188] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
170 Weatherall T, Denbo J, Sharpe J, Martin M, O'Brien T, Gupta R, Groshart K, Behrman S, Dickson P. Well-Differentiated, Non-Functional, Non-Ampullary Duodenal Neuroendocrine Tumors: Toward Defining Evaluation and Management. World J Surg. 2017;41:844-850. [PMID: 27743074 DOI: 10.1007/s00268-016-3770-0] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
171 Atkinson C, Ganeshan B, Endozo R, Wan S, Aldridge MD, Groves AM, Bomanji JB, Gaze MN. Radiomics-Based Texture Analysis of 68Ga-DOTATATE Positron Emission Tomography and Computed Tomography Images as a Prognostic Biomarker in Adults With Neuroendocrine Cancers Treated With 177Lu-DOTATATE. Front Oncol 2021;11:686235. [PMID: 34408979 DOI: 10.3389/fonc.2021.686235] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
172 O'Connor JM, Marmissolle F, Bestani C, Pesce V, Belli S, Dominichini E, Mendez G, Price P, Giacomi N, Pairola A, Loria FS, Huertas E, Martin C, Patane K, Poleri C, Rosenberg M, Cabanne A, Kujaruk M, Caino A, Zamora V, Mariani J, Dioca M, Parma P, Podesta G, Andriani O, Gondolesi G, Roca E. Observational study of patients with gastroenteropancreatic and bronchial neuroendocrine tumors in Argentina: Results from the large database of a multidisciplinary group clinical multicenter study. Mol Clin Oncol. 2014;2:673-684. [PMID: 25054030 DOI: 10.3892/mco.2014.332] [Cited by in Crossref: 27] [Cited by in F6Publishing: 29] [Article Influence: 3.9] [Reference Citation Analysis]
173 Man D, Wu J, Shen Z, Zhu X. Prognosis of patients with neuroendocrine tumor: a SEER database analysis. Cancer Manag Res. 2018;10:5629-5638. [PMID: 30519109 DOI: 10.2147/cmar.s174907] [Cited by in Crossref: 40] [Cited by in F6Publishing: 20] [Article Influence: 13.3] [Reference Citation Analysis]
174 Phan AT, Halperin DM, Chan JA, Fogelman DR, Hess KR, Malinowski P, Regan E, Ng CS, Yao JC, Kulke MH. Pazopanib and depot octreotide in advanced, well-differentiated neuroendocrine tumours: a multicentre, single-group, phase 2 study. Lancet Oncol. 2015;16:695-703. [PMID: 25956795 DOI: 10.1016/s1470-2045(15)70136-1] [Cited by in Crossref: 79] [Cited by in F6Publishing: 41] [Article Influence: 13.2] [Reference Citation Analysis]
175 Dores GM, Qubaiah O, Mody A, Ghabach B, Devesa SS. A population-based study of incidence and patient survival of small cell carcinoma in the United States, 1992-2010. BMC Cancer. 2015;15:185. [PMID: 25885914 DOI: 10.1186/s12885-015-1188-y] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 3.3] [Reference Citation Analysis]
176 Johnson A, Wright JP, Zhao Z, Komaya T, Parikh A, Merchant N, Shi C. Cadherin 17 is frequently expressed by 'sclerosing variant' pancreatic neuroendocrine tumour. Histopathology 2015;66:225-33. [PMID: 25307987 DOI: 10.1111/his.12535] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
177 Farina DA, Krogh KM, Boike JR. Chronic Diarrhea Secondary to Newly Diagnosed VIPoma. Case Rep Gastroenterol 2019;13:225-9. [PMID: 31123451 DOI: 10.1159/000494554] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
178 Aoki T, Kokudo N, Komoto I, Takaori K, Kimura W, Sano K, Takamoto T, Hashimoto T, Okusaka T, Morizane C, Ito T, Imamura M. Streptozocin chemotherapy for advanced/metastatic well-differentiated neuroendocrine tumors: an analysis of a multi-center survey in Japan. J Gastroenterol 2015;50:769-75. [PMID: 25348496 DOI: 10.1007/s00535-014-1006-3] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
179 Capdevila J, Casanovas O, Salazar R, Castellano D, Segura A, Fuster P, Aller J, García-Carbonero R, Jimenez-Fonseca P, Grande E, Castaño JP. Translational research in neuroendocrine tumors: pitfalls and opportunities. Oncogene 2017;36:1899-907. [PMID: 27641330 DOI: 10.1038/onc.2016.316] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 4.2] [Reference Citation Analysis]
180 Herrmann K, Czernin J, Wolin EM, Gupta P, Barrio M, Gutierrez A, Schiepers C, Mosessian S, Phelps ME, Allen-Auerbach MS. Impact of 68Ga-DOTATATE PET/CT on the management of neuroendocrine tumors: the referring physician's perspective. J Nucl Med 2015;56:70-5. [PMID: 25500825 DOI: 10.2967/jnumed.114.148247] [Cited by in Crossref: 42] [Cited by in F6Publishing: 41] [Article Influence: 6.0] [Reference Citation Analysis]
181 Froelich MF, Schnitzer ML, Holzgreve A, Gassert FG, Gresser E, Overhoff D, Schwarze V, Fabritius MP, Nörenberg D, von Münchhausen N, Hokamp NG, Auernhammer CJ, Ilhan H, Todica A, Rübenthaler J. Cost-Effectiveness Analysis of 68Ga DOTA-TATE PET/CT, 111In-Pentetreotide SPECT/CT and CT for Diagnostic Workup of Neuroendocrine Tumors. Diagnostics (Basel) 2021;11:334. [PMID: 33670457 DOI: 10.3390/diagnostics11020334] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
182 Zhao W, Quan Z, Huang X, Ren J, Wen D, Zhang G, Shi Z, Yin H, Huan Y. Grading of pancreatic neuroendocrine neoplasms using pharmacokinetic parameters derived from dynamic contrast-enhanced MRI. Oncol Lett 2018;15:8349-56. [PMID: 29805568 DOI: 10.3892/ol.2018.8384] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
183 Li J, Wang Y, Han F, Wang Z, Xu L, Tong J. Disadvantage of survival outcomes in widowed patients with colorectal neuroendocrine neoplasm: an analysis of surveillance, epidemiology and end results database. Oncotarget 2016;7:83200-7. [PMID: 27825123 DOI: 10.18632/oncotarget.13078] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
184 Niu C, Wang S, Guan Q, Ren X, Ji B, Liu Y. Neuroendocrine tumors of the gallbladder. Oncol Lett 2020;19:3381-8. [PMID: 32269610 DOI: 10.3892/ol.2020.11461] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
185 Lamberti G, Brighi N, Maggio I, Manuzzi L, Peterle C, Ambrosini V, Ricci C, Casadei R, Campana D. The Role of mTOR in Neuroendocrine Tumors: Future Cornerstone of a Winning Strategy? Int J Mol Sci. 2018;19. [PMID: 29509701 DOI: 10.3390/ijms19030747] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 10.0] [Reference Citation Analysis]
186 Gajate P, Martínez-Sáez O, Alonso-Gordoa T, Grande E. Emerging use of everolimus in the treatment of neuroendocrine tumors. Cancer Manag Res 2017;9:215-24. [PMID: 28684922 DOI: 10.2147/CMAR.S113382] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
187 Zhao ZM, Wang J, Ugwuowo UC, Wang L, Townsend JP. Primary hepatic neuroendocrine carcinoma: report of two cases and literature review. BMC Clin Pathol 2018;18:3. [PMID: 29507528 DOI: 10.1186/s12907-018-0070-7] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
188 Srirajaskanthan R, Caplin ME, Waugh MG, Watkins J, Meyer T, Hsuan JJ, Beaumont NJ. Identification of Mac-2-binding protein as a putative marker of neuroendocrine tumors from the analysis of cell line secretomes. Mol Cell Proteomics 2010;9:656-66. [PMID: 20019050 DOI: 10.1074/mcp.M900401-MCP200] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
189 Feng X, Wei G, Wang W, Zhang Y, Zeng Y, Chen M, Chen Y, Chen J, Zhou Z, Li Y. Nomogram for individually predicting overall survival in rectal neuroendocrine tumours. BMC Cancer 2020;20:865. [PMID: 32907602 DOI: 10.1186/s12885-020-07328-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
190 Gebauer N, Schmidt-Werthern C, Bernard V, Feller AC, Keck T, Begum N, Rades D, Lehnert H, Brabant G, Thorns C. Genomic landscape of pancreatic neuroendocrine tumors. World J Gastroenterol 2014; 20(46): 17498-17506 [PMID: 25516664 DOI: 10.3748/wjg.v20.i46.17498] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
191 Ramella Munhoz R, de Mendonça Rego JF, de Celis Ferrari AR, Ignez Braghiroli M, Mendonça Bariani G, Marcelo Hoff P, Perego Costa F, Eduardo Flesch Pfiffer T, Riechelmann R. Combination of irinotecan and a platinum agent for poorly differentiated neuroendocrine carcinomas. Rare Tumors 2013;5:e39. [PMID: 24179651 DOI: 10.4081/rt.2013.e39] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 1.5] [Reference Citation Analysis]
192 Boch M, Rinke A, Rexin P, Seipelt M, Brödje D, Schober M, Gress TM, Michl P, Krug S. Paraneoplastic brainstem encephalitis in a patient with exceptionally long course of a metastasized neuroendocrine rectum neoplasm. BMC Cancer 2014;14:691. [PMID: 25244967 DOI: 10.1186/1471-2407-14-691] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 0.9] [Reference Citation Analysis]
193 Fehrenbach U, Xin S, Hartenstein A, Auer TA, Dräger F, Froböse K, Jann H, Mogl M, Amthauer H, Geisel D, Denecke T, Wiedenmann B, Penzkofer T. Automatized Hepatic Tumor Volume Analysis of Neuroendocrine Liver Metastases by Gd-EOB MRI-A Deep-Learning Model to Support Multidisciplinary Cancer Conference Decision-Making. Cancers (Basel) 2021;13:2726. [PMID: 34072865 DOI: 10.3390/cancers13112726] [Reference Citation Analysis]
194 Hughes MS, Azoury SC, Assadipour Y, Straughan DM, Trivedi AN, Lim RM, Joy G, Voellinger MT, Tang DM, Venkatesan AM. Prospective evaluation and treatment of familial carcinoid small intestine neuroendocrine tumors (SI-NETs). Surgery. 2016;159:350-356. [PMID: 26454678 DOI: 10.1016/j.surg.2015.05.041] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
195 Wei IH, Harmon CM, Arcerito M, Cheng DF, Minter RM, Simeone DM. Tumor-associated macrophages are a useful biomarker to predict recurrence after surgical resection of nonfunctional pancreatic neuroendocrine tumors. Ann Surg 2014;260:1088-94. [PMID: 25389924 DOI: 10.1097/SLA.0000000000000262] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 4.8] [Reference Citation Analysis]
196 Howe JR, Cardona K, Fraker DL, Kebebew E, Untch BR, Wang YZ, Law CH, Liu EH, Kim MK, Menda Y, Morse BG, Bergsland EK, Strosberg JR, Nakakura EK, Pommier RF. The Surgical Management of Small Bowel Neuroendocrine Tumors: Consensus Guidelines of the North American Neuroendocrine Tumor Society. Pancreas. 2017;46:715-731. [PMID: 28609357 DOI: 10.1097/mpa.0000000000000846] [Cited by in Crossref: 127] [Cited by in F6Publishing: 58] [Article Influence: 42.3] [Reference Citation Analysis]
197 Chen Y, Ohki R. p53-PHLDA3-Akt Network: The Key Regulators of Neuroendocrine Tumorigenesis. Int J Mol Sci 2020;21:E4098. [PMID: 32521808 DOI: 10.3390/ijms21114098] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
198 Cui T, Hurtig M, Elgue G, Li SC, Veronesi G, Essaghir A, Demoulin JB, Pelosi G, Alimohammadi M, Öberg K, Giandomenico V. Paraneoplastic antigen Ma2 autoantibodies as specific blood biomarkers for detection of early recurrence of small intestine neuroendocrine tumors. PLoS One 2010;5:e16010. [PMID: 21209860 DOI: 10.1371/journal.pone.0016010] [Cited by in Crossref: 31] [Cited by in F6Publishing: 36] [Article Influence: 2.8] [Reference Citation Analysis]
199 Zhang JZ, Li S, Zhu WH, Zhang DF. Microwave ablation combined with hepatectomy for treatment of neuroendocrine tumor liver metastases. World J Clin Cases 2021; 9(19): 5064-5072 [PMID: 34307557 DOI: 10.12998/wjcc.v9.i19.5064] [Reference Citation Analysis]
200 Olsen IH, Knigge U, Federspiel B, Hansen CP, Skov A, Kjær A, Langer SW. Topotecan monotherapy in heavily pretreated patients with progressive advanced stage neuroendocrine carcinomas. J Cancer 2014;5:628-32. [PMID: 25157273 DOI: 10.7150/jca.9409] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 2.7] [Reference Citation Analysis]
201 Arif AA, Kim PTW, Melck A, Churg A, Schwartz Z, Stuart HC. Pancreatic Gastrinoma, Gastrointestinal Stromal Tumor (GIST), Pheochromocytoma, and Hürthle Cell Neoplasm in a Patient with Neurofibromatosis Type 1: A Case Report and Literature Review. Am J Case Rep 2021;22:e927761. [PMID: 33452231 DOI: 10.12659/AJCR.927761] [Reference Citation Analysis]
202 Scherübl H, Jensen RT, Cadiot G, Stölzel U, Klöppel G. Neuroendocrine tumors of the small bowels are on the rise: Early aspects and management. World J Gastrointest Endosc 2010; 2(10): 325-334 [PMID: 21160582 DOI: 10.4253/wjge.v2.i10.325] [Cited by in CrossRef: 60] [Cited by in F6Publishing: 44] [Article Influence: 5.5] [Reference Citation Analysis]
203 Peters C, Lewin E, Wu T, Nakanishi Y. "Pure" High-Grade Large Cell Neuroendocrine Carcinoma Arising from Low- and High-Grade Dysplasia of the Gallbladder: Case Report and Review of the Literature. J Gastrointest Cancer 2019;50:967-71. [PMID: 30043226 DOI: 10.1007/s12029-018-0148-6] [Reference Citation Analysis]
204 Eto K, Yoshida N, Iwagami S, Iwatsuki M, Baba H. Surgical treatment for gastrointestinal neuroendocrine tumors. Ann Gastroenterol Surg 2020;4:652-9. [PMID: 33319155 DOI: 10.1002/ags3.12396] [Reference Citation Analysis]
205 Bleicher J, Lombardo S, Carbine S, Kapitonov D, Pletneva MA, Mulvihill SJ. Adrenocorticotropin Hormone Secreting Carcinoma of the Pancreas: A Case Report. J Pancreat Cancer 2019;5:22-5. [PMID: 31236541 DOI: 10.1089/pancan.2019.0004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
206 Wang Z, Jiang W, Zheng L, Yan J, Dai J, Huang C, Zhang Q, Yin Z, Gong X, Zhang Y. Consideration of Age Is Necessary for Increasing the Accuracy of the AJCC TNM Staging System of Pancreatic Neuroendocrine Tumors. Front Oncol 2019;9:906. [PMID: 31608226 DOI: 10.3389/fonc.2019.00906] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
207 Navalkele P, O’Dorisio MS, O’Dorisio TM, Zamba GK, Lynch CF. Incidence, survival, and prevalence of neuroendocrine tumors versus neuroblastoma in children and young adults: nine standard SEER registries, 1975-2006. Pediatr Blood Cancer. 2011;56:50-57. [PMID: 21108439 DOI: 10.1002/pbc.22559] [Cited by in Crossref: 43] [Cited by in F6Publishing: 37] [Article Influence: 3.9] [Reference Citation Analysis]
208 Yao JC, Guthrie KA, Moran C, Strosberg JR, Kulke MH, Chan JA, LoConte N, McWilliams RR, Wolin EM, Mattar B, McDonough S, Chen H, Blanke CD, Hochster HS. Phase III Prospective Randomized Comparison Trial of Depot Octreotide Plus Interferon Alfa-2b Versus Depot Octreotide Plus Bevacizumab in Patients With Advanced Carcinoid Tumors: SWOG S0518. J Clin Oncol. 2017;35:1695-1703. [PMID: 28384065 DOI: 10.1200/jco.2016.70.4072] [Cited by in Crossref: 65] [Cited by in F6Publishing: 45] [Article Influence: 16.3] [Reference Citation Analysis]
209 Kim HJ, Choi BG, Kim CY, Cho CK, Kim JW, Lee JH, Hur YH. Collision tumor of the ampulla of Vater - Coexistence of neuroendocrine carcinoma and adenocarcinoma: report of a case. Korean J Hepatobiliary Pancreat Surg 2013;17:186-90. [PMID: 26155238 DOI: 10.14701/kjhbps.2013.17.4.186] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
210 Xourafas D, Tavakkoli A, Clancy TE, Ashley SW. Distal pancreatic resection for neuroendocrine tumors: is laparoscopic really better than open? J Gastrointest Surg. 2015;19:831-840. [PMID: 25759075 DOI: 10.1007/s11605-015-2788-] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
211 Crabtree JS, Singleton CS, Miele L. Notch Signaling in Neuroendocrine Tumors. Front Oncol. 2016;6:94. [PMID: 27148486 DOI: 10.3389/fonc.2016.00094] [Cited by in Crossref: 34] [Cited by in F6Publishing: 34] [Article Influence: 6.8] [Reference Citation Analysis]
212 Bozkaya Y, Aydın U, Avcı A, Tuncer D, Yılmaz E. Alpha-fetoprotein Secreting Neuroendocrine Carcinoma of the Liver: a Case Report and Literature Review. J Gastrointest Cancer 2018. [PMID: 30003493 DOI: 10.1007/s12029-018-0140-1] [Reference Citation Analysis]
213 Skertich NJ, Gerard J, Poirier J, Hertl M, Pappas SG, Schadde E, Keutgen XM. Do All Abdominal Neuroendocrine Tumors Require Extended Postoperative VTE Prophylaxis? J Gastrointest Surg. 2019;23:788-793. [PMID: 30671795 DOI: 10.1007/s11605-018-04075-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
214 Kidd M, Modlin IM, Drozdov I. Gene network-based analysis identifies two potential subtypes of small intestinal neuroendocrine tumors. BMC Genomics 2014;15:595. [PMID: 25023465 DOI: 10.1186/1471-2164-15-595] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 3.6] [Reference Citation Analysis]
215 Rustgi SD, Oh A, Yang JY, Kang D, Wolin E, Kong CY, Hur C, Kim MK. Initiation of Somatostatin analogues for neuroendocrine tumor patients: a cost-effectiveness analysis. BMC Cancer 2021;21:597. [PMID: 34030646 DOI: 10.1186/s12885-021-08306-5] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
216 Zhang S, Xue Z, Wen J, Wang B, Chu X. [Surgical Resection and Prognosis of Bronchopulmonary Carcinoid]. Zhongguo Fei Ai Za Zhi 2019;22:494-9. [PMID: 31451139 DOI: 10.3779/j.issn.1009-3419.2019.08.03] [Reference Citation Analysis]
217 Patel P, Galoian K. Molecular challenges of neuroendocrine tumors. Oncol Lett. 2018;15:2715-2725. [PMID: 29456718 DOI: 10.3892/ol.2017.7680] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
218 Shen C, Dasari A, Gu D, Chu Y, Zhou S, Xu Y, Halperin D, Fu S, Yao JC, Shih YT. Costs of Cancer Care for Elderly Patients with Neuroendocrine Tumors. Pharmacoeconomics 2018;36:1005-13. [PMID: 29682693 DOI: 10.1007/s40273-018-0656-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
219 Fenoglio LM, Severini S, Ferrigno D, Gollè G, Serraino C, Bracco C, Castagna E, Brignone C, Pomero F, Migliore E, David E, Salizzoni M. Primary hepatic carcinoid: A case report and literature review. World J Gastroenterol 2009; 15(19): 2418-2422 [PMID: 19452590 DOI: 10.3748/wjg.15.2418] [Cited by in CrossRef: 43] [Cited by in F6Publishing: 29] [Article Influence: 3.6] [Reference Citation Analysis]
220 Volante M, Mete O, Pelosi G, Roden AC, Speel EJM, Uccella S. Molecular Pathology of Well-Differentiated Pulmonary and Thymic Neuroendocrine Tumors: What Do Pathologists Need to Know? Endocr Pathol 2021;32:154-68. [PMID: 33641055 DOI: 10.1007/s12022-021-09668-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
221 Barbier L, Neuzillet C, Dokmak S, Sauvanet A, Ruszniewski P, Belghiti J. Liver transplantation for metastatic neuroendocrine tumors. Hepat Oncol 2014;1:409-21. [PMID: 30190976 DOI: 10.2217/hep.14.21] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
222 Ramage JK, Ahmed A, Ardill J, Bax N, Breen DJ, Caplin ME, Corrie P, Davar J, Davies AH, Lewington V, Meyer T, Newell-Price J, Poston G, Reed N, Rockall A, Steward W, Thakker RV, Toubanakis C, Valle J, Verbeke C, Grossman AB;  UK and Ireland Neuroendocrine Tumour Society. Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs). Gut. 2012;61:6-32. [PMID: 22052063 DOI: 10.1136/gutjnl-2011-300831] [Cited by in Crossref: 353] [Cited by in F6Publishing: 279] [Article Influence: 35.3] [Reference Citation Analysis]
223 Leyden S, Kolarova T, Bouvier C, Caplin M, Conroy S, Davies P, Dureja S, Falconi M, Ferolla P, Fisher G, Goldstein G, Hicks RJ, Lawrence B, Majima Y, Metz DC, O'Toole D, Ruszniewski P, Wiedenmann B, Hollander R; International Neuroendocrine Cancer Alliance (INCA). Unmet needs in the international neuroendocrine tumor (NET) community: Assessment of major gaps from the perspective of patients, patient advocates and NET health care professionals. Int J Cancer 2020;146:1316-23. [PMID: 31509608 DOI: 10.1002/ijc.32678] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
224 Wells SA Jr. Progress in Endocrine Neoplasia. Clin Cancer Res 2016;22:4981-8. [PMID: 27742784 DOI: 10.1158/1078-0432.CCR-16-0384] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
225 Song YL, Yu R, Qiao XW, Bai CM, Lu CM, Xiao Y, Zhong DR, Chen J, Zhao YP, Zhang TP, Song TT, Gao HL, Wan YH, Shen L, Chen J, Lv B, Hao JJ, Zhang Y, Tang L, Chen YJ. Prognostic relevance of UCH-L1 and α-internexin in pancreatic neuroendocrine tumors. Sci Rep 2017;7:2205. [PMID: 28526880 DOI: 10.1038/s41598-017-02051-1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.8] [Reference Citation Analysis]
226 Maggi EC, Trillo-Tinoco J, Struckhoff AP, Vijayaraghavan J, Del Valle L, Crabtree JS. Retinoblastoma-binding protein 2 (RBP2) is frequently expressed in neuroendocrine tumors and promotes the neoplastic phenotype. Oncogenesis 2016;5:e257. [PMID: 27548814 DOI: 10.1038/oncsis.2016.58] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
227 Vinagre J, Pinheiro J, Martinho O, Reis RM, Preto J, Soares P, Lopes JM. A 30-Year Long-Term Experience in Appendix Neuroendocrine Neoplasms-Granting a Positive Outcome. Cancers (Basel) 2020;12:E1357. [PMID: 32466539 DOI: 10.3390/cancers12061357] [Reference Citation Analysis]
228 Calabrese F, Fortarezza F, Pezzuto F, Lunardi F, Comacchio G, Sbaraglia M, Pasello G, Marulli G, Dei Tos AP, Rea F. The Rarest of Rare Thymic Lesions: A 10-Year Surgical Pathology Experience. Cancers (Basel) 2021;13:4056. [PMID: 34439210 DOI: 10.3390/cancers13164056] [Reference Citation Analysis]
229 Byun J, Kim SH, Jeong HS, Rhee Y, Lee WJ, Kang CM. ACTH-producing neuroendocrine tumor of the pancreas: a case report and literature review. Ann Hepatobiliary Pancreat Surg 2017;21:61-5. [PMID: 28317048 DOI: 10.14701/ahbps.2017.21.1.61] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
230 Tidjane A, Boudjenan N, Bengueddach A, Kadri A, Ikhlef N, Benmaarouf N, Tabeti B. Pure large cell neuroendocrine carcinoma of the gallbladder, is surgical relentlessness beneficial? A case report and literature review. Int Cancer Conf J 2021;:1-7. [PMID: 33425643 DOI: 10.1007/s13691-020-00461-z] [Reference Citation Analysis]
231 Radulova-Mauersberger O, Stelzner S, Witzigmannn H. [Rectal neuroendocrine tumors: surgical therapy]. Chirurg 2016;87:292-7. [PMID: 26888707 DOI: 10.1007/s00104-016-0153-x] [Cited by in Crossref: 2] [Article Influence: 0.4] [Reference Citation Analysis]
232 Zhou H, Zhang Y, Wei X, Yang K, Tan W, Qiu Z, Li S, Chen Q, Song Y, Gao S. Racial disparities in pancreatic neuroendocrine tumors survival: a SEER study. Cancer Med 2017;6:2745-56. [PMID: 28980417 DOI: 10.1002/cam4.1220] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 4.8] [Reference Citation Analysis]
233 de Nucci G, Imperatore N, Mandelli ED, di Nuovo F, d'Urbano C, Manes G. Endoscopic ultrasound-guided radiofrequency ablation of pancreatic neuroendocrine tumors: a case series. Endosc Int Open 2020;8:E1754-8. [PMID: 33269307 DOI: 10.1055/a-1261-9359] [Reference Citation Analysis]
234 Dogeas E, Karagkounis G, Heaphy CM, Hirose K, Pawlik TM, Wolfgang CL, Meeker A, Hruban RH, Cameron JL, Choti MA. Alternative lengthening of telomeres predicts site of origin in neuroendocrine tumor liver metastases. J Am Coll Surg 2014;218:628-35. [PMID: 24655849 DOI: 10.1016/j.jamcollsurg.2014.01.001] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 3.6] [Reference Citation Analysis]
235 Bertin N, Favretto S, Pelizzo F, Mos L, Pertoldi F, Vriz O. Carcinoid Heart Disease: Starting From Heart Failure. J Investig Med High Impact Case Rep. 2017;5:2324709617713511. [PMID: 28634593 DOI: 10.1177/2324709617713511] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
236 Han B, Sun JM, Ahn JS, Park K, Ahn MJ. Clinical outcomes of atypical carcinoid tumors of the lung and thymus: 7-year experience of a rare malignancy at single institute. Med Oncol 2013;30:479. [PMID: 23377986 DOI: 10.1007/s12032-013-0479-x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
237 Fernandes I, Pacheco TR, Costa A, Santos AC, Fernandes AR, Santos M, Oliveira AG, Casimiro S, Quintela A, Fernandes A, Ramos M, Costa L. Prognostic significance of AKT/mTOR signaling in advanced neuroendocrine tumors treated with somatostatin analogs. Onco Targets Ther 2012;5:409-16. [PMID: 23226698 DOI: 10.2147/OTT.S36330] [Cited by in Crossref: 13] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
238 Park MI. Endoscopic treatment for early foregut neuroendocrine tumors. Clin Endosc 2013;46:450-5. [PMID: 24143301 DOI: 10.5946/ce.2013.46.5.450] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
239 Ohmoto A, Rokutan H, Yachida S. Pancreatic Neuroendocrine Neoplasms: Basic Biology, Current Treatment Strategies and Prospects for the Future. Int J Mol Sci 2017;18:E143. [PMID: 28098761 DOI: 10.3390/ijms18010143] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 7.8] [Reference Citation Analysis]
240 Xu JM, Wang Y, Chen YL, Jia R, Li J, Gong JF, Li J, Qi C, Hua Y, Tan CR, Wang J, Li K, Sai Y, Zhou F, Ren YX, Qing WG, Jia H, Su WG, Shen L. Sulfatinib, a novel kinase inhibitor, in patients with advanced solid tumors: results from a phase I study. Oncotarget 2017;8:42076-86. [PMID: 28159938 DOI: 10.18632/oncotarget.14942] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 6.0] [Reference Citation Analysis]
241 Rinzivillo M, De Felice I, Magi L, Annibale B, Panzuto F. Octreotide long-acting release (LAR) in combination with other therapies for treatment of neuroendocrine neoplasia: a systematic review. J Gastrointest Oncol 2021;12:845-55. [PMID: 34012671 DOI: 10.21037/jgo-20-292] [Reference Citation Analysis]
242 Shi H, Zhang Q, Han C, Zhen D, Lin R. Variability of the Ki-67 proliferation index in gastroenteropancreatic neuroendocrine neoplasms - a single-center retrospective study. BMC Endocr Disord 2018;18:51. [PMID: 30055596 DOI: 10.1186/s12902-018-0274-y] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
243 Menda Y, O'Dorisio MS, Kao S, Khanna G, Michael S, Connolly M, Babich J, O'Dorisio T, Bushnell D, Madsen M. Phase I trial of 90Y-DOTATOC therapy in children and young adults with refractory solid tumors that express somatostatin receptors. J Nucl Med 2010;51:1524-31. [PMID: 20847174 DOI: 10.2967/jnumed.110.075226] [Cited by in Crossref: 47] [Cited by in F6Publishing: 36] [Article Influence: 4.3] [Reference Citation Analysis]
244 Chen L, Zhou L, Zhang M, Shang L, Zhang P, Wang W, Fang C, Li J, Xu T, Tan H, Zhang P, Qiu M, Yu X, Jin K, Chen Y, Chen H, Lin R, Zhang Q, Shen L, Chen M, Li J, Li L, Chen J. Clinicopathological features and prognostic validity of WHO grading classification of SI-NENs. BMC Cancer 2017;17:521. [PMID: 28778195 DOI: 10.1186/s12885-017-3490-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
245 Basuroy R, Bouvier C, Ramage JK, Sissons M, Srirajaskanthan R. Delays and routes to diagnosis of neuroendocrine tumours. BMC Cancer 2018;18:1122. [PMID: 30445941 DOI: 10.1186/s12885-018-5057-3] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 5.7] [Reference Citation Analysis]
246 Manneh R, Castellano D, Caso O, Loinaz C, Jiménez J, Estenoz J, Calatayud M, Sepúlveda JM, García-Carbonero R. Well-Differentiated Grade 2, Type 3 Gastrointestinal Neuroendocrine Tumour with Bilateral Metastatic Ovarian Involvement: Report of an Unusual Case. Case Rep Oncol 2016;9:255-61. [PMID: 27239181 DOI: 10.1159/000445940] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
247 Pu N, Habib JR, Bejjani M, Yin H, Nagai M, Chen J, Kinny-Köster B, Chen Q, Zhang J, Yu J, Wu W, Lou W. The effect of primary site, functional status and treatment modality on survival in gastroenteropancreatic neuroendocrine neoplasms with synchronous liver metastasis: a US population-based study. Ann Transl Med 2021;9:329. [PMID: 33708956 DOI: 10.21037/atm-20-5348] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
248 Sugimoto M, Takagi T, Suzuki R, Konno N, Asama H, Watanabe K, Nakamura J, Kikuchi H, Waragai Y, Takasumi M, Kawana S, Hashimoto Y, Hikichi T, Ohira H. Pancreatic neuroendocrine tumor Grade 1 patients followed up without surgery: Case series. World J Clin Oncol 2017; 8(3): 293-299 [PMID: 28638801 DOI: 10.5306/wjco.v8.i3.293] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
249 Alì G, Di Stefano I, Poma AM, Ricci S, Proietti A, Davini F, Lucchi M, Melfi F, Fontanini G. Prevalence of Delta-Like Protein 3 in a Consecutive Series of Surgically Resected Lung Neuroendocrine Neoplasms. Front Oncol 2021;11:729765. [PMID: 34568063 DOI: 10.3389/fonc.2021.729765] [Reference Citation Analysis]
250 Kim HR, Lee WY, Jung KU, Chung HJ, Kim CJ, Yun HR, Cho YB, Yun SH, Kim HC, Chun HK. Transanal endoscopic microsurgery for the treatment of well-differentiated rectal neuroendocrine tumors. J Korean Soc Coloproctol. 2012;28:201-204. [PMID: 22993706 DOI: 10.3393/jksc.2012.28.4.201] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
251 Raj N, Klimstra DS, Horvat N, Zhang L, Chou JF, Capanu M, Basturk O, Do RKG, Allen PJ, Reidy-Lagunes D. O6-Methylguanine DNA Methyltransferase Status Does Not Predict Response or Resistance to Alkylating Agents in Well-Differentiated Pancreatic Neuroendocrine Tumors. Pancreas 2017;46:758-63. [PMID: 28609363 DOI: 10.1097/MPA.0000000000000842] [Cited by in Crossref: 14] [Cited by in F6Publishing: 5] [Article Influence: 4.7] [Reference Citation Analysis]
252 Al-Azzawi Y, Stein LL, Shrestha R, Bhasin D, Citron SJ, Rubin RA. Donor-Derived Hepatic Neuroendocrine Tumor: Pause Before Proceeding With Liver Retransplantation. Transplant Direct. 2016;2:e88. [PMID: 27830182 DOI: 10.1097/txd.0000000000000549] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
253 Quinn TJ, Yuan Z, Adem A, Geha R, Vrikshajanani C, Koba W, Fine E, Hughes DT, Schmid HA, Libutti SK. Pasireotide (SOM230) is effective for the treatment of pancreatic neuroendocrine tumors (PNETs) in a multiple endocrine neoplasia type 1 (MEN1) conditional knockout mouse model. Surgery 2012;152:1068-77. [PMID: 23102680 DOI: 10.1016/j.surg.2012.08.021] [Cited by in Crossref: 30] [Cited by in F6Publishing: 21] [Article Influence: 3.3] [Reference Citation Analysis]
254 Sampedro-Núñez M, Luque RM, Ramos-Levi AM, Gahete MD, Serrano-Somavilla A, Villa-Osaba A, Adrados M, Ibáñez-Costa A, Martín-Pérez E, Culler MD, Marazuela M, Castaño JP. Presence of sst5TMD4, a truncated splice variant of the somatostatin receptor subtype 5, is associated to features of increased aggressiveness in pancreatic neuroendocrine tumors. Oncotarget 2016;7:6593-608. [PMID: 26673010 DOI: 10.18632/oncotarget.6565] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 5.2] [Reference Citation Analysis]
255 Hijioka M, Ito T, Igarashi H, Fujimori N, Lee L, Nakamura T, Jensen RT, Takayanagi R. Serum chromogranin A is a useful marker for Japanese patients with pancreatic neuroendocrine tumors. Cancer Sci. 2014;105:1464-1471. [PMID: 25220535 DOI: 10.1111/cas.12533] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 3.0] [Reference Citation Analysis]
256 Zuckerman DA, Kennard RF, Roy A, Parikh PJ, Weiner AA. Outcomes and toxicity following Yttrium-90 radioembolization for hepatic metastases from neuroendocrine tumors-a single-institution experience. J Gastrointest Oncol 2019;10:118-27. [PMID: 30788167 DOI: 10.21037/jgo.2018.10.05] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 4.3] [Reference Citation Analysis]
257 Hallet J, Davis LE, Mahar AL, Law CHL, Isenberg-Grzeda E, Bubis LD, Singh S, Myrehaug S, Zhao H, Beyfuss K, Moody L, Coburn NG. Patterns of Symptoms Burden in Neuroendocrine Tumors: A Population-Based Analysis of Prospective Patient-Reported Outcomes. Oncologist 2019;24:1384-94. [PMID: 31270268 DOI: 10.1634/theoncologist.2019-0112] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
258 Kimura T, Sugimoto M, Takagi T, Suzuki R, Konno N, Asama H, Sato Y, Irie H, Nakamura J, Takasumi M, Hashimoto M, Kato T, Kofunato Y, Kimura T, Yamada S, Hashimoto Y, Marubashi S, Hikichi T, Ohira H. Pancreatic Neuroendocrine Neoplasm Invading the Entire Main Pancreatic Duct Diagnosed by a Preoperative Endoscopic Biopsy. Intern Med 2020;59:1991-6. [PMID: 32448838 DOI: 10.2169/internalmedicine.4546-20] [Reference Citation Analysis]
259 Pea A, Hruban RH, Wood LD. Genetics of pancreatic neuroendocrine tumors: implications for the clinic. Expert Rev Gastroenterol Hepatol. 2015;9:1407-1419. [PMID: 26413978 DOI: 10.1586/17474124.2015.1092383] [Cited by in Crossref: 25] [Cited by in F6Publishing: 19] [Article Influence: 4.2] [Reference Citation Analysis]
260 Wang L, Matkar S, Xie G, An C, He X, Kong X, Liu X, Hua X. BRD4 inhibitor IBET upregulates p27kip/cip protein stability in neuroendocrine tumor cells. Cancer Biol Ther 2017;18:229-36. [PMID: 28281917 DOI: 10.1080/15384047.2017.1294291] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
261 Soler A, Figueiredo AM, Castel P, Martin L, Monelli E, Angulo-Urarte A, Milà-Guasch M, Viñals F, Baselga J, Casanovas O, Graupera M. Therapeutic Benefit of Selective Inhibition of p110α PI3-Kinase in Pancreatic Neuroendocrine Tumors. Clin Cancer Res 2016;22:5805-17. [PMID: 27225693 DOI: 10.1158/1078-0432.CCR-15-3051] [Cited by in Crossref: 28] [Cited by in F6Publishing: 16] [Article Influence: 5.6] [Reference Citation Analysis]
262 Bösch F, Werner J, Angele MK, Guba MO. [Oligometastases of neuroendocrine tumors-extent of surgery]. Chirurg 2018;89:516-22. [PMID: 29876615 DOI: 10.1007/s00104-018-0644-z] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
263 Perälä J, Klemola R, Kallio R, Li C, Vihriälä I, Salmela PI, Tervonen O, Sequeiros RB. MRI-guided laser ablation of neuroendocrine tumor hepatic metastases. Acta Radiol Short Rep 2014;3:2047981613499753. [PMID: 24778794 DOI: 10.1177/2047981613499753] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
264 Chauhan A, Horn M, Magee G, Hodges K, Evers M, Arnold S, Anthony L. Immune checkpoint inhibitors in neuroendocrine tumors: A single institution experience with review of literature. Oncotarget 2018;9:8801-9. [PMID: 29507655 DOI: 10.18632/oncotarget.23753] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 4.5] [Reference Citation Analysis]
265 Lotfalizadeh E, Ronot M, Wagner M, Cros J, Couvelard A, Vullierme MP, Allaham W, Hentic O, Ruzniewski P, Vilgrain V. Prediction of pancreatic neuroendocrine tumour grade with MR imaging features: added value of diffusion-weighted imaging. Eur Radiol 2017;27:1748-59. [PMID: 27543074 DOI: 10.1007/s00330-016-4539-4] [Cited by in Crossref: 54] [Cited by in F6Publishing: 51] [Article Influence: 10.8] [Reference Citation Analysis]
266 Xiao C, Song B, Yi P, Xie Y, Li B, Lian P, Ding S, Lu Y. Deaths of colon neuroendocrine tumors are associated with increasing metastatic lymph nodes and lymph node ratio. J Gastrointest Oncol 2020;11:1146-54. [PMID: 33456989 DOI: 10.21037/jgo-20-444] [Reference Citation Analysis]
267 Windmöller BA, Greiner JFW, Förster C, Wilkens L, Mertzlufft F, Schulte Am Esch J, Kaltschmidt B, Kaltschmidt C, Beshay M. A typical carcinoid of the lung - a case report with pathological correlation and propagation of the cancer stem cell line BKZ1 with synaptophysin expression. Medicine (Baltimore) 2019;98:e18174. [PMID: 31804333 DOI: 10.1097/MD.0000000000018174] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
268 Colao A, de Nigris F, Modica R, Napoli C. Clinical Epigenetics of Neuroendocrine Tumors: The Road Ahead. Front Endocrinol (Lausanne) 2020;11:604341. [PMID: 33384663 DOI: 10.3389/fendo.2020.604341] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
269 Curtin K, Cannon-Albright LA, VanDerslice J, Yu Z, Herget KA, Thota R, Neklason DW. Associations of Tobacco and Alcohol Use with Risk of Neuroendocrine Tumors of the Small Intestine in Utah. Cancer Epidemiol Biomarkers Prev 2019;28:1998-2004. [PMID: 31558509 DOI: 10.1158/1055-9965.EPI-19-0465] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
270 Amine MM, Mohamed B, Mourad H, Majed H, Slim C, Mehdi B, Hela M, Nouri R, Rim K, Tahya B, Nabil MM. Neuroendocrine Testicular Tumors: A Systematic Review and Meta-Analysis. Curr Urol 2017;10:15-25. [PMID: 28559773 DOI: 10.1159/000447146] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
271 Ito T, Honma Y, Hijioka S, Kudo A, Fukutomi A, Nozaki A, Kimura Y, Motoi F, Isayama H, Komoto I, Hisamatsu S, Nakajima A, Shimatsu A. Phase II study of lanreotide autogel in Japanese patients with unresectable or metastatic well-differentiated neuroendocrine tumors. Invest New Drugs 2017;35:499-508. [PMID: 28470558 DOI: 10.1007/s10637-017-0466-8] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.8] [Reference Citation Analysis]
272 Quartey B. Primary Hepatic Neuroendocrine Tumor: What Do We Know Now? World J Oncol. 2011;2:209-216. [PMID: 29147250 DOI: 10.4021/wjon341w] [Cited by in Crossref: 11] [Cited by in F6Publishing: 15] [Article Influence: 1.1] [Reference Citation Analysis]
273 Xavier S, Rosa B, Cotter J. Small bowel neuroendocrine tumors: From pathophysiology to clinical approach. World J Gastrointest Pathophysiol 2016; 7(1): 117-124 [PMID: 26909234 DOI: 10.4291/wjgp.v7.i1.117] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 7] [Article Influence: 2.2] [Reference Citation Analysis]
274 Wolin EM, Hu K, Hughes G, Bouillaud E, Giannone V, Resendiz KH. Safety, tolerability, pharmacokinetics, and pharmacodynamics of a long-acting release (LAR) formulation of pasireotide (SOM230) in patients with gastroenteropancreatic neuroendocrine tumors: results from a randomized, multicenter, open-label, phase I study. Cancer Chemother Pharmacol. 2013;72:387-395. [PMID: 23765178 DOI: 10.1007/s00280-013-2202-1] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 3.5] [Reference Citation Analysis]
275 Asa SL, Mete O, Cusimano MD, McCutcheon IE, Perry A, Yamada S, Nishioka H, Casar-Borota O, Uccella S, La Rosa S, Grossman AB, Ezzat S; Attendees of the 15th Meeting of the International Pituitary Pathology Club, Istanbul October 2019. Pituitary neuroendocrine tumors: a model for neuroendocrine tumor classification. Mod Pathol 2021;34:1634-50. [PMID: 34017065 DOI: 10.1038/s41379-021-00820-y] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
276 Yuan F, Shi M, Ji J, Shi H, Zhou C, Yu Y, Liu B, Zhu Z, Zhang J. KRAS and DAXX/ATRX gene mutations are correlated with the clinicopathological features, advanced diseases, and poor prognosis in Chinese patients with pancreatic neuroendocrine tumors. Int J Biol Sci. 2014;10:957-965. [PMID: 25210493 DOI: 10.7150/ijbs.9773] [Cited by in Crossref: 38] [Cited by in F6Publishing: 37] [Article Influence: 5.4] [Reference Citation Analysis]
277 Kim MK, Warner RR, Roayaie S, Harpaz N, Ward SC, Itzkowitz S, Wisnivesky JP. Revised staging classification improves outcome prediction for small intestinal neuroendocrine tumors. J Clin Oncol 2013;31:3776-81. [PMID: 24043726 DOI: 10.1200/JCO.2013.51.1477] [Cited by in Crossref: 31] [Cited by in F6Publishing: 13] [Article Influence: 3.9] [Reference Citation Analysis]
278 Melosky B. Low Grade Neuroendocrine Tumors of the Lung. Front Oncol 2017;7:119. [PMID: 28660170 DOI: 10.3389/fonc.2017.00119] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
279 Korotaeva A, Mansorunov D, Apanovich N, Kuzevanova A, Karpukhin A. MiRNA Expression in Neuroendocrine Neoplasms of Frequent Localizations. Noncoding RNA 2021;7:38. [PMID: 34202122 DOI: 10.3390/ncrna7030038] [Reference Citation Analysis]
280 Selberherr A, Freermann S, Koperek O, Niederle MB, Riss P, Scheuba C, Niederle B. Neuroendocrine liver metastasis from the small intestine: Is surgery beneficial for survival? Orphanet J Rare Dis 2021;16:30. [PMID: 33446229 DOI: 10.1186/s13023-021-01677-9] [Reference Citation Analysis]
281 Costa F, Gumz B. Octreotide - A Review of its Use in Treating Neuroendocrine Tumours. Eur Endocrinol 2014;10:70-4. [PMID: 29872467 DOI: 10.17925/EE.2014.10.01.70] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
282 Chauhan A, Yu Q, Ray N, Farooqui Z, Huang B, Durbin EB, Tucker T, Evers M, Arnold S, Anthony LB. Global burden of neuroendocrine tumors and changing incidence in Kentucky. Oncotarget 2018;9:19245-54. [PMID: 29721198 DOI: 10.18632/oncotarget.24983] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
283 Ben Q, Zhong J, Fei J, Chen H, Yv L, Tan J, Yuan Y. Risk Factors for Sporadic Pancreatic Neuroendocrine Tumors: A Case-Control Study. Sci Rep 2016;6:36073. [PMID: 27782199 DOI: 10.1038/srep36073] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
284 Shenoy S. Primary small-bowel malignancy: update in tumor biology, markers, and management strategies. J Gastrointest Cancer. 2014;45:421-430. [PMID: 25339426 DOI: 10.1007/s12029-014-9658-z] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
285 Tirosh A, Papadakis GZ, Millo C, Hammoud D, Sadowski SM, Herscovitch P, Pacak K, Marx SJ, Yang L, Nockel P, Shell J, Green P, Keutgen XM, Patel D, Nilubol N, Kebebew E. Prognostic Utility of Total 68Ga-DOTATATE-Avid Tumor Volume in Patients With Neuroendocrine Tumors. Gastroenterology 2018;154:998-1008.e1. [PMID: 29155309 DOI: 10.1053/j.gastro.2017.11.008] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 6.0] [Reference Citation Analysis]
286 Yang W, Pham D, Vierra AT, Azam S, Gui D, Yoon JC. Pulmonary embolism as the presenting symptom and a confounder in ACTH-secreting bronchial carcinoid. Endocrinol Diabetes Metab Case Rep 2019;2019. [PMID: 31352698 DOI: 10.1530/EDM-19-0033] [Reference Citation Analysis]
287 Torniai M, Scortichini L, Tronconi F, Rubini C, Morgese F, Rinaldi S, Mazzanti P, Berardi R. Systemic treatment for lung carcinoids: from bench to bedside. Clin Transl Med 2019;8:22. [PMID: 31273555 DOI: 10.1186/s40169-019-0238-5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
288 Menda Y, O'Dorisio TM, Howe JR, Schultz M, Dillon JS, Dick D, Watkins GL, Ginader T, Bushnell DL, Sunderland JJ, Zamba GKD, Graham M, O'Dorisio MS. Localization of Unknown Primary Site with 68Ga-DOTATOC PET/CT in Patients with Metastatic Neuroendocrine Tumor. J Nucl Med. 2017;58:1054-1057. [PMID: 28153957 DOI: 10.2967/jnumed.116.180984] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.8] [Reference Citation Analysis]
289 Wu Y, Yue L, Li J, Yuan M, Chai Y. Cushing's syndrome secondary to typical pulmonary carcinoid with mutation in BCOR gene: A case report. Medicine (Baltimore) 2017;96:e7870. [PMID: 28834902 DOI: 10.1097/MD.0000000000007870] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
290 Tamura R, Kuroshima Y, Nakamura Y. Primary neuroendocrine tumor in brain. Case Rep Neurol Med 2014;2014:295253. [PMID: 25506006 DOI: 10.1155/2014/295253] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
291 Strosberg JR, Yao JC, Bajetta E, Aout M, Bakker B, Hainsworth JD, Ruszniewski PB, Van Cutsem E, Öberg K, Pavel ME. Efficacy of octreotide long-acting repeatable in neuroendocrine tumors: RADIANT-2 placebo arm post hoc analysis. Endocr Relat Cancer 2015;22:933-40. [PMID: 26373569 DOI: 10.1530/ERC-15-0314] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
292 Gibson WE, Gonzalez RS, Cates JMM, Liu E, Shi C. Hepatic micrometastases are associated with poor prognosis in patients with liver metastases from neuroendocrine tumors of the digestive tract. Hum Pathol 2018;79:109-15. [PMID: 29763717 DOI: 10.1016/j.humpath.2018.05.006] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 4.3] [Reference Citation Analysis]
293 Cives M, Strosberg J. Treatment Strategies for Metastatic Neuroendocrine Tumors of the Gastrointestinal Tract. Curr Treat Options Oncol 2017;18:14. [PMID: 28286921 DOI: 10.1007/s11864-017-0461-5] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 7.5] [Reference Citation Analysis]
294 Sze WC, Grossman AB, Goddard I, Amendra D, Shieh SC, Plowman PN, Drake WM, Akker SA, Druce MR. Sequelae and survivorship in patients treated with (131)I-MIBG therapy. Br J Cancer 2013;109:565-72. [PMID: 23860527 DOI: 10.1038/bjc.2013.365] [Cited by in Crossref: 22] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
295 Nakatake R, Ishizaki M, Matui K, Yanagimoto H, Inoue K, Kaibori M, Kawaguchi Y, Kon M. Combination therapies for primary hepatic neuroendocrine carcinoma: a case report. Surg Case Rep. 2017;3:102. [PMID: 28895097 DOI: 10.1186/s40792-017-0378-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
296 Öberg K. Medical Therapy of Gastrointestinal Neuroendocrine Tumors. Visc Med 2017;33:352-6. [PMID: 29177164 DOI: 10.1159/000475831] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
297 De Divitiis C, von Arx C, Carbone R, Tatangelo F, Di Girolamo E, Romano GM, Ottaiano A, de Lutio di Castelguidone E, Iaffaioli RV, Tafuto S. A clinical and radiological objective tumor response with somatostatin analogs (SSA) in well-differentiated neuroendocrine metastatic tumor of the ileum: a case report. Onco Targets Ther 2015;8:669-75. [PMID: 25878507 DOI: 10.2147/OTT.S71025] [Reference Citation Analysis]
298 Rindi G, Wiedenmann B. Neuroendocrine neoplasms of the gut and pancreas: new insights. Nat Rev Endocrinol. 2011;8:54-64. [PMID: 21808296 DOI: 10.1038/nrendo.2011.120] [Cited by in Crossref: 116] [Cited by in F6Publishing: 98] [Article Influence: 11.6] [Reference Citation Analysis]
299 Hindié E. The NETPET Score: Combining FDG and Somatostatin Receptor Imaging for Optimal Management of Patients with Metastatic Well-Differentiated Neuroendocrine Tumors. Theranostics 2017;7:1159-63. [PMID: 28435455 DOI: 10.7150/thno.19588] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 7.0] [Reference Citation Analysis]
300 Li Q, Chen Q, Chen J, Wang Z, Wang P, Zhao H, Zhao J. Prognostic nomogram for predicting long-term survival in bronchopulmonary carcinoid tumor patients receiving resection. Ann Transl Med 2021;9:1402. [PMID: 34733954 DOI: 10.21037/atm-21-1929] [Reference Citation Analysis]
301 Barrett JR, Rendell V, Pokrzywa C, Lopez-Aguiar AG, Cannon J, Poultsides GA, Rocha F, Crown A, Beal E, Michael Pawlik T, Fields R, Panni RZ, Smith P, Idrees K, Cho C, Beems M, Maithel S, Weber S, Erik Abbott D. Adjuvant therapy following resection of gastroenteropancreatic neuroendocrine tumors provides no recurrence or survival benefit. J Surg Oncol 2020;121:1067-73. [PMID: 32153032 DOI: 10.1002/jso.25896] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 6.0] [Reference Citation Analysis]
302 Ono K, Shiozawa E, Ohike N, Fujii T, Shibata H, Kitajima T, Fujimasa K, Okamoto N, Kawaguchi Y, Nagumo T, Tazawa S, Homma M, Yamochi-Onizuka T, Norose T, Yoshida H, Murakami M, Tate G, Takimoto M. Immunohistochemical CD73 expression status in gastrointestinal neuroendocrine neoplasms: A retrospective study of 136 patients. Oncol Lett 2018;15:2123-30. [PMID: 29434915 DOI: 10.3892/ol.2017.7569] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
303 Krieg A, Mersch S, Boeck I, Dizdar L, Weihe E, Hilal Z, Krausch M, Möhlendick B, Topp SA, Piekorz RP, Huckenbeck W, Stoecklein NH, Anlauf M, Knoefel WT. New model for gastroenteropancreatic large-cell neuroendocrine carcinoma: establishment of two clinically relevant cell lines. PLoS One 2014;9:e88713. [PMID: 24551139 DOI: 10.1371/journal.pone.0088713] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.4] [Reference Citation Analysis]
304 Lv Y, Pu N, Mao W, Chen W, Wang H, Han X, Ji Y, Zhang L, Jin D, Lou W, Xu X. Development of predictive prognostic nomogram for NECs of rectum on population-based exploration. Endocr Connect 2018:/journals/ec/aop/ec-18-0353. [PMID: 30352397 DOI: 10.1530/EC-18-0353] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
305 Giraldi L, Vecchioni A, Carioli G, Bilotta M, La Rosa S, Imperatori A, Volante M, Brizzi MP, Inzani F, Petrone G, Schinzari G, Bianchi A, Margaritora S, Alfieri S, La Vecchia C, Boccia S, Rindi G. Risk factors for pancreas and lung neuroendocrine neoplasms: a case-control study. Endocrine 2021;71:233-41. [PMID: 32869113 DOI: 10.1007/s12020-020-02464-5] [Reference Citation Analysis]
306 Lombard-Bohas C, Yao JC, Hobday T, Van Cutsem E, Wolin EM, Panneerselvam A, Stergiopoulos S, Shah MH, Capdevila J, Pommier R. Impact of prior chemotherapy use on the efficacy of everolimus in patients with advanced pancreatic neuroendocrine tumors: a subgroup analysis of the phase III RADIANT-3 trial. Pancreas 2015;44:181-9. [PMID: 25479584 DOI: 10.1097/MPA.0000000000000262] [Cited by in Crossref: 25] [Cited by in F6Publishing: 16] [Article Influence: 4.2] [Reference Citation Analysis]
307 Han X, Xu X, Ma H, Ji Y, Wang D, Kuang T, Wu W, Song B, Li G, Jin G, Lou W. Clinical relevance of different WHO grade 3 pancreatic neuroendocrine neoplasms based on morphology. Endocr Connect 2018;7:355-63. [PMID: 29472376 DOI: 10.1530/EC-17-0388] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 3.7] [Reference Citation Analysis]
308 Anthony LB, Kulke MH, Caplin ME, Bergsland E, Öberg K, Pavel M, Hörsch D, Warner RRP, O'Dorisio TM, Dillon JS, Lapuerta P, Kassler-Taub K, Jiang W. Long-Term Safety Experience with Telotristat Ethyl Across Five Clinical Studies in Patients with Carcinoid Syndrome. Oncologist 2019;24:e662-70. [PMID: 30651397 DOI: 10.1634/theoncologist.2018-0236] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
309 Gock M, Mullins CS, Harnack C, Prall F, Ramer R, Göder A, Krämer OH, Klar E, Linnebacher M. Establishment, functional and genetic characterization of a colon derived large cell neuroendocrine carcinoma cell line. World J Gastroenterol 2018; 24(33): 3749-3759 [PMID: 30197480 DOI: 10.3748/wjg.v24.i33.3749] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
310 Shah S, Gosain R, Groman A, Gosain R, Dasari A, Halfdanarson TR, Mukherjee S. Incidence and Survival Outcomes in Patients with Lung Neuroendocrine Neoplasms in the United States. Cancers (Basel) 2021;13:1753. [PMID: 33916960 DOI: 10.3390/cancers13081753] [Reference Citation Analysis]
311 Costa RDD, Kemp R, Santos JSD, Costa DAPD, Ardengh JC, Ribas-Filho JM, Ribas CAPM. THE ROLE OF CONVENTIONAL ECHOENDOSCOPY (EUS) IN THERAPEUTIC DECISIONS IN PATIENTS WITH NEUROENDOCRINE GASTROINTESTINAL TUMORS. Arq Bras Cir Dig 2020;33:e1512. [PMID: 32844878 DOI: 10.1590/0102-672020190001e1512] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
312 Keck KJ, Maxwell JE, Menda Y, Bellizzi A, Dillon J, O'Dorisio TM, Howe JR. Identification of primary tumors in patients presenting with metastatic gastroenteropancreatic neuroendocrine tumors. Surgery 2017;161:272-9. [PMID: 27863780 DOI: 10.1016/j.surg.2016.05.055] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 3.8] [Reference Citation Analysis]
313 Benslama N, Bollard J, Vercherat C, Massoma P, Roche C, Hervieu V, Peron J, Lombard-Bohas C, Scoazec JY, Walter T. Prediction of response to everolimus in neuroendocrine tumors: evaluation of clinical, biological and histological factors. Invest New Drugs 2016;34:654-62. [PMID: 27230034 DOI: 10.1007/s10637-016-0363-6] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
314 Hasic Telalovic J, Pillozzi S, Fabbri R, Laffi A, Lavacchi D, Rossi V, Dreoni L, Spada F, Fazio N, Amedei A, Iadanza E, Antonuzzo L. A Machine Learning Decision Support System (DSS) for Neuroendocrine Tumor Patients Treated with Somatostatin Analog (SSA) Therapy. Diagnostics (Basel) 2021;11:804. [PMID: 33925256 DOI: 10.3390/diagnostics11050804] [Reference Citation Analysis]
315 Tsikitis VL, Wertheim BC, Guerrero MA. Trends of incidence and survival of gastrointestinal neuroendocrine tumors in the United States: a seer analysis. J Cancer. 2012;3:292-302. [PMID: 22773933 DOI: 10.7150/jca.4502] [Cited by in Crossref: 103] [Cited by in F6Publishing: 95] [Article Influence: 11.4] [Reference Citation Analysis]
316 Chau I, Casciano R, Willet J, Wang X, Yao JC. Quality of life, resource utilisation and health economics assessment in advanced neuroendocrine tumours: a systematic review. Eur J Cancer Care (Engl). 2013;22:714-725. [PMID: 23895457 DOI: 10.1111/ecc.12085] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 3.4] [Reference Citation Analysis]
317 Kamikihara Y, Tanoue S, Kawahira M, Iwaya H, Arima S, Sasaki F, Nasu Y, Hashimoto S, Kanmura S, Higashi M, Gejima K, Ido A. A case of gallbladder neuroendocrine carcinoma diagnosed preoperatively using somatostatin receptor scintigraphy. Oncol Lett 2020;19:247-54. [PMID: 31897136 DOI: 10.3892/ol.2019.11101] [Reference Citation Analysis]
318 Krug S, Weissbach J, Blank A, Perren A, Haybaeck J, Fendrich V, Rinke A, Gress TM, Rosendahl J, Michl P. CUX1-Transcriptional Master Regulator of Tumor Progression in Pancreatic Neuroendocrine Tumors. Cancers (Basel) 2020;12:E1957. [PMID: 32707646 DOI: 10.3390/cancers12071957] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
319 Liu W, Wang L, He XD, Feng C, Chang XY, Lu ZH. Mixed large cell neuroendocrine carcinoma and adenocarcinoma of the gallbladder: a case report and brief review of the literature. World J Surg Oncol 2015;13:114. [PMID: 25890047 DOI: 10.1186/s12957-015-0533-6] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
320 Byrne RM, Pommier RF. Small Bowel and Colorectal Carcinoids. Clin Colon Rectal Surg. 2018;31:301-308. [PMID: 30186052 DOI: 10.1055/s-0038-1642054] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
321 Ito T, Igarashi H, Jensen RT. Therapy of metastatic pancreatic neuroendocrine tumors (pNETs): recent insights and advances. J Gastroenterol. 2012;47:941-960. [PMID: 22886480 DOI: 10.1007/s00535-012-0642-8] [Cited by in Crossref: 69] [Cited by in F6Publishing: 63] [Article Influence: 7.7] [Reference Citation Analysis]
322 Lu X, Lu C, Yang Y, Shi X, Wang H, Yang N, Yang K, Zhang X. Current Status and Trends in Peptide Receptor Radionuclide Therapy in the Past 20 Years (2000-2019): A Bibliometric Study. Front Pharmacol 2021;12:624534. [PMID: 33986664 DOI: 10.3389/fphar.2021.624534] [Reference Citation Analysis]
323 Gangi A, Howe JR. The Landmark Series: Neuroendocrine Tumor Liver Metastases. Ann Surg Oncol 2020;27:3270-80. [PMID: 32632880 DOI: 10.1245/s10434-020-08787-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
324 Strosberg JR, Fisher GA, Benson AB, Anthony LB, Arslan B, Gibbs JF, Greeno E, Iyer RV, Kim MK, Maples WJ, Philip PA, Wolin EM, Cherepanov D, Broder MS. Appropriateness of systemic treatments in unresectable metastatic well-differentiated pancreatic neuroendocrine tumors. World J Gastroenterol 2015; 21(8): 2450-2459 [PMID: 25741154 DOI: 10.3748/wjg.v21.i8.2450] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
325 Alwan H, La Rosa S, Andreas Kopp P, Germann S, Maspoli-Conconi M, Sempoux C, Bulliard JL. Incidence trends of lung and gastroenteropancreatic neuroendocrine neoplasms in Switzerland. Cancer Med 2020;9:9454-61. [PMID: 33078908 DOI: 10.1002/cam4.3524] [Reference Citation Analysis]
326 Saeed A, Buell JF, Kandil E. Surgical treatment of liver metastases in patients with neuroendocrine tumors. Ann Transl Med 2013;1:6. [PMID: 25332951 DOI: 10.3978/j.issn.2305-5839.2013.01.08] [Cited by in F6Publishing: 7] [Reference Citation Analysis]
327 Pavel ME, Phan AT, Wolin EM, Mirakhur B, Liyanage N, Pitman Lowenthal S, Fisher GA Jr, Vinik AI; CLARINET Study Investigators. Effect of Lanreotide Depot/Autogel on Urinary 5-Hydroxyindoleacetic Acid and Plasma Chromogranin A Biomarkers in Nonfunctional Metastatic Enteropancreatic Neuroendocrine Tumors. Oncologist 2019;24:463-74. [PMID: 30355775 DOI: 10.1634/theoncologist.2018-0217] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
328 Fujii M, Saito H, Shiode J. Rare case of a gallbladder neuroendocrine carcinoma. Clin J Gastroenterol. 2019;12:38-45. [PMID: 30003469 DOI: 10.1007/s12328-018-0883-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
329 Chakrabarti D, Qayoom S, Ghosh A, Gupta R. Neuroendocrine carcinoma of the gall bladder in a young lady presenting with upper abdominal heaviness: a common complaint and a rare diagnosis. BMJ Case Rep 2019;12:e229684. [PMID: 30954965 DOI: 10.1136/bcr-2019-229684] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
330 Al-Kurd A, Chapchay K, Grozinsky-Glasberg S, Mazeh H. Laparoscopic resection of pancreatic neuroendocrine tumors. World J Gastroenterol 2014; 20(17): 4908-4916 [PMID: 24803802 DOI: 10.3748/wjg.v20.i17.4908] [Cited by in CrossRef: 22] [Cited by in F6Publishing: 20] [Article Influence: 3.1] [Reference Citation Analysis]
331 Abreu P, Gorgen A, Oldani G, Hibi T, Sapisochin G. Recent advances in liver transplantation for cancer: The future of transplant oncology. JHEP Rep 2019;1:377-91. [PMID: 32039389 DOI: 10.1016/j.jhepr.2019.07.004] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 7.0] [Reference Citation Analysis]
332 Bison SM, Konijnenberg MW, Melis M, Pool SE, Bernsen MR, Teunissen JJ, Kwekkeboom DJ, de Jong M. Peptide receptor radionuclide therapy using radiolabeled somatostatin analogs: focus on future developments. Clin Transl Imaging 2014;2:55-66. [PMID: 24765618 DOI: 10.1007/s40336-014-0054-2] [Cited by in Crossref: 43] [Cited by in F6Publishing: 34] [Article Influence: 6.1] [Reference Citation Analysis]
333 Lv Y, Han X, Xu XF, Ji Y, Zhou YH, Sun HC, Zhou J, Fan J, Lou WH, Huang C. Risk factors affecting prognosis in metachronous liver metastases from WHO classification G1 and G2 gastroenteropancreatic neuroendocrine tumors after initial R0 surgical resection. BMC Cancer 2019;19:335. [PMID: 30961559 DOI: 10.1186/s12885-019-5457-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
334 Momeni M, Kolev V, Costin D, Mizrachi HH, Chuang L, Warner RR, Gretz HF. Primary pulmonary carcinoid tumor with metastasis to endometrial polyp. Int J Surg Case Rep 2013;4:91-3. [PMID: 23127865 DOI: 10.1016/j.ijscr.2012.10.007] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
335 Gosain R, Ball S, Rana N, Groman A, Gage-Bouchard E, Dasari A, Mukherjee S. Geographic and demographic features of neuroendocrine tumors in the United States of America: A population-based study. Cancer 2020;126:792-9. [PMID: 31714595 DOI: 10.1002/cncr.32607] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
336 Aversa JG, De Abreu FB, Yano S, Xi L, Hadley DW, Manoli I, Raffeld M, Sadowski SM, Nilubol N. The first pancreatic neuroendocrine tumor in Li-Fraumeni syndrome: a case report. BMC Cancer 2020;20:256. [PMID: 32228502 DOI: 10.1186/s12885-020-06723-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
337 Ferrata M, Schad A, Zimmer S, Musholt TJ, Bahr K, Kuenzel J, Becker S, Springer E, Roth W, Weber MM, Fottner C. PD-L1 Expression and Immune Cell Infiltration in Gastroenteropancreatic (GEP) and Non-GEP Neuroendocrine Neoplasms With High Proliferative Activity. Front Oncol 2019;9:343. [PMID: 31134150 DOI: 10.3389/fonc.2019.00343] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 10.0] [Reference Citation Analysis]
338 Ahn HK, Choi JY, Kim KM, Kim H, Choi SH, Park SH, Park JO, Lim HY, Kang WK, Lee J. Phase II study of pazopanib monotherapy in metastatic gastroenteropancreatic neuroendocrine tumours. Br J Cancer. 2013;109:1414-1419. [PMID: 23989950 DOI: 10.1038/bjc.2013.470] [Cited by in Crossref: 58] [Cited by in F6Publishing: 53] [Article Influence: 7.3] [Reference Citation Analysis]
339 Paragliola RM, Prete A, Papi G, Torino F, Corsello A, Pontecorvi A, Corsello SM. Clinical utility of lanreotide Autogel® in gastroenteropancreatic neuroendocrine tumors. Drug Des Devel Ther 2016;10:3459-70. [PMID: 27822010 DOI: 10.2147/DDDT.S76732] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
340 Coriat R, Walter T, Terris B, Couvelard A, Ruszniewski P. Gastroenteropancreatic Well-Differentiated Grade 3 Neuroendocrine Tumors: Review and Position Statement. Oncologist. 2016;21:1191-1199. [PMID: 27401895 DOI: 10.1634/theoncologist.2015-0476] [Cited by in Crossref: 70] [Cited by in F6Publishing: 63] [Article Influence: 14.0] [Reference Citation Analysis]
341 Chan JA, Kulke MH. New treatment options for patients with advanced neuroendocrine tumors. Curr Treat Options Oncol 2011;12:136-48. [PMID: 21437592 DOI: 10.1007/s11864-011-0148-2] [Cited by in Crossref: 37] [Cited by in F6Publishing: 28] [Article Influence: 3.7] [Reference Citation Analysis]
342 Yamaguchi T, Takahashi K, Yamada K, Bando H, Baba H, Ito M, Funahashi K, Ueno H, Fujita S, Hasegawa S, Sakai Y, Sugihara K. A nationwide, multi-institutional collaborative retrospective study of colorectal neuroendocrine tumors in Japan. Ann Gastroenterol Surg 2021;5:215-20. [PMID: 33860141 DOI: 10.1002/ags3.12403] [Reference Citation Analysis]
343 Hijioka S, Morizane C, Ikeda M, Ishii H, Okusaka T, Furuse J. Current status of medical treatment for gastroenteropancreatic neuroendocrine neoplasms and future perspectives. Jpn J Clin Oncol 2021;51:1185-96. [PMID: 34038547 DOI: 10.1093/jjco/hyab076] [Reference Citation Analysis]
344 Goksu SY, Ozer M, Kazmi SMA, Sanford NN, Aguilera TA, Ahn C, Hsiehchen D, Sanjeevaiah A, Khosama L, Bleeker J, Atiq M, Beg MS. Distinct Clinical Characteristics in Young-Onset Pancreatic Neuroendocrine Tumor. Cancers (Basel) 2020;12:E2501. [PMID: 32899271 DOI: 10.3390/cancers12092501] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
345 Abdel-Rahman O. Vascular endothelial growth factor (VEGF) pathway and neuroendocrine neoplasms (NENs): prognostic and therapeutic considerations. Tumour Biol 2014;35:10615-25. [PMID: 25230786 DOI: 10.1007/s13277-014-2612-7] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
346 Di Martino M, Saba L, Bosco S, Rossi M, Miles KA, Di Miscio R, Lombardo CV, Tamponi E, Piga M, Catalano C. Hepatocellular carcinoma (HCC) in non-cirrhotic liver: clinical, radiological and pathological findings. Eur Radiol 2014;24:1446-54. [DOI: 10.1007/s00330-014-3173-2] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 2.4] [Reference Citation Analysis]
347 Mahmud N, Tomizawa Y, Stashek K, Katona BW, Ginsberg GG, Metz DC. Endoscopic Resection of Duodenal Carcinoid Tumors: A Single-Center Comparison Between Simple Polypectomy and Endoscopic Mucosal Resection. Pancreas 2019;48:60-5. [PMID: 30451799 DOI: 10.1097/MPA.0000000000001197] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
348 Rao X, Chen W, Li J, Peng G, Wu G, Zhou R, Ding Q. Primary thymic atypical carcinoid with rare multiple bone metastasis: A case report and literature review. Mol Clin Oncol 2021;14:78. [PMID: 33758659 DOI: 10.3892/mco.2021.2240] [Reference Citation Analysis]
349 Kulke MH, Benson AB, Dasari A, Huynh L, Cai B, Totev T, Roesner N, Duh MS, Neary MP, Maurer VE, Shih BE, Dagohoy CG, Chan J, Bergsland EK. Real-World Treatment Patterns and Clinical Outcomes in Advanced Gastrointestinal Neuroendocrine Tumors (GI NET): A Multicenter Retrospective Chart Review Study. Oncologist 2019;24:1056-65. [PMID: 30606883 DOI: 10.1634/theoncologist.2018-0519] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
350 Merath K, Bagante F, Beal EW, Lopez-Aguiar AG, Poultsides G, Makris E, Rocha F, Kanji Z, Weber S, Fisher A, Fields R, Krasnick BA, Idrees K, Smith PM, Cho C, Beems M, Schmidt CR, Dillhoff M, Maithel SK, Pawlik TM. Nomogram predicting the risk of recurrence after curative-intent resection of primary non-metastatic gastrointestinal neuroendocrine tumors: An analysis of the U.S. Neuroendocrine Tumor Study Group. J Surg Oncol. 2018;117:868-878. [PMID: 29448303 DOI: 10.1002/jso.24985] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 6.0] [Reference Citation Analysis]
351 Lombard-Bohas C, Yao JC, Hobday T, Van Cutsem E, Wolin EM, Panneerselvam A, Stergiopoulos S, Shah MH, Capdevila J, Pommier R. Impact of prior chemotherapy use on the efficacy of everolimus in patients with advanced pancreatic neuroendocrine tumors: a subgroup analysis of the phase III RADIANT-3 trial. Pancreas. 2015;44:181-189. [PMID: 25479584 DOI: 10.1097/mpa] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
352 Bundschuh RA, Habacha B, Lütje S, Essler M. Therapy of Patients with Neuroendocrine Neoplasia-Evidence-Based Approaches and New Horizons. J Clin Med 2019;8:E1474. [PMID: 31527438 DOI: 10.3390/jcm8091474] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
353 Koshy AA, Gordon IO, Van Ha TG, Kaplan EL, Philipson LH. Metastatic Insulinoma Following Resection of Nonsecreting Pancreatic Islet Cell Tumor: A Case Report and Review of the Literature. J Investig Med High Impact Case Rep 2013;1:2324709612473274. [PMID: 26425568 DOI: 10.1177/2324709612473274] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
354 Jedrych J, Busam K, Klimstra DS, Pulitzer M. Cutaneous metastases as an initial manifestation of visceral well-differentiated neuroendocrine tumor: a report of four cases and a review of literature. J Cutan Pathol. 2014;41:113-122. [PMID: 24218988 DOI: 10.1111/cup.12263] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.5] [Reference Citation Analysis]
355 Raman V, Jawitz OK, Yang CJ, Tong BC, D'Amico TA, Berry MF, Harpole DH Jr. Adjuvant Therapy for Patients With Early Large Cell Lung Neuroendocrine Cancer: A National Analysis. Ann Thorac Surg 2019;108:377-83. [PMID: 31004586 DOI: 10.1016/j.athoracsur.2019.03.053] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
356 Ohki R, Saito K, Chen Y, Kawase T, Hiraoka N, Saigawa R, Minegishi M, Aita Y, Yanai G, Shimizu H, Yachida S, Sakata N, Doi R, Kosuge T, Shimada K, Tycko B, Tsukada T, Kanai Y, Sumi S, Namiki H, Taya Y, Shibata T, Nakagama H. PHLDA3 is a novel tumor suppressor of pancreatic neuroendocrine tumors. Proc Natl Acad Sci U S A 2014;111:E2404-13. [PMID: 24912192 DOI: 10.1073/pnas.1319962111] [Cited by in Crossref: 61] [Cited by in F6Publishing: 59] [Article Influence: 8.7] [Reference Citation Analysis]
357 Jiao X, Li Y, Wang H, Liu S, Zhang D, Zhou Y. Clinicopathological features and survival analysis of gastroenteropancreatic neuroendocrine neoplasms: a retrospective study in a single center of China. Chin J Cancer Res 2015;27:258-66. [PMID: 26157322 DOI: 10.3978/j.issn.1000-9604.2015.06.04] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
358 Lim KHJ, Valle JW, Lamarca A. Unusual skull base metastasis from neuroendocrine tumor: a case report. J Med Case Rep 2019;13:273. [PMID: 31466520 DOI: 10.1186/s13256-019-2214-5] [Reference Citation Analysis]
359 Amin SV, Kumaran A, Bharatnur S, Vasudeva A, Udupa K, Venkateshiah DB, Bhat ST. Neuroendocrine Cancer of Rectum Metastasizing to Ovary. Case Rep Oncol Med 2016;2016:7149821. [PMID: 27293931 DOI: 10.1155/2016/7149821] [Reference Citation Analysis]
360 Nikou GC, Pazaitou-Panayiotou K, Dimitroulopoulos D, Alexandrakis G, Papakostas P, Vaslamatzis M, Kaldrymidis P, Markussis V, Koumarianou A; “G-NET-Registry” investigators. Results of a prospective multicenter neuroendocrine tumor registry reporting on clinicopathologic characteristics of Greek patients. BMC Endocr Disord 2016;16:8. [PMID: 26872616 DOI: 10.1186/s12902-016-0089-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
361 Jin K, Luo G, Xu J, Zhang B, Liu C, Ji S, Liu L, Long J, Ni Q, Yu X. Clinical outcomes and prognostic factors of resected pancreatic neuroendocrine neoplasms: A single-center experience in China. Oncol Lett 2017;13:3163-8. [PMID: 28521422 DOI: 10.3892/ol.2017.5834] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
362 Majala S, Seppänen H, Kemppainen J, Sundström J, Schalin-Jäntti C, Gullichsen R, Schildt J, Mustonen H, Vesterinen T, Arola J, Kauhanen S. Prediction of the aggressiveness of non-functional pancreatic neuroendocrine tumors based on the dual-tracer PET/CT. EJNMMI Res 2019;9:116. [PMID: 31872324 DOI: 10.1186/s13550-019-0585-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
363 Wang Y, Huang K, Chen J, Luo Y, Zhang Y, Jia Y, Xu L, Chen M, Huang B, Ni D, Li ZP, Feng ST. Combined Volumetric and Density Analyses of Contrast-Enhanced CT Imaging to Assess Drug Therapy Response in Gastroenteropancreatic Neuroendocrine Diffuse Liver Metastasis. Contrast Media Mol Imaging 2018;2018:6037273. [PMID: 30510495 DOI: 10.1155/2018/6037273] [Reference Citation Analysis]
364 Kose E, Kahramangil B, Aydin H, Donmez M, Takahashi H, Aucejo F, Siperstein A, Berber E. Outcomes of laparoscopic tumor ablation for neuroendocrine liver metastases: a 20-year experience. Surg Endosc. 2020;34:249-256. [PMID: 30945061 DOI: 10.1007/s00464-019-06759-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
365 Mahajan S, O'Donoghue J, Weber W, Bodei L. Integrating Early Rapid Post-Peptide Receptor Radionuclide Therapy Quality Assurance Scan into the Outpatient Setting. J Nucl Med Radiat Ther 2019;10:395. [PMID: 31057988 DOI: 10.4172/2155-9619.1000395] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
366 Wolin EM, Jarzab B, Eriksson B, Walter T, Toumpanakis C, Morse MA, Tomassetti P, Weber MM, Fogelman DR, Ramage J. Phase III study of pasireotide long-acting release in patients with metastatic neuroendocrine tumors and carcinoid symptoms refractory to available somatostatin analogues. Drug Des Devel Ther. 2015;9:5075-5086. [PMID: 26366058 DOI: 10.2147/dddt.s84177] [Cited by in Crossref: 105] [Cited by in F6Publishing: 52] [Article Influence: 17.5] [Reference Citation Analysis]
367 Jang S, Janssen A, Aburjania Z, Robers MB, Harrison A, Dammalapati A, Cheng YQ, Chen H, Jaskula-Sztul R. Histone deacetylase inhibitor thailandepsin-A activates Notch signaling and suppresses neuroendocrine cancer cell growth in vivo. Oncotarget 2017;8:70828-40. [PMID: 29050323 DOI: 10.18632/oncotarget.19993] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
368 Haugvik SP, Gorunova L, Haugom L, Eibak AM, Gladhaug IP, Heim S, Micci F. Loss of 11p11 is a frequent and early event in sporadic nonfunctioning pancreatic neuroendocrine neoplasms. Oncol Rep 2014;32:906-12. [PMID: 25018013 DOI: 10.3892/or.2014.3328] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
369 Ito T, Sasano H, Tanaka M, Osamura RY, Sasaki I, Kimura W, Takano K, Obara T, Ishibashi M, Nakao K, Doi R, Shimatsu A, Nishida T, Komoto I, Hirata Y, Nakamura K, Igarashi H, Jensen RT, Wiedenmann B, Imamura M. Epidemiological study of gastroenteropancreatic neuroendocrine tumors in Japan. J Gastroenterol 2010;45:234-43. [PMID: 20058030 DOI: 10.1007/s00535-009-0194-8] [Cited by in Crossref: 246] [Cited by in F6Publishing: 177] [Article Influence: 22.4] [Reference Citation Analysis]
370 Ambrosini V, Campana D, Nanni C, Cambioli S, Tomassetti P, Rubello D, Fanti S. Is ⁶⁸Ga-DOTA-NOC PET/CT indicated in patients with clinical, biochemical or radiological suspicion of neuroendocrine tumour? Eur J Nucl Med Mol Imaging 2012;39:1278-83. [PMID: 22584487 DOI: 10.1007/s00259-012-2146-4] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 2.6] [Reference Citation Analysis]
371 Pan J, Bao Q, Enders G. The Altered Metabolic Molecular Signatures Contribute to the RAD001 Resistance in Gastric Neuroendocrine Tumor. Front Oncol 2020;10:546. [PMID: 32373532 DOI: 10.3389/fonc.2020.00546] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
372 Tirosh A, Mukherjee S, Lack J, Gara SK, Wang S, Quezado MM, Keutgen XM, Wu X, Cam M, Kumar S, Patel D, Nilubol N, Tyagi MV, Kebebew E. Distinct genome-wide methylation patterns in sporadic and hereditary nonfunctioning pancreatic neuroendocrine tumors. Cancer 2019;125:1247-57. [PMID: 30620390 DOI: 10.1002/cncr.31930] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 9.0] [Reference Citation Analysis]
373 Lee SY, Cheow PC, Teo JY, Ooi LL. Surgical treatment of neuroendocrine liver metastases. Int J Hepatol 2012;2012:146590. [PMID: 22319650 DOI: 10.1155/2012/146590] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
374 Huang HF, Jin PP, Yang HJ, Zhang CJ, Zhang X, Wang JS, Yu JJ, Zhang B, Zhang Y, Hu QD. Primary Hepatic Neuroendocrine Tumor Mimicking Ruptured Hepatocellular Carcinoma with AFP Elevation: A Case Report and Literature Review. Onco Targets Ther 2020;13:975-9. [PMID: 32099400 DOI: 10.2147/OTT.S236728] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
375 Guccione L, Gough K, Drosdowsky A, Fisher K, Price T, Pavlakis N, Khasraw M, Wyld D, Ransom D, Kong G, Rogers M, Leyden S, Leyden J, Michael M, Schofield P. Defining the Supportive Care Needs and Psychological Morbidity of Patients With Functioning Versus Nonfunctioning Neuroendocrine Tumors: Protocol for a Phase 1 Trial of a Nurse-Led Online and Phone-Based Intervention. JMIR Res Protoc 2019;8:e14361. [PMID: 31793892 DOI: 10.2196/14361] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
376 Lea D, Gudlaugsson EG, Skaland I, Lillesand M, Søreide K, Søreide JA. Digital Image Analysis of the Proliferation Markers Ki67 and Phosphohistone H3 in Gastroenteropancreatic Neuroendocrine Neoplasms: Accuracy of Grading Compared With Routine Manual Hot Spot Evaluation of the Ki67 Index. Appl Immunohistochem Mol Morphol 2021;29:499-505. [PMID: 33758143 DOI: 10.1097/PAI.0000000000000934] [Reference Citation Analysis]
377 Tong Z, Liu L, Zheng Y, Jiang W, Zhao P, Fang W, Wang W. Predictive value of preoperative peripheral blood neutrophil/lymphocyte ratio for lymph node metastasis in patients of resectable pancreatic neuroendocrine tumors: a nomogram-based study. World J Surg Oncol 2017;15:108. [PMID: 28558772 DOI: 10.1186/s12957-017-1169-5] [Cited by in Crossref: 21] [Cited by in F6Publishing: 25] [Article Influence: 5.3] [Reference Citation Analysis]
378 He H, Guo W, Song P, Liu L, Zhang G, Wang Y, Qiu B, Tan F, Xue Q, Gao S. Preoperative systemic immune-inflammation index and prognostic nutritional index predict prognosis of patients with pulmonary neuroendocrine tumors after surgical resection. Ann Transl Med 2020;8:630. [PMID: 32566567 DOI: 10.21037/atm-19-4476] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
379 Rendell MS. The journey from gene knockout to clinical medicine: telotristat and sotagliflozin. Drug Des Devel Ther 2019;13:817-24. [PMID: 30880915 DOI: 10.2147/DDDT.S144556] [Cited by in Crossref: 5] [Article Influence: 2.5] [Reference Citation Analysis]
380 Cha JW, Yang M, Mo A. Large cell neuroendocrine carcinoma in the unusual location of the descending colon. Radiol Case Rep 2020;15:1841-4. [PMID: 32817774 DOI: 10.1016/j.radcr.2020.07.045] [Reference Citation Analysis]
381 Köseoğlu H, Duzenli T, Sezikli M. Gastric neuroendocrine neoplasms: A review. World J Clin Cases 2021; 9(27): 7973-7985 [PMID: 34621854 DOI: 10.12998/wjcc.v9.i27.7973] [Reference Citation Analysis]
382 Huang SF, Kuo IM, Lee CW, Pan KT, Chen TC, Lin CJ, Hwang TL, Yu MC. Comparison study of gastrinomas between gastric and non-gastric origins. World J Surg Oncol. 2015;13:202. [PMID: 26077245 DOI: 10.1186/s12957-015-0614-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
383 Wang XY, Chai NL, Linghu EQ, Qiu ST, Li LS, Zou JL, Xiang JY, Li XX. The outcomes of modified endoscopic mucosal resection and endoscopic submucosal dissection for the treatment of rectal neuroendocrine tumors and the value of endoscopic morphology classification in endoscopic resection. BMC Gastroenterol 2020;20:200. [PMID: 32586282 DOI: 10.1186/s12876-020-01340-w] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
384 Sigel C, Reidy-Lagunes D, Lin O, Basturk O, Aggarwal G, Klimstra DS, Tang L. Cytological features contributing to the misclassification of pancreatic neuroendocrine tumors. J Am Soc Cytopathol 2016;5:266-76. [PMID: 31042503 DOI: 10.1016/j.jasc.2016.01.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
385 Rindi G, Petrone G, Inzani F. The 2010 WHO classification of digestive neuroendocrine neoplasms: a critical appraisal four years after its introduction. Endocr Pathol. 2014;25:186-192. [PMID: 24699927 DOI: 10.1007/s12022-014-9313-z] [Cited by in Crossref: 100] [Cited by in F6Publishing: 89] [Article Influence: 16.7] [Reference Citation Analysis]
386 Al-Efraij K, Aljama MA, Kennecke HF. Association of dose escalation of octreotide long-acting release on clinical symptoms and tumor markers and response among patients with neuroendocrine tumors. Cancer Med 2015;4:864-70. [PMID: 25727756 DOI: 10.1002/cam4.435] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 4.0] [Reference Citation Analysis]
387 Chen JX, Lin Y, Meng YL, Zhao AX, Huang XJ, Liang R, Li YQ, Liu ZH. Predicting the Survival Probability of Neuroendocrine Tumor Populations: Developing and Evaluating a New Predictive Nomogram. Biomed Res Int 2021;2021:9126351. [PMID: 33575356 DOI: 10.1155/2021/9126351] [Reference Citation Analysis]
388 Dasari A, Bergsland EK, Benson AB, Cai B, Huynh L, Totev T, Shea J, Duh MS, Neary MP, Dagohoy CG, Shih BE, Maurer VE, Chan J, Kulke MH. Treatment Patterns and Clinical Outcomes in Advanced Lung Neuroendocrine Tumors in Real-World Settings: A Multicenter Retrospective Chart Review Study. Oncologist 2019;24:1066-75. [PMID: 30610008 DOI: 10.1634/theoncologist.2018-0520] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
389 Yao JC, Lombard-Bohas C, Baudin E, Kvols LK, Rougier P, Ruszniewski P, Hoosen S, St Peter J, Haas T, Lebwohl D. Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial. J Clin Oncol. 2010;28:69-76. [PMID: 19933912 DOI: 10.1200/jco.2009.24.2669] [Cited by in Crossref: 460] [Cited by in F6Publishing: 180] [Article Influence: 38.3] [Reference Citation Analysis]
390 Do MY, Jang SI, Kang HP, Kim EJ, Lee KJ, Park GE, Lee SJ, Lee DK, Woo SM, Cho JH. Comparison of the Clinical Features and Outcomes of Gallbladder Neuroendocrine Carcinoma with Those of Adenocarcinoma: A Propensity Score-Matched Analysis. Cancers (Basel) 2021;13:4713. [PMID: 34572940 DOI: 10.3390/cancers13184713] [Reference Citation Analysis]
391 Walter D, Harter PN, Battke F, Winkelmann R, Schneider M, Holzer K, Koch C, Bojunga J, Zeuzem S, Hansmann ML, Peveling-Oberhag J, Waidmann O. Genetic heterogeneity of primary lesion and metastasis in small intestine neuroendocrine tumors. Sci Rep 2018;8:3811. [PMID: 29491456 DOI: 10.1038/s41598-018-22115-0] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 6.0] [Reference Citation Analysis]
392 Zhang L, Yang Z, Chen Q, Li M, Zhu X, Wan D, Xie H, Zheng S. Mixed adenoendocrine carcinoma in the extrahepatic biliary tract: A case report and literature review. Oncol Lett 2019;18:1585-96. [PMID: 31423226 DOI: 10.3892/ol.2019.10502] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
393 Umesalma S, Kaemmer CA, Kohlmeyer JL, Letney B, Schab AM, Reilly JA, Sheehy RM, Hagen J, Tiwari N, Zhan F, Leidinger MR, O'Dorisio TM, Dillon J, Merrill RA, Meyerholz DK, Perl AL, Brown BJ, Braun TA, Scott AT, Ginader T, Taghiyev AF, Zamba GK, Howe JR, Strack S, Bellizzi AM, Narla G, Darbro BW, Quelle FW, Quelle DE. RABL6A inhibits tumor-suppressive PP2A/AKT signaling to drive pancreatic neuroendocrine tumor growth. J Clin Invest 2019;129:1641-53. [PMID: 30721156 DOI: 10.1172/JCI123049] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 6.5] [Reference Citation Analysis]
394 Inoue Y, Horie H, Homma Y, Sadatomo A, Tahara M, Koinuma K, Yamaguchi H, Mimura T, Kihara A, Lefor AK, Sata N. Goblet cell carcinoid of the rectum: a case report. Surg Case Rep 2020;6:174. [PMID: 32683504 DOI: 10.1186/s40792-020-00937-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
395 Chan JA, Kulke MH. Progress in the treatment of neuroendocrine tumors. Curr Oncol Rep 2009;11:193-9. [PMID: 19336011 DOI: 10.1007/s11912-009-0028-0] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 2.1] [Reference Citation Analysis]
396 杨洋, 李良庆, 郑建涛, 陈群, 王密. 胃神经内分泌癌的临床诊治及预后情况. 世界华人消化杂志 2014; 22(25): 3831-3834 [DOI: 10.11569/wcjd.v22.i25.3831] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
397 Zhang J, Zeng M. Cardiac metastasis of neuroendocrine tumor of the thymus diagnosed by cardiac magnetic resonance T1 mapping: a case report. J Int Med Res 2020;48:300060520931678. [PMID: 32558603 DOI: 10.1177/0300060520931678] [Reference Citation Analysis]
398 Zeichner SB, Cusnir M, Francavilla M, Hirzel A. Typical bronchial carcinoid metastasizing to the brain: a case presentation. Case Rep Oncol 2011;4:602-10. [PMID: 22291640 DOI: 10.1159/000335557] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
399 Gu P, Wu J, Newman E, Muggia F. Treatment of liver metastases in patients with neuroendocrine tumors of gastroesophageal and pancreatic origin. Int J Hepatol 2012;2012:131659. [PMID: 22518318 DOI: 10.1155/2012/131659] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
400 Kanetkar AV, Patkar S, Khobragade KH, Ostwal V, Ramaswamy A, Goel M. Neuroendocrine Carcinoma of Gallbladder: A Step Beyond Palliative Therapy, Experience of 25 Cases. J Gastrointest Cancer 2019;50:298-303. [PMID: 29435905 DOI: 10.1007/s12029-018-0070-y] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
401 Chen RW, Qiu MJ, Chen Y, Zhang T, He XX, Li Y, Sun WJ, Xie T, Yang SL, Hu JL. Analysis of the clinicopathological features and prognostic factors of primary hepatic neuroendocrine tumors. Oncol Lett 2018;15:8604-10. [PMID: 30065788 DOI: 10.3892/ol.2018.8413] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
402 Peri M, Botteri E, Pisa E, De Marinis F, Ungaro A, Spada F, Grana CM, Gasparri R, Spaggiari L, Romentz N, Badalamenti G, Russo A, Fazio N. A single-institution retrospective analysis of metachronous and synchronous metastatic bronchial neuroendocrine tumors. J Thorac Dis 2018;10:3928-39. [PMID: 30174834 DOI: 10.21037/jtd.2018.06.78] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
403 Aamir MA, Sahebally SM, Gyorffy H, Aremu M. Extra-pulmonary primary small-cell neuroendocrine carcinoma arising from the duodenum: rare tumor, unusual location. Clin Case Rep 2017;5:2117-20. [PMID: 29225868 DOI: 10.1002/ccr3.1267] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
404 Wagner M, Samaha D, Khoury H, O'Neil WM, Lavoie L, Bennetts L, Badgley D, Gabriel S, Berthon A, Dolan J, Kulke MH, Goetghebeur M. Development of a Framework Based on Reflective MCDA to Support Patient-Clinician Shared Decision-Making: The Case of the Management of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET) in the United States. Adv Ther 2018;35:81-99. [PMID: 29270780 DOI: 10.1007/s12325-017-0653-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
405 Chiramel J, Almond R, Slagter A, Khan A, Wang X, Lim KHJ, Frizziero M, Chakrabarty B, Minicozzi A, Lamarca A, Mansoor W, Hubner RA, Valle JW, McNamara MG. Prognostic importance of lymph node yield after curative resection of gastroenteropancreatic neuroendocrine tumours. World J Clin Oncol 2020; 11(4): 205-216 [PMID: 32355642 DOI: 10.5306/wjco.v11.i4.205] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
406 Habbe N, Fendrich V, Heverhagen A, Ramaswamy A, Bartsch DK. Outcome of surgery for ileojejunal neuroendocrine tumors. Surg Today 2013;43:1168-74. [PMID: 23143168 DOI: 10.1007/s00595-012-0408-1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
407 Scott AT, Howe JR. Management of Small Bowel Neuroendocrine Tumors. J Oncol Pract. 2018;14: 471-482. [PMID: 30096273 DOI: 10.1200/jop.18.00135] [Cited by in Crossref: 20] [Cited by in F6Publishing: 12] [Article Influence: 10.0] [Reference Citation Analysis]
408 Langer SW, Ringholm L, Dali CI, Petersen RH, Rasmussen ÅK, Gerdes AM, Federspiel B, Knigge UP. Cowden Syndrome and Concomitant Pulmonary Neuroendocrine Tumor: A Presentation of Two Cases. Case Rep Med 2015;2015:265786. [PMID: 26798346 DOI: 10.1155/2015/265786] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
409 Kaifi JT, Kayser G, Ruf J, Passlick B. The Diagnosis and Treatment of Bronchopulmonary Carcinoid. Dtsch Arztebl Int 2015;112:479-85. [PMID: 26214234 DOI: 10.3238/arztebl.2015.0479] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
410 Gabrielsen J, Girone G, Bennett B, Jung A. Long-Acting Somatostatin Analogue Safety Monitoring Protocol for Outpatients With Neuroendocrine Tumors. J Adv Pract Oncol 2019;10:646-59. [PMID: 33391850 DOI: 10.6004/jadpro.2019.10.7.2] [Reference Citation Analysis]
411 Sposito C, Droz Dit Busset M, Citterio D, Bongini M, Mazzaferro V. The place of liver transplantation in the treatment of hepatic metastases from neuroendocrine tumors: Pros and cons. Rev Endocr Metab Disord 2017;18:473-83. [PMID: 29359266 DOI: 10.1007/s11154-017-9439-7] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 4.3] [Reference Citation Analysis]
412 Lehrman ED, Fidelman N. Liver-Directed Therapy for Neuroendocrine Tumor Liver Metastases in the Era of Peptide Receptor Radionuclide Therapy. Semin Intervent Radiol 2020;37:499-507. [PMID: 33328706 DOI: 10.1055/s-0040-1720951] [Reference Citation Analysis]
413 Taki K, Hashimoto D, Nakagawa S, Ozaki N, Tomiyasu S, Ohmuraya M, Arima K, Kaida T, Higashi T, Sakamoto K, Sakata K, Okabe H, Nitta H, Hayashi H, Chikamoto A, Beppu T, Takamori H, Hirota M, Baba H. Significance of lymph node metastasis in pancreatic neuroendocrine tumor. Surg Today 2017;47:1104-10. [PMID: 28229300 DOI: 10.1007/s00595-017-1485-y] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
414 Han SH, Han IW, Heo JS, Choi SH, Choi DW, Han S, You YH. Laparoscopic versus open distal pancreatectomy for nonfunctioning pancreatic neuroendocrine tumors: a large single-center study. Surg Endosc. 2018;32:443-449. [PMID: 28664429 DOI: 10.1007/s00464-017-5702-y] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
415 Ushigome H, Fukunaga Y, Nagasaki T, Akiyoshi T, Konishi T, Fujimoto Y, Nagayama S, Ueno M. Difficulty of predicting lymph node metastasis on CT in patients with rectal neuroendocrine tumors. PLoS One 2019;14:e0211675. [PMID: 30742649 DOI: 10.1371/journal.pone.0211675] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
416 李伟, 隋红, 周建华. 胃肠胰神经内分泌肿瘤的临床病理特点及其与预后的关系. 世界华人消化杂志 2014; 22(6): 846-852 [DOI: 10.11569/wcjd.v22.i6.846] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
417 Furukori M, Imai K, Karasaki H, Watanabe K, Oikawa K, Miyokawa N, Taniguchi M, Furukawa H. Clinicopathological features of small nonfunctioning pancreatic neuroendocrine tumors. World J Gastroenterol 2014; 20(47): 17949-17954 [PMID: 25548493 DOI: 10.3748/wjg.v20.i47.17949] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
418 Plage S, Gibson A, Burge M, Wyld D. Cancer on the margins: experiences of living with neuroendocrine tumours. Health Sociology Review 2018;27:153-67. [DOI: 10.1080/14461242.2017.1387068] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
419 Døssing KB, Binderup T, Kaczkowski B, Jacobsen A, Rossing M, Winther O, Federspiel B, Knigge U, Kjær A, Friis-Hansen L. Down-Regulation of miR-129-5p and the let-7 Family in Neuroendocrine Tumors and Metastases Leads to Up-Regulation of Their Targets Egr1, G3bp1, Hmga2 and Bach1. Genes (Basel) 2014;6:1-21. [PMID: 25546138 DOI: 10.3390/genes6010001] [Cited by in Crossref: 39] [Cited by in F6Publishing: 36] [Article Influence: 5.6] [Reference Citation Analysis]
420 Robbins HL, Hague A. The PI3K/Akt Pathway in Tumors of Endocrine Tissues. Front Endocrinol (Lausanne) 2015;6:188. [PMID: 26793165 DOI: 10.3389/fendo.2015.00188] [Cited by in Crossref: 38] [Cited by in F6Publishing: 49] [Article Influence: 7.6] [Reference Citation Analysis]
421 Pozo K, Hillmann A, Augustyn A, Plattner F, Hai T, Singh T, Ramezani S, Sun X, Pfragner R, Minna JD, Cote GJ, Chen H, Bibb JA, Nwariaku FE. Differential expression of cell cycle regulators in CDK5-dependent medullary thyroid carcinoma tumorigenesis. Oncotarget 2015;6:12080-93. [PMID: 25900242 DOI: 10.18632/oncotarget.3813] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 4.8] [Reference Citation Analysis]
422 Yao JC, Fazio N, Singh S, Buzzoni R, Carnaghi C, Wolin E, Tomasek J, Raderer M, Lahner H, Voi M, Pacaud LB, Rouyrre N, Sachs C, Valle JW, Fave GD, Van Cutsem E, Tesselaar M, Shimada Y, Oh DY, Strosberg J, Kulke MH, Pavel ME; RAD001 in Advanced Neuroendocrine Tumours; Fourth Trial (RADIANT-4) Study Group. Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study. Lancet. 2016;387:968-977. [PMID: 26703889 DOI: 10.1016/s0140-6736(15)00817-x] [Cited by in Crossref: 560] [Cited by in F6Publishing: 290] [Article Influence: 93.3] [Reference Citation Analysis]
423 Yao JC, Pavel M, Lombard-Bohas C, Van Cutsem E, Voi M, Brandt U, He W, Chen D, Capdevila J, de Vries EGE, Tomassetti P, Hobday T, Pommier R, Öberg K. Everolimus for the Treatment of Advanced Pancreatic Neuroendocrine Tumors: Overall Survival and Circulating Biomarkers From the Randomized, Phase III RADIANT-3 Study. J Clin Oncol 2016;34:3906-13. [PMID: 27621394 DOI: 10.1200/JCO.2016.68.0702] [Cited by in Crossref: 113] [Cited by in F6Publishing: 64] [Article Influence: 22.6] [Reference Citation Analysis]
424 Chevalier B, Dupuis H, Jannin A, Lemaitre M, Do Cao C, Cardot-Bauters C, Espiard S, Vantyghem MC. Phakomatoses and Endocrine Gland Tumors: Noteworthy and (Not so) Rare Associations. Front Endocrinol (Lausanne) 2021;12:678869. [PMID: 34025587 DOI: 10.3389/fendo.2021.678869] [Reference Citation Analysis]
425 Liu IH, Kunz PL. Biologics in gastrointestinal and pancreatic neuroendocrine tumors. J Gastrointest Oncol 2017;8:457-65. [PMID: 28736633 DOI: 10.21037/jgo.2016.12.09] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
426 Kamei K, Shindoh J, Kiya Y, Matsumoto I, Hashimoto M, Takeyama Y. Conversion surgery after extensive chemotherapy for stage IV mixed adenoneuroendocrine carcinoma (MANEC) of the gallbladder: clinical implications from the patterns of response and recurrence. Clin J Gastroenterol 2020;13:240-6. [PMID: 31617127 DOI: 10.1007/s12328-019-01053-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
427 Xie GD, Liu YR, Jiang YZ, Shao ZM. Epidemiology and survival outcomes of mucinous adenocarcinomas: A SEER population-based study. Sci Rep 2018;8:6117. [PMID: 29666453 DOI: 10.1038/s41598-018-24540-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
428 Pinchot SN, Holen K, Sippel RS, Chen H. Carcinoid tumors. Oncologist. 2008;13:1255-1269. [PMID: 19091780 DOI: 10.1634/theoncologist.2008-0207] [Cited by in Crossref: 140] [Cited by in F6Publishing: 110] [Article Influence: 10.8] [Reference Citation Analysis]
429 Cloyd JM, Wiseman JT, Pawlik TM. Surgical management of pancreatic neuroendocrine liver metastases. J Gastrointest Oncol 2020;11:590-600. [PMID: 32655938 DOI: 10.21037/jgo.2019.11.02] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
430 Binesh F, Samet M, Bovanlu TR. A case of pulmonary carcinoid tumour in a pregnant woman successfully treated with bronchoscopic (electrocautery) therapy. BMJ Case Rep 2013;2013:bcr2013009250. [PMID: 23608865 DOI: 10.1136/bcr-2013-009250] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
431 Lin W, Francis JM, Li H, Gao X, Pedamallu CS, Ernst P, Meyerson M. Kmt2a cooperates with menin to suppress tumorigenesis in mouse pancreatic islets. Cancer Biol Ther 2016;17:1274-81. [PMID: 27801610 DOI: 10.1080/15384047.2016.1250986] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
432 Hallet J, Coburn NG, Singh S, Beyfuss K, Koujanian S, Liu N, Law CHL. Access to care and outcomes for neuroendocrine tumours: does socioeconomic status matter? Curr Oncol 2018;25:e356-64. [PMID: 30464685 DOI: 10.3747/co.35.3930] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
433 Capurso G, Fendrich V, Rinzivillo M, Panzuto F, Bartsch DK, Delle Fave G. Novel molecular targets for the treatment of gastroenteropancreatic endocrine tumors: answers and unsolved problems. Int J Mol Sci 2012;14:30-45. [PMID: 23344019 DOI: 10.3390/ijms14010030] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
434 Cummins M, Pavlakis N. The use of targeted therapies in pancreatic neuroendocrine tumours: patient assessment, treatment administration, and management of adverse events. Ther Adv Med Oncol 2013;5:286-300. [PMID: 23997829 DOI: 10.1177/1758834013501016] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
435 Strosberg J, Kvols L. Antiproliferative effect of somatostatin analogs in gastroenteropancreatic neuroendocrine tumors. World J Gastroenterol 2010; 16(24): 2963-2970 [PMID: 20572298 DOI: 10.3748/wjg.v16.i24.2963] [Cited by in CrossRef: 71] [Cited by in F6Publishing: 63] [Article Influence: 6.5] [Reference Citation Analysis]
436 Larghi A, Rizzatti G, Rimbaş M, Crino SF, Gasbarrini A, Costamagna G. EUS-guided radiofrequency ablation as an alternative to surgery for pancreatic neuroendocrine neoplasms: Who should we treat? Endosc Ultrasound 2019;8:220-6. [PMID: 31249164 DOI: 10.4103/eus.eus_28_19] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 7.0] [Reference Citation Analysis]
437 Hagen J, Muniz VP, Falls KC, Reed SM, Taghiyev AF, Quelle FW, Gourronc FA, Klingelhutz AJ, Major HJ, Askeland RW, Sherman SK, O'Dorisio TM, Bellizzi AM, Howe JR, Darbro BW, Quelle DE. RABL6A promotes G1-S phase progression and pancreatic neuroendocrine tumor cell proliferation in an Rb1-dependent manner. Cancer Res 2014;74:6661-70. [PMID: 25273089 DOI: 10.1158/0008-5472.CAN-13-3742] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 3.3] [Reference Citation Analysis]
438 do Amor Divino PH, Marchetti KR, Almeida MQ, Riechelmann RP. Functional pancreatic neuroendocrine tumour causing Cushing's syndrome: the effect of chemotherapy on clinical symptoms. Ecancermedicalscience 2017;11:773. [PMID: 29104610 DOI: 10.3332/ecancer.2017.773] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
439 Oberg K, Krenning E, Sundin A, Bodei L, Kidd M, Tesselaar M, Ambrosini V, Baum RP, Kulke M, Pavel M, Cwikla J, Drozdov I, Falconi M, Fazio N, Frilling A, Jensen R, Koopmans K, Korse T, Kwekkeboom D, Maecke H, Paganelli G, Salazar R, Severi S, Strosberg J, Prasad V, Scarpa A, Grossman A, Walenkamp A, Cives M, Virgolini I, Kjaer A, Modlin IM. A Delphic consensus assessment: imaging and biomarkers in gastroenteropancreatic neuroendocrine tumor disease management. Endocr Connect 2016;5:174-87. [PMID: 27582247 DOI: 10.1530/EC-16-0043] [Cited by in Crossref: 49] [Cited by in F6Publishing: 28] [Article Influence: 9.8] [Reference Citation Analysis]
440 李晓琼, 张华, 李健丁. 肝脏原发性神经内分泌肿瘤的研究现状. 世界华人消化杂志 2013; 21(11): 984-989 [DOI: 10.11569/wcjd.v21.i11.984] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
441 Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, Mittra E, Kunz PL, Kulke MH, Jacene H, Bushnell D, O'Dorisio TM, Baum RP, Kulkarni HR, Caplin M, Lebtahi R, Hobday T, Delpassand E, Van Cutsem E, Benson A, Srirajaskanthan R, Pavel M, Mora J, Berlin J, Grande E, Reed N, Seregni E, Öberg K, Lopera Sierra M, Santoro P, Thevenet T, Erion JL, Ruszniewski P, Kwekkeboom D, Krenning E; NETTER-1 Trial Investigators. Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors. N Engl J Med 2017;376:125-35. [PMID: 28076709 DOI: 10.1056/NEJMoa1607427] [Cited by in Crossref: 1120] [Cited by in F6Publishing: 537] [Article Influence: 280.0] [Reference Citation Analysis]
442 Wang R, Zheng-Pywell R, Chen HA, Bibb JA, Chen H, Rose JB. Management of Gastrointestinal Neuroendocrine Tumors. Clin Med Insights Endocrinol Diabetes. 2019;12:1179551419884058. [PMID: 31695546 DOI: 10.1177/1179551419884058] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 8.0] [Reference Citation Analysis]
443 Shatveryan GA, Karagyozyan GA, Chardarov NK, Bagmet NN, Ratnikova NP. [Surgical management of non-functioning pancreatic neuroendocrine tumors]. Khirurgiia (Mosk) 2018;:4-9. [PMID: 29376950 DOI: 10.17116/hirurgia201814-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
444 Stump R, Haueis S, Kalt N, Tschuor C, Limani P, Raptis DA, Puhan MA, Breitenstein S. Transplantation and surgical strategies in patients with neuroendocrine liver metastases: protocol of four systematic reviews. JMIR Res Protoc. 2013;2:e58. [PMID: 24366112 DOI: 10.2196/resprot.2891] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
445 Haug AR, Assmann G, Rist C, Tiling R, Schmidt GP, Bartenstein P, Hacker M. [Quantification of immunohistochemical expression of somatostatin receptors in neuroendocrine tumors using 68Ga-DOTATATE PET/CT]. Radiologe 2010;50:349-54. [PMID: 20333502 DOI: 10.1007/s00117-009-1972-2] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
446 Ogimi T, Sadahiro S, Kamei Y, Chan LF, Miyakita H, Saito G, Okada K, Suzuki T, Kajiwara H. Distribution of Neuroendocrine Marker-Positive Cells in Colorectal Cancer Tissue and Normal Mucosal Tissue: Consideration of Histogenesis of Neuroendocrine Cancer. Oncology 2019;97:294-300. [PMID: 31390635 DOI: 10.1159/000501521] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
447 Zhang Z, Mäkinen N, Kasai Y, Kim GE, Diosdado B, Nakakura E, Meyerson M. Patterns of chromosome 18 loss of heterozygosity in multifocal ileal neuroendocrine tumors. Genes Chromosomes Cancer 2020;59:535-9. [PMID: 32291827 DOI: 10.1002/gcc.22850] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
448 Tran CG, Scott AT, Li G, Sherman SK, Ear PH, Howe JR. Metastatic pancreatic neuroendocrine tumors have decreased somatostatin expression and increased Akt signaling. Surgery 2021;169:155-61. [PMID: 32611516 DOI: 10.1016/j.surg.2020.04.034] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
449 Zaidi MY, Lopez-Aguiar AG, Dillhoff M, Beal E, Poultsides G, Makris E, Rocha F, Crown A, Idrees K, Marincola Smith P, Nathan H, Beems M, Abbott D, Barrett JR, Fields RC, Davidson J, Cardona K, Maithel SK. Prognostic Role of Lymph Node Positivity and Number of Lymph Nodes Needed for Accurately Staging Small-Bowel Neuroendocrine Tumors. JAMA Surg. 2019;154:134-140. [PMID: 30383112 DOI: 10.1001/jamasurg.2018.3865] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 11.0] [Reference Citation Analysis]
450 Kessoku T, Kobayashi N, Yoneda M, Kasai Y, Ozaki A, Okubo N, Iwaki M, Kobayashi T, Yoshihara T, Kurita Y, Honda Y, Tokuhisa M, Ishiki H, Hibiya T, Fujii S, Nakajima A, Ichikawa Y. Case Reports: Transformation of End-Stage Neuroendocrine Tumors With Uncontrollable Liver Metastasis Into a Novel or Additional Functional Phenotype. Front Oncol 2020;10:555963. [PMID: 33102220 DOI: 10.3389/fonc.2020.555963] [Reference Citation Analysis]
451 Sadowski SM, Neychev V, Millo C, Shih J, Nilubol N, Herscovitch P, Pacak K, Marx SJ, Kebebew E. Prospective Study of 68Ga-DOTATATE Positron Emission Tomography/Computed Tomography for Detecting Gastro-Entero-Pancreatic Neuroendocrine Tumors and Unknown Primary Sites. J Clin Oncol. 2016;34:588-596. [PMID: 26712231 DOI: 10.1200/jco.2015.64.0987] [Cited by in Crossref: 168] [Cited by in F6Publishing: 83] [Article Influence: 28.0] [Reference Citation Analysis]
452 Gao LP, Kong GX, Wang X, Ma HM, Ding FF, Li TD. Pancreatic neuroendocrine carcinoma in a pregnant woman: A case report and review of the literature . World J Clin Cases 2021; 9(17): 4327-4335 [PMID: 34141797 DOI: 10.12998/wjcc.v9.i17.4327] [Reference Citation Analysis]
453 Soliman ML, Tiwari A, Zhao Q. Coexisting tubular adenoma with a neuroendocrine carcinoma of colon allowing early surgical intervention and implicating a shared stem cell origin. World J Gastroenterol 2017; 23(6): 1106-1112 [PMID: 28246485 DOI: 10.3748/wjg.v23.i6.1106] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
454 Peltola E, Hannula P, Huhtala H, Metso S, Kiviniemi U, Vornanen M, Sand J, Laukkarinen J, Tiikkainen M, Schalin-Jäntti C, Arola J, Sirén J, Piiroinen A, Soinio M, Nuutila P, Söderström M, Hämäläinen H, Moilanen L, Laaksonen D, Pirinen E, Sundelin F, Ebeling T, Salmela P, Mäkinen MJ, Jaatinen P. Characteristics and Outcomes of 79 Patients with an Insulinoma: A Nationwide Retrospective Study in Finland. Int J Endocrinol 2018;2018:2059481. [PMID: 30425741 DOI: 10.1155/2018/2059481] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
455 Yao JC, Phan AT, Hess K, Fogelman D, Jacobs C, Dagohoy C, Leary C, Xie K, Ng CS. Perfusion computed tomography as functional biomarker in randomized run-in study of bevacizumab and everolimus in well-differentiated neuroendocrine tumors. Pancreas. 2015;44:190-197. [PMID: 25426617 DOI: 10.1097/mpa.0000000000000255] [Cited by in Crossref: 35] [Cited by in F6Publishing: 19] [Article Influence: 5.8] [Reference Citation Analysis]
456 Eriksson J, Garmo JEH, Ihre-Lundgren C, Hellman P. Prognostic factors for death after surgery for small intestinal neuroendocrine tumours. BJS Open 2018;2:345-52. [PMID: 30263986 DOI: 10.1002/bjs5.76] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
457 Testoni SGG, Healey AJ, Dietrich CF, Arcidiacono PG. Systematic review of endoscopy ultrasound-guided thermal ablation treatment for pancreatic cancer. Endosc Ultrasound 2020;9:83-100. [PMID: 32295966 DOI: 10.4103/eus.eus_74_19] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 10.0] [Reference Citation Analysis]
458 de Wilde RF, Heaphy CM, Maitra A, Meeker AK, Edil BH, Wolfgang CL, Ellison TA, Schulick RD, Molenaar IQ, Valk GD. Loss of ATRX or DAXX expression and concomitant acquisition of the alternative lengthening of telomeres phenotype are late events in a small subset of MEN-1 syndrome pancreatic neuroendocrine tumors. Mod Pathol. 2012;25:1033-1039. [PMID: 22575867 DOI: 10.1038/modpathol.2012.53] [Cited by in Crossref: 108] [Cited by in F6Publishing: 98] [Article Influence: 12.0] [Reference Citation Analysis]
459 Signoretti M, Valente R, Repici A, Delle Fave G, Capurso G, Carrara S. Endoscopy-guided ablation of pancreatic lesions: Technical possibilities and clinical outlook. World J Gastrointest Endosc 2017; 9(2): 41-54 [PMID: 28250896 DOI: 10.4253/wjge.v9.i2.41] [Cited by in CrossRef: 26] [Cited by in F6Publishing: 12] [Article Influence: 6.5] [Reference Citation Analysis]
460 Zhang Z, Zhao X, Li Z, Wu Y, Liu Y, Li Z, Li G. Development of a nomogram model to predict survival outcomes in patients with primary hepatic neuroendocrine tumors based on SEER database. BMC Cancer 2021;21:567. [PMID: 34006241 DOI: 10.1186/s12885-021-08337-y] [Reference Citation Analysis]
461 Zhang J, Francois R, Iyer R, Seshadri M, Zajac-Kaye M, Hochwald SN. Current understanding of the molecular biology of pancreatic neuroendocrine tumors. J Natl Cancer Inst. 2013;105:1005-1017. [PMID: 23840053 DOI: 10.1093/jnci/djt135] [Cited by in Crossref: 77] [Cited by in F6Publishing: 63] [Article Influence: 9.6] [Reference Citation Analysis]
462 Boons G, Vandamme T, Peeters M, Beyens M, Driessen A, Janssens K, Zwaenepoel K, Roeyen G, Van Camp G, Op de Beeck K. Cell-Free DNA From Metastatic Pancreatic Neuroendocrine Tumor Patients Contains Tumor-Specific Mutations and Copy Number Variations. Front Oncol 2018;8:467. [PMID: 30443491 DOI: 10.3389/fonc.2018.00467] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 3.7] [Reference Citation Analysis]
463 Xu W, Yan H, Xu L, Li M, Gao W, Jiang K, Wu J, Miao Y. Correlation between radiologic features on contrast-enhanced CT and pathological tumor grades in pancreatic neuroendocrine neoplasms. J Biomed Res 2020;35:179-88. [PMID: 33637654 DOI: 10.7555/JBR.34.20200039] [Reference Citation Analysis]
464 Werner RA, Bengel FM, Derlin T. [Theranostics and hybrid imaging for somatostatin receptor-expressing tumors]. Radiologe. 2020;60:413-420. [PMID: 32052116 DOI: 10.1007/s00117-020-00652-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
465 Calissendorff J, Maret E, Sundin A, Falhammar H. Ileal neuroendocrine tumors and heart: not only valvular consequences. Endocrine 2015;48:743-55. [PMID: 25319177 DOI: 10.1007/s12020-014-0446-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
466 Chang JS, Chen LT, Shan YS, Lin SF, Hsiao SY, Tsai CR, Yu SJ, Tsai HJ. Comprehensive Analysis of the Incidence and Survival Patterns of Lung Cancer by Histologies, Including Rare Subtypes, in the Era of Molecular Medicine and Targeted Therapy: A Nation-Wide Cancer Registry-Based Study From Taiwan. Medicine (Baltimore) 2015;94:e969. [PMID: 26091466 DOI: 10.1097/MD.0000000000000969] [Cited by in Crossref: 20] [Cited by in F6Publishing: 14] [Article Influence: 3.3] [Reference Citation Analysis]
467 Souche R, Hobeika C, Hain E, Gaujoux S. Surgical Management of Neuroendocrine Tumours of the Pancreas. J Clin Med. 2020;9. [PMID: 32947997 DOI: 10.3390/jcm9092993] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
468 Hirose Y, Sakata J, Endo K, Takahashi M, Saito R, Imano H, Kido T, Yoshino K, Sasaki T, Wakai T. A 0.8-cm clear cell neuroendocrine tumor G1 of the gallbladder with lymph node metastasis: a case report. World J Surg Oncol. 2018;16:150. [PMID: 30037336 DOI: 10.1186/s12957-018-1454-y] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
469 Strojan P, Šifrer R, Ferlito A, Grašič-Kuhar C, Lanišnik B, Plavc G, Zidar N. Neuroendocrine Carcinoma of the Larynx and Pharynx: A Clinical and Histopathological Study. Cancers (Basel) 2021;13:4813. [PMID: 34638312 DOI: 10.3390/cancers13194813] [Reference Citation Analysis]
470 Matthaei H, Semaan A, Hruban RH. The genetic classification of pancreatic neoplasia. J Gastroenterol 2015;50:520-32. [PMID: 25605630 DOI: 10.1007/s00535-015-1037-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
471 Abell SK, Teng J, Dowling A, Hofman MS, MacIsaac RJ, Sachithanandan N. Prolonged life-threatening hypoglycaemia following dose escalation of octreotide LAR in a patient with malignant polysecreting pancreatic neuroendocrine tumour. Endocrinol Diabetes Metab Case Rep 2015;2015:140097. [PMID: 25755880 DOI: 10.1530/EDM-14-0097] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
472 Hoej LB, Nykjær KM, Gronbaek H. Incidence and survival of patients with small intestinal neuroendocrine tumours in a Danish NET center. ScientificWorldJournal 2012;2012:206350. [PMID: 23304081 DOI: 10.1100/2012/206350] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
473 Pinato DJ, Tan TM, Toussi ST, Ramachandran R, Martin N, Meeran K, Ngo N, Dina R, Sharma R. An expression signature of the angiogenic response in gastrointestinal neuroendocrine tumours: correlation with tumour phenotype and survival outcomes. Br J Cancer 2014;110:115-22. [PMID: 24231952 DOI: 10.1038/bjc.2013.682] [Cited by in Crossref: 27] [Cited by in F6Publishing: 30] [Article Influence: 3.4] [Reference Citation Analysis]
474 Xie JW, Lu J, Wang JB, Lin JX, Chen QY, Cao LL, Lin M, Tu RH, Huang ZN, Lin JL, Zheng CH, Li P, Huang CM. Prognostic factors for survival after curative resection of gastric mixed adenoneuroendocrine carcinoma: a series of 80 patients. BMC Cancer 2018;18:1021. [PMID: 30348122 DOI: 10.1186/s12885-018-4943-z] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 5.3] [Reference Citation Analysis]
475 Xiang QY, Xu J, Liu L. A rare case of thymic carcinoid presenting with gastrointestinal symptoms and pericardium effusion. BMC Cardiovasc Disord 2021;21:54. [PMID: 33509095 DOI: 10.1186/s12872-021-01871-4] [Reference Citation Analysis]
476 Li X, Gou S, Liu Z, Ye Z, Wang C. Assessment of the American Joint Commission on Cancer 8th Edition Staging System for Patients with Pancreatic Neuroendocrine Tumors: A Surveillance, Epidemiology, and End Results analysis. Cancer Med 2018;7:626-34. [PMID: 29380547 DOI: 10.1002/cam4.1336] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
477 Samsom KG, van Veenendaal LM, Valk GD, Vriens MR, Tesselaar MET, van den Berg JG. Molecular prognostic factors in small-intestinal neuroendocrine tumours. Endocr Connect 2019;8:906-22. [PMID: 31189127 DOI: 10.1530/EC-19-0206] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
478 Contractor T, Kobayashi S, da Silva E, Clausen R, Chan C, Vosburgh E, Tang LH, Levine AJ, Harris CR. Sexual dimorphism of liver metastasis by murine pancreatic neuroendocrine tumors is affected by expression of complement C5. Oncotarget 2016;7:30585-96. [PMID: 27105526 DOI: 10.18632/oncotarget.8874] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
479 Musholt TJ, Lang H. [Indications and operative procedures for neuroendocrine liver metastases]. Chirurg 2009;80:113-21. [PMID: 19212693 DOI: 10.1007/s00104-008-1614-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
480 Sampedro-Núñez M, Bouthelier A, Serrano-Somavilla A, Martínez-Hernández R, Adrados M, Martín-Pérez E, Muñoz de Nova JL, Cameselle-Teijeiro JM, Blanco-Carrera C, Cabezas-Agricola JM, Díaz JÁ, García-Centeno R, Aragones J, Marazuela M. LAT-1 and GLUT-1 Carrier Expression and Its Prognostic Value in Gastroenteropancreatic Neuroendocrine Tumors. Cancers (Basel) 2020;12:E2968. [PMID: 33066332 DOI: 10.3390/cancers12102968] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
481 Wang SM, Ye M, Ni SM. Multiple scalp metastases from colonic neuroendocrine carcinoma: case report and literature review. BMC Cancer 2014;14:305. [PMID: 24884973 DOI: 10.1186/1471-2407-14-305] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
482 Teulé A, Casanovas O. Relevance of angiogenesis in neuroendocrine tumors. Target Oncol. 2012;7:93-98. [PMID: 22592949 DOI: 10.1007/s11523-012-0217-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
483 Salama A, Badawy O, Mokhtar N. Ki-67 is a powerful tool for grading neuroendocrine tumors among Egyptian patients: a 10-year experience. J Cancer Res Clin Oncol 2014;140:653-61. [PMID: 24515911 DOI: 10.1007/s00432-014-1603-9] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
484 Forero Molina MA, Garcia E, Gonzalez-Devia D, García-Duperly R, Vera A. A 17-year-old male with a Small Bowel Neuroendocrine Tumor: flushing differential diagnosis. World Allergy Organ J 2017;10:30. [PMID: 28904734 DOI: 10.1186/s40413-017-0161-4] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
485 Kelly KJ. Management of Appendix Cancer. Clin Colon Rectal Surg 2015;28:247-55. [PMID: 26648795 DOI: 10.1055/s-0035-1564433] [Cited by in Crossref: 60] [Cited by in F6Publishing: 56] [Article Influence: 10.0] [Reference Citation Analysis]
486 Oh S, Park JT. Zebrafish model of KRAS-initiated pancreatic endocrine tumor. Anim Cells Syst (Seoul) 2019;23:209-18. [PMID: 31231585 DOI: 10.1080/19768354.2019.1610058] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
487 Zou J, Chen S, Lian G, Li R, Li Y, Huang K, Chen Y. Prognostic and metastasis-related factors in colorectal neuroendocrine tumors: A cross-sectional study based on the Surveillance, Epidemiology and End Results. Oncol Lett 2019;18:5129-38. [PMID: 31612024 DOI: 10.3892/ol.2019.10876] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
488 Haugvik SP, Labori KJ, Waage A, Line PD, Mathisen Ø, Gladhaug IP. Pancreatic surgery with vascular reconstruction in patients with locally advanced pancreatic neuroendocrine tumors. J Gastrointest Surg. 2013;17:1224-1232. [PMID: 23670519 DOI: 10.1007/s11605-013-2221-6] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
489 Ter-Minassian M, Wang Z, Asomaning K, Wu MC, Liu CY, Paulus JK, Liu G, Bradbury PA, Zhai R, Su L, Frauenhoffer CS, Hooshmand SM, De Vivo I, Lin X, Christiani DC, Kulke MH. Genetic associations with sporadic neuroendocrine tumor risk. Carcinogenesis 2011;32:1216-22. [PMID: 21606320 DOI: 10.1093/carcin/bgr095] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 2.2] [Reference Citation Analysis]
490 Milione M, Maisonneuve P, Pellegrinelli A, Pusceddu S, Centonze G, Dominoni F, Brambilla C, Rubino M, Faggiano A, Buzzoni R, Concas L, Giacomelli L, Coppa J, Mazzaferro V, de Braud F. Loss of succinate dehydrogenase subunit B (SDHB) as a prognostic factor in advanced ileal well-differentiated neuroendocrine tumors. Endocrine 2017;57:512-7. [PMID: 27905048 DOI: 10.1007/s12020-016-1180-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
491 Nuñez JE, Donadio M, Filho DR, Rego JF, Barros M, Formiga MN, Lopez R, Riechelmann R. The efficacy of everolimus and sunitinib in patients with sporadic or germline mutated metastatic pancreatic neuroendocrine tumors. J Gastrointest Oncol 2019;10:645-51. [PMID: 31392045 DOI: 10.21037/jgo.2019.01.33] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
492 Salazar R, Reidy-Lagunes D, Yao J. Potential synergies for combined targeted therapy in the treatment of neuroendocrine cancer. Drugs 2011;71:841-52. [PMID: 21568362 DOI: 10.2165/11585500-000000000-00000] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
493 Chan DL, Segelov E, Singh S. Everolimus in the management of metastatic neuroendocrine tumours. Therap Adv Gastroenterol. 2017;10:132-141. [PMID: 28286565 DOI: 10.1177/1756283x16674660] [Cited by in Crossref: 21] [Cited by in F6Publishing: 12] [Article Influence: 4.2] [Reference Citation Analysis]
494 Filosso PL, Ferolla P, Guerrera F, Ruffini E, Travis WD, Rossi G, Lausi PO, Oliaro A; European Society of Thoracic Surgeons Lung Neuroendocrine Tumors Working-Group Steering Committee. Multidisciplinary management of advanced lung neuroendocrine tumors. J Thorac Dis 2015;7:S163-71. [PMID: 25984363 DOI: 10.3978/j.issn.2072-1439.2015.04.20] [Cited by in F6Publishing: 21] [Reference Citation Analysis]
495 Kim ST, Ha SY, Lee S, Ahn S, Lee J, Park SH, Park JO, Lim HY, Kang WK, Kim KM, Park YS. The Impact of PD-L1 Expression in Patients with Metastatic GEP-NETs. J Cancer. 2016;7:484-489. [PMID: 26958083 DOI: 10.7150/jca.13711] [Cited by in Crossref: 65] [Cited by in F6Publishing: 62] [Article Influence: 13.0] [Reference Citation Analysis]
496 Andriantsoa M, Hoibian S, Autret A, Gilabert M, Sarran A, Niccoli P, Raoul JL. An elevated serum alkaline phosphatase level in hepatic metastases of grade 1 and 2 gastrointestinal neuroendocrine tumors is unusual and of prognostic value. PLoS One 2017;12:e0177971. [PMID: 28562682 DOI: 10.1371/journal.pone.0177971] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
497 Cai B, Broder MS, Chang E, Yan T, Metz DC. Predictive factors associated with carcinoid syndrome in patients with gastrointestinal neuroendocrine tumors. World J Gastroenterol 2017; 23(40): 7283-7291 [PMID: 29142475 DOI: 10.3748/wjg.v23.i40.7283] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
498 Yachida S, Vakiani E, White CM, Zhong Y, Saunders T, Morgan R, de Wilde RF, Maitra A, Hicks J, Demarzo AM, Shi C, Sharma R, Laheru D, Edil BH, Wolfgang CL, Schulick RD, Hruban RH, Tang LH, Klimstra DS, Iacobuzio-Donahue CA. Small cell and large cell neuroendocrine carcinomas of the pancreas are genetically similar and distinct from well-differentiated pancreatic neuroendocrine tumors. Am J Surg Pathol. 2012;36:173-184. [PMID: 22251937 DOI: 10.1097/pas.0b013e3182417d36] [Cited by in Crossref: 308] [Cited by in F6Publishing: 134] [Article Influence: 34.2] [Reference Citation Analysis]
499 Hashmi AA, Ali J, Yaqeen SR, Ahmed O, Asghar IA, Irfan M, Asif MG, Edhi MM, Hashmi S. Clinicopathological Features of Primary Neuroendocrine Tumors of Gastrointestinal/Pancreatobiliary Tract With Emphasis on High-Grade (Grade 3) Well-Differentiated Neuroendocrine Tumors. Cureus 2021;13:e12640. [PMID: 33585126 DOI: 10.7759/cureus.12640] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
500 Marincek N, Jörg AC, Brunner P, Schindler C, Koller MT, Rochlitz C, Müller-Brand J, Maecke HR, Briel M, Walter MA. Somatostatin-based radiotherapy with [90Y-DOTA]-TOC in neuroendocrine tumors: long-term outcome of a phase I dose escalation study. J Transl Med 2013;11:17. [PMID: 23320604 DOI: 10.1186/1479-5876-11-17] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
501 Li M, Xu S, Fan H, Zhang H, Li Y, Li Y, Liu M, Liu H, Chen J. [Expression and Clinical Significance of PD-1 and PD-L1 in Pulmonary Carcinoids]. Zhongguo Fei Ai Za Zhi 2016;19:847-53. [PMID: 27978870 DOI: 10.3779/j.issn.1009-3419.2016.12.07] [Reference Citation Analysis]
502 Wang Z, Li W, Chen T, Yang J, Luo L, Zhang L, Sun B, Liang R. Retrospective analysis of the clinicopathological characteristics of gastrointestinal neuroendocrine neoplasms. Exp Ther Med. 2015;10:1084-1088. [PMID: 26622444 DOI: 10.3892/etm.2015.2634] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.8] [Reference Citation Analysis]
503 Ida H, Honma Y, Hirano H, Shoji H, Iwasa S, Okita N, Takashima A, Kato K, Fukuda T, Boku N. Clinical outcomes of patients with G1/G2 neuroendocrine tumors arising from foregut or hindgut treated with somatostatin analogs: a retrospective study. Invest New Drugs 2019;37:573-8. [PMID: 30267338 DOI: 10.1007/s10637-018-0669-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
504 Minczeles NS, Hofland J, de Herder WW, Brabander T. Strategies Towards Improving Clinical Outcomes of Peptide Receptor Radionuclide Therapy. Curr Oncol Rep 2021;23:46. [PMID: 33721105 DOI: 10.1007/s11912-021-01037-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
505 Mehlis K, Witte J, Surmann B, Kudlich M, Apostolidis L, Walther J, Jäger D, Greiner W, Winkler EC. The patient-level effect of the cost of Cancer care - financial burden in German Cancer patients. BMC Cancer 2020;20:529. [PMID: 32503459 DOI: 10.1186/s12885-020-07028-4] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 9.0] [Reference Citation Analysis]
506 Bellorin O, Shuchleib A, Halevi AE, Aksenov S, Saldinger PF. Giant type III well-differentiated neuroendocrine tumor of the stomach: A case report. Int J Surg Case Rep 2016;25:62-5. [PMID: 27327559 DOI: 10.1016/j.ijscr.2016.06.008] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
507 Al Natour RH, Saund MS, Sanchez VM, Whang EE, Sharma AM, Huang Q, Boosalis VA, Gold JS. Tumor size and depth predict rate of lymph node metastasis in colon carcinoids and can be used to select patients for endoscopic resection. J Gastrointest Surg. 2012;16:595-602. [PMID: 22143420 DOI: 10.1007/s11605-011-1786-1] [Cited by in Crossref: 40] [Cited by in F6Publishing: 32] [Article Influence: 4.0] [Reference Citation Analysis]
508 Herring M, Huynh L, Duh MS, Vekeman F, Tiew A, Neary M, Bergsland E. Real-world treatment patterns in advanced pancreatic neuroendocrine tumors in the era of targeted therapy: perspectives from an academic tertiary center and community oncology practices. Med Oncol 2017;34:88. [PMID: 28393314 DOI: 10.1007/s12032-017-0927-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
509 Bösch F, Bazhin AV, Heublein S, Brüwer K, Knösel T, Reiter FP, Auernhammer CJ, Guba MO, Spitzweg C, Werner J, Angele MK. Treatment with somatostatin analogs induces differentially expressed let-7c-5p and mir-3137 in small intestine neuroendocrine tumors. BMC Cancer 2019;19:575. [PMID: 31196127 DOI: 10.1186/s12885-019-5794-y] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
510 Lee E, Leon Pachter H, Sarpel U. Hepatic arterial embolization for the treatment of metastatic neuroendocrine tumors. Int J Hepatol. 2012;2012:471203. [PMID: 22319651 DOI: 10.1155/2012/471203] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
511 Raj N, Reidy-Lagunes D. Systemic therapies for advanced pancreatic neuroendocrine tumors. Hematol Oncol Clin North Am. 2016;30:119-133. [PMID: 26614372 DOI: 10.1016/j.hoc.2015.09.005] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
512 de M Rêgo JF, de Medeiros RSS, Braghiroli MI, Galvão B, Neto JEB, Munhoz RR, Guerra J, Nonogaki S, Kimura L, Pfiffer TE, de Castro G Jr, Hoff PM, Filho DR, Costa FP, Riechelmann RP. Expression of ERCC1, Bcl-2, Lin28a, and Ki-67 as biomarkers of response to first-line platinum-based chemotherapy in patients with high-grade extrapulmonary neuroendocrine carcinomas or small cell lung cancer. Ecancermedicalscience 2017;11:767. [PMID: 28955403 DOI: 10.3332/ecancer.2017.767] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
513 Bartolini I, Bencini L, Risaliti M, Ringressi MN, Moraldi L, Taddei A. Current Management of Pancreatic Neuroendocrine Tumors: From Demolitive Surgery to Observation. Gastroenterol Res Pract 2018;2018:9647247. [PMID: 30140282 DOI: 10.1155/2018/9647247] [Cited by in Crossref: 8] [Cited by in F6Publishing: 12] [Article Influence: 2.7] [Reference Citation Analysis]
514 Kaemmer CA, Umesalma S, Maharjan CK, Moose DL, Narla G, Mott SL, Zamba GKD, Breheny P, Darbro BW, Bellizzi AM, Henry MD, Quelle DE. Development and comparison of novel bioluminescent mouse models of pancreatic neuroendocrine neoplasm metastasis. Sci Rep 2021;11:10252. [PMID: 33986468 DOI: 10.1038/s41598-021-89866-1] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
515 Figueiredo MN, Maggiori L, Gaujoux S, Couvelard A, Guedj N, Ruszniewski P, Panis Y. Surgery for small-bowel neuroendocrine tumors: is there any benefit of the laparoscopic approach? Surg Endosc 2014;28:1720-6. [PMID: 24380996 DOI: 10.1007/s00464-013-3381-x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 2.7] [Reference Citation Analysis]
516 Severi S, Nanni O, Bodei L, Sansovini M, Ianniello A, Nicoletti S, Scarpi E, Matteucci F, Gilardi L, Paganelli G. Role of 18FDG PET/CT in patients treated with 177Lu-DOTATATE for advanced differentiated neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2013;40:881-888. [PMID: 23443937 DOI: 10.1007/s00259-013-2369-z] [Cited by in Crossref: 78] [Cited by in F6Publishing: 51] [Article Influence: 9.8] [Reference Citation Analysis]
517 Krokker L, Patócs A, Butz H. Essential Role of the 14q32 Encoded miRNAs in Endocrine Tumors. Genes (Basel) 2021;12:698. [PMID: 34066712 DOI: 10.3390/genes12050698] [Reference Citation Analysis]
518 Chang TM, Shan YS, Chu PY, Jiang SS, Hung WC, Chen YL, Tu HC, Lin HY, Tsai HJ, Chen LT. The regulatory role of aberrant Phosphatase and Tensin Homologue and Liver Kinase B1 on AKT/mTOR/c-Myc axis in pancreatic neuroendocrine tumors. Oncotarget 2017;8:98068-83. [PMID: 29228674 DOI: 10.18632/oncotarget.20956] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
519 Sandvik OM, Søreide K, Gudlaugsson E, Kvaløy JT, Søreide JA. Epidemiology and classification of gastroenteropancreatic neuroendocrine neoplasms using current coding criteria. Br J Surg 2016;103:226-32. [PMID: 26511392 DOI: 10.1002/bjs.10034] [Cited by in Crossref: 38] [Cited by in F6Publishing: 36] [Article Influence: 6.3] [Reference Citation Analysis]
520 Naheed S, Holden C, Tanno L, Jaynes E, Cave J, Ottensmeier CH, Pelosi G. The utility of Ki-67 as a prognostic biomarker in pulmonary neuroendocrine tumours: protocol for a systematic review and meta-analysis. BMJ Open 2019;9:e031531. [PMID: 31446421 DOI: 10.1136/bmjopen-2019-031531] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
521 Tsai HJ, Wu CC, Tsai CR, Lin SF, Chen LT, Chang JS. Second cancers in patients with neuroendocrine tumors. PLoS One 2013;8:e86414. [PMID: 24392036 DOI: 10.1371/journal.pone.0086414] [Cited by in Crossref: 12] [Cited by in F6Publishing: 16] [Article Influence: 1.5] [Reference Citation Analysis]
522 Furrukh M, Qureshi A, Saparamadu A, Kumar S. Malignant neuroendocrine tumour of the gallbladder with elevated carcinoembryonic antigen: case report and literature review. BMJ Case Rep 2013;2013:bcr2013008778. [PMID: 23661652 DOI: 10.1136/bcr-2013-008778] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
523 Sato H, Saito T, Horii H, Kajiura M, Kikuchi N, Takada N, Taguchi K, Yoshida M, Hasegawa M, Taguchi H, Yoshida Y, Ando K, Fujiya M, Omori Y, Hank T, Liss AS, Gala MK, Makita Y, Ono Y, Mizukami Y, Okumura T. Case Report: A Rare Case of Esophagogastric Junctional Squamous Cell Carcinoma After the Successful Treatment of Neuroendocrine Carcinoma: Clonal Tumor Evolution Revealed by Genetic Analysis. Front Genet 2021;12:608324. [PMID: 34616420 DOI: 10.3389/fgene.2021.608324] [Reference Citation Analysis]
524 Fan ST, Le Treut YP, Mazzaferro V, Burroughs AK, Olausson M, Breitenstein S, Frilling A. Liver transplantation for neuroendocrine tumour liver metastases. HPB (Oxford) 2015;17:23-8. [PMID: 24992381 DOI: 10.1111/hpb.12308] [Cited by in Crossref: 52] [Cited by in F6Publishing: 32] [Article Influence: 7.4] [Reference Citation Analysis]
525 Bainbridge HE, Larbi E, Middleton G. Symptomatic Control of Neuroendocrine Tumours with Everolimus. Horm Cancer. 2015;6:254-259. [PMID: 26245686 DOI: 10.1007/s12672-015-0233-2] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 3.7] [Reference Citation Analysis]
526 Kayano D, Kinuya S. Current Consensus on I-131 MIBG Therapy. Nucl Med Mol Imaging 2018;52:254-65. [PMID: 30100938 DOI: 10.1007/s13139-018-0523-z] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 7.7] [Reference Citation Analysis]
527 Abou Jokh Casas E, Pubul Núñez V, Anido-Herranz U, del Carmen Mallón Araujo M, del Carmen Pombo Pasín M, Garrido Pumar M, Cabezas Agrícola JM, Cameselle-Teijeiro JM, Hilal A, Ruibal Morell Á. Evaluation of 177Lu-Dotatate treatment in patients with metastatic neuroendocrine tumors and prognostic factors. World J Gastroenterol 2020; 26(13): 1513-1524 [PMID: 32308351 DOI: 10.3748/wjg.v26.i13.1513] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 3] [Article Influence: 6.0] [Reference Citation Analysis]
528 Tong Z, Wang L, Shi W, Zeng Y, Zhang H, Liu L, Zheng Y, Chen C, Xia W, Fang W, Zhao P. Clonal Evolution Dynamics in Primary and Metastatic Lesions of Pancreatic Neuroendocrine Neoplasms. Front Med (Lausanne) 2021;8:620988. [PMID: 34026777 DOI: 10.3389/fmed.2021.620988] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
529 Roy R, Zurakowski D, Wischhusen J, Frauenhoffer C, Hooshmand S, Kulke M, Moses MA. Urinary TIMP-1 and MMP-2 levels detect the presence of pancreatic malignancies. Br J Cancer. 2014;111:1772-1779. [PMID: 25137018 DOI: 10.1038/bjc.2014.462] [Cited by in Crossref: 42] [Cited by in F6Publishing: 38] [Article Influence: 6.0] [Reference Citation Analysis]
530 Park C, Ha SY, Kim ST, Kim HC, Heo JS, Park YS, Lauwers G, Lee J, Kim KM. Identification of the BRAF V600E mutation in gastroenteropancreatic neuroendocrine tumors. Oncotarget 2016;7:4024-35. [PMID: 26684240 DOI: 10.18632/oncotarget.6602] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 4.8] [Reference Citation Analysis]
531 Poncet G, Faucheron JL, Walter T. Recent trends in the treatment of well-differentiated endocrine carcinoma of the small bowel. World J Gastroenterol 2010; 16(14): 1696-1706 [PMID: 20380000 DOI: 10.3748/wjg.v16.i14.1696] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
532 Vijayvergia N, Boland PM, Handorf E, Gustafson KS, Gong Y, Cooper HS, Sheriff F, Astsaturov I, Cohen SJ, Engstrom PF. Molecular profiling of neuroendocrine malignancies to identify prognostic and therapeutic markers: a Fox Chase Cancer Center Pilot Study. Br J Cancer. 2016;115:564-570. [PMID: 27482646 DOI: 10.1038/bjc.2016.229] [Cited by in Crossref: 50] [Cited by in F6Publishing: 52] [Article Influence: 10.0] [Reference Citation Analysis]
533 Pellat A, Cottereau AS, Terris B, Coriat R. Neuroendocrine Carcinomas of the Digestive Tract: What Is New? Cancers (Basel) 2021;13:3766. [PMID: 34359666 DOI: 10.3390/cancers13153766] [Reference Citation Analysis]
534 Lorz C, Oteo M, Santos M. Neuroendocrine Lung Cancer Mouse Models: An Overview. Cancers (Basel) 2020;13:E14. [PMID: 33375066 DOI: 10.3390/cancers13010014] [Reference Citation Analysis]
535 Ali R, Baldeo C, Onyenekwe J, Lala R, Landa C, Siddiqi A. Atypical Endobronchial Carcinoid with Postobstructive Pneumonia Obscuring the Diagnosis of Granulomatosis with Polyangiitis. Case Rep Rheumatol 2015;2015:513602. [PMID: 26347844 DOI: 10.1155/2015/513602] [Reference Citation Analysis]
536 Broder MS, Chang E, Romanus D, Cherepanov D, Neary MP. Healthcare and economic impact of diarrhea in patients with carcinoid syndrome. World J Gastroenterol 2016; 22(6): 2118-2125 [PMID: 26877616 DOI: 10.3748/wjg.v22.i6.2118] [Cited by in CrossRef: 24] [Cited by in F6Publishing: 22] [Article Influence: 4.8] [Reference Citation Analysis]
537 Yang M, Tan CL, Zhang Y, Ke NW, Zeng L, Li A, Zhang H, Xiong JJ, Guo ZH, Tian BL, Liu XB. Applications of a novel tumor-grading-metastasis staging system for pancreatic neuroendocrine tumors: An analysis of surgical patients from a Chinese institution. Medicine (Baltimore) 2016;95:e4213. [PMID: 27428224 DOI: 10.1097/MD.0000000000004213] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
538 Kelgiorgi D, Dervenis C. Pancreatic neuroendocrine tumors: the basics, the gray zone, and the target. F1000Res 2017;6:663. [PMID: 28529726 DOI: 10.12688/f1000research.10188.1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
539 Levy S, van Veenendaal LM, Korse CM, Breekveldt ECH, Verbeek WHM, Vriens MR, Kuhlmann KFD, van den Berg JG, Valk GD, Tesselaar MET. Survival in Patients with Neuroendocrine Tumours of the Small Intestine: Nomogram Validation and Predictors of Survival. J Clin Med 2020;9:E2502. [PMID: 32756529 DOI: 10.3390/jcm9082502] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
540 Pobłocki J, Jasińska A, Syrenicz A, Andrysiak-Mamos E, Szczuko M. The Neuroendocrine Neoplasms of the Digestive Tract: Diagnosis, Treatment and Nutrition. Nutrients 2020;12:E1437. [PMID: 32429294 DOI: 10.3390/nu12051437] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 6.0] [Reference Citation Analysis]
541 Sartori S, Bianchi L, Di Vece F, Tombesi P. Liver-directed therapies for liver metastases from neuroendocrine neoplasms: Can laser ablation play any role? World J Gastroenterol 2020; 26(23): 3118-3125 [PMID: 32684730 DOI: 10.3748/wjg.v26.i23.3118] [Reference Citation Analysis]
542 Li DH, Wang C, Chen HJ, Huang H, Ding ZY. Clinical characteristics of the mixed form of neuroendocrine tumor in the lung: A retrospective study in 2501 lung cancer cases. Thorac Cancer 2015;6:25-30. [PMID: 26273331 DOI: 10.1111/1759-7714.12128] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
543 Klöppel G. [Neoplasms of the disseminated neuroendocrine cell system of the gastrointestinal tract]. Pathologe 2015;36:237-45. [PMID: 25947223 DOI: 10.1007/s00292-015-0015-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
544 Cossetti RJ, Bezerra RO, Gumz B, Telles A, Costa FP. Whole body diffusion for metastatic disease assessment in neuroendocrine carcinomas: comparison with OctreoScan® in two cases. World J Surg Oncol. 2012;10:82. [PMID: 22591909 DOI: 10.1186/1477-7819-10-82] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
545 Abdelaal A, El Ansari W, Al-Bozom I, Khawar M, Shahid F, Aleter A, Abunuwar MR, El-Menyar A. Frequency, characteristics and outcomes of appendicular neuroendocrine tumors: A cross-sectional study from an academic tertiary care hospital. Ann Med Surg (Lond) 2017;21:20-4. [PMID: 28761642 DOI: 10.1016/j.amsu.2017.07.043] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
546 Strosberg J, Casciano R, Stern L, Parikh R, Chulikavit M, Willet J, Liu Z, Wang X, Grzegorzewski KJ. United States-based practice patterns and resource utilization in advanced neuroendocrine tumor treatment. World J Gastroenterol 2013; 19(15): 2348-2354 [PMID: 23613628 DOI: 10.3748/wjg.v19.i15.2348] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 17] [Article Influence: 1.9] [Reference Citation Analysis]
547 Welter S, Aigner C, Roesel C. The role of surgery in high grade neuroendocrine tumours of the lung. J Thorac Dis 2017;9:S1474-83. [PMID: 29201450 DOI: 10.21037/jtd.2017.01.60] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
548 Lau SC, Abdel-Rahman O, Cheung WY. Improved survival with higher doses of octreotide long-acting release in gastroenteropancreatic neuroendocrine tumors. Med Oncol 2018;35:123. [PMID: 30078166 DOI: 10.1007/s12032-018-1189-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
549 Scherübl H, Jensen RT, Cadiot G, Stölzel U, Klöppel G. Management of early gastrointestinal neuroendocrine neoplasms. World J Gastrointest Endosc 2011; 3(7): 133-139 [PMID: 21860682 DOI: 10.4253/wjge.v3.i7.133] [Cited by in CrossRef: 51] [Cited by in F6Publishing: 36] [Article Influence: 5.1] [Reference Citation Analysis]
550 Albertelli M, Dotto A, Nista F, Veresani A, Patti L, Gay S, Sciallero S, Boschetti M, Ferone D. "Present and future of immunotherapy in Neuroendocrine Tumors". Rev Endocr Metab Disord 2021;22:615-36. [PMID: 33851319 DOI: 10.1007/s11154-021-09647-z] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
551 McMullen T, Al-Jahdali A, de Gara C, Ghosh S, McEwan A, Schiller D. A population-based study of outcomes in patients with gastrointestinal neuroendocrine tumours. Can J Surg. 2017;60:192-197. [PMID: 28327275 DOI: 10.1503/cjs.007616] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
552 Norlén O, Daskalakis K, Öberg K, Åkerström G, Stålberg P, Hellman P. Indication for liver transplantation in young patients with small intestinal NETs is rare? World J Surg 2014;38:742-7. [PMID: 24233660 DOI: 10.1007/s00268-013-2331-z] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
553 Cives M, Strosberg J. Radionuclide Therapy for Neuroendocrine Tumors. Curr Oncol Rep. 2017;19:9. [PMID: 28220446 DOI: 10.1007/s11912-017-0567-8] [Cited by in Crossref: 72] [Cited by in F6Publishing: 69] [Article Influence: 18.0] [Reference Citation Analysis]
554 Mehta R, Lam-Chung CE, Hinojosa-Amaya JM, Roldán-Sarmiento P, Guillen-Placencia MF, Villanueva-Rodriguez G, Juarez-Leon OA, Leon-Domínguez J, Grajales-Gómez M, Ventura-Gallegos JL, León-Suárez A, Gómez-Pérez FJ, Cuevas-Ramos D. High Molecular Weight ACTH-Precursor Presence in a Metastatic Pancreatic Neuroendocrine Tumor Causing Severe Ectopic Cushing's Syndrome: A Case Report. Front Endocrinol (Lausanne) 2020;11:557. [PMID: 32903471 DOI: 10.3389/fendo.2020.00557] [Reference Citation Analysis]
555 Schulz C, Schütte K, Malfertheiner P. Rare Neoplasia of the Stomach. Gastrointest Tumors 2015;2:52-60. [PMID: 26674659 DOI: 10.1159/000435899] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
556 Süveg K, Putora PM, Joerger M, Iseli T, Fischer GF, Ammann K, Glatzer M. Radiotherapy for thymic epithelial tumours: a review. Transl Lung Cancer Res 2021;10:2088-100. [PMID: 34012817 DOI: 10.21037/tlcr-20-458] [Reference Citation Analysis]
557 Molina-Cerrillo J, Alonso-Gordoa T, Martínez-Sáez O, Grande E. Inhibition of Peripheral Synthesis of Serotonin as a New Target in Neuroendocrine Tumors. Oncologist 2016;21:701-7. [PMID: 27107003 DOI: 10.1634/theoncologist.2015-0455] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 3.4] [Reference Citation Analysis]
558 Singh S, Law C. Multidisciplinary reference centers: the care of neuroendocrine tumors. J Oncol Pract. 2010;6:e11-e16. [PMID: 21358944 DOI: 10.1200/jop.2010.000098] [Cited by in Crossref: 27] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
559 Park JK, Paik WH, Lee K, Ryu JK, Lee SH, Kim YT. DAXX/ATRX and MEN1 genes are strong prognostic markers in pancreatic neuroendocrine tumors. Oncotarget 2017;8:49796-806. [PMID: 28591701 DOI: 10.18632/oncotarget.17964] [Cited by in Crossref: 33] [Cited by in F6Publishing: 30] [Article Influence: 11.0] [Reference Citation Analysis]
560 Signorovitch J, Swallow E, Kantor E, Wang X, Klimovsky J, Haas T, Devine B, Metrakos P. Everolimus and sunitinib for advanced pancreatic neuroendocrine tumors: a matching-adjusted indirect comparison. Exp Hematol Oncol. 2013;2:32. [PMID: 24314093 DOI: 10.1186/2162-3619-2-32] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 3.1] [Reference Citation Analysis]
561 Nakamura T, Igarashi H, Ito T, Jensen RT. Important of case-reports/series, in rare diseases: Using neuroendocrine tumors as an example. World J Clin Cases 2014; 2(11): 608-613 [PMID: 25405184 DOI: 10.12998/wjcc.v2.i11.608] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]
562 Shen C, Chen H, Chen H, Yin Y, Han L, Chen J, Tang S, Yin X, Zhou Z, Zhang B, Chen Z. Surgical treatment and prognosis of gastric neuroendocrine neoplasms: a single-center experience. BMC Gastroenterol 2016;16:111. [PMID: 27613657 DOI: 10.1186/s12876-016-0505-5] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 5.2] [Reference Citation Analysis]
563 Mizuno Y, Kudo A, Akashi T, Akahoshi K, Ogura T, Ogawa K, Ono H, Mitsunori Y, Ban D, Tanaka S, Tateishi U, Tanabe M. Sunitinib shrinks NET-G3 pancreatic neuroendocrine neoplasms. J Cancer Res Clin Oncol 2018;144:1155-63. [PMID: 29602973 DOI: 10.1007/s00432-018-2636-2] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 6.0] [Reference Citation Analysis]
564 Marinova M, Mücke M, Fischer F, Essler M, Cuhls H, Radbruch L, Ghaei S, Conrad R, Ahmadzadehfar H. Quality of life in patients with midgut NET following peptide receptor radionuclide therapy. Eur J Nucl Med Mol Imaging 2019;46:2252-9. [PMID: 31338547 DOI: 10.1007/s00259-019-04431-3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
565 Cai W, Tan Y, Ge W, Ding K, Hu H. Pattern and risk factors for distant metastases in gastrointestinal neuroendocrine neoplasms: a population-based study. Cancer Med 2018;7:2699-709. [PMID: 29733523 DOI: 10.1002/cam4.1507] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
566 Wang JB, Xue Z, Lu J, He QL, Zheng ZF, Xu BB, Xie JW, Li P, Xu Y, Lin JX, Chen QY, Cao LL, Lin M, Tu RH, Huang ZN, Lin JL, Huang CM, Zheng CH. Effect of sarcopenia on short- and long-term outcomes in patients with gastric neuroendocrine neoplasms after radical gastrectomy: results from a large, two-institution series. BMC Cancer 2020;20:1002. [PMID: 33059606 DOI: 10.1186/s12885-020-07506-9] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
567 Kleiman DA, Beninato T, Sultan S, Crowley MJ, Finnerty B, Kumar R, Panarelli NC, Liu YF, Lieberman MD, Seandel M. Silencing of UCHL1 by CpG promoter hyper-methylation is associated with metastatic gastroenteropancreatic well-differentiated neuroendocrine (carcinoid) tumors. Ann Surg Oncol. 2014;21 Suppl 4:S672-S679. [PMID: 24854489 DOI: 10.1245/s10434-014-3787-2] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
568 Chan DT, Luk AO, So WY, Kong AP, Chow FC, Ma RC, Lo AW. Natural history and outcome in Chinese patients with gastroenteropancreatic neuroendocrine tumours: - a 17-year retrospective analysis. BMC Endocr Disord. 2016;16:12. [PMID: 26911576 DOI: 10.1186/s12902-016-0087-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
569 Eriksson J, Garmo H, Hellman P, Ihre-Lundgren C. The Influence of Preoperative Symptoms on the Death of Patients with Small Intestinal Neuroendocrine Tumors. Ann Surg Oncol 2017;24:1214-20. [PMID: 27904972 DOI: 10.1245/s10434-016-5703-4] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
570 Worhunsky DJ, Krampitz GW, Poullos PD, Visser BC, Kunz PL, Fisher GA, Norton JA, Poultsides GA. Pancreatic neuroendocrine tumours: hypoenhancement on arterial phase computed tomography predicts biological aggressiveness. HPB (Oxford). 2014;16:304-311. [PMID: 23991643 DOI: 10.1111/hpb.12139] [Cited by in Crossref: 40] [Cited by in F6Publishing: 37] [Article Influence: 5.0] [Reference Citation Analysis]
571 Póvoa S, Azevedo D, Marques C, Barroca H, Costa A. Unknown primary large-cell neuroendocrine tumor. Autops Case Rep 2018;8:e2018025. [PMID: 30533401 DOI: 10.4322/acr.2018.025] [Reference Citation Analysis]
572 Cen P, Amato RJ. Treatment of advanced pancreatic neuroendocrine tumors: potential role of everolimus. Onco Targets Ther 2012;5:217-24. [PMID: 22870038 DOI: 10.2147/OTT.S16289] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
573 Oberg K. Diagnostic work-up of gastroenteropancreatic neuroendocrine tumors. Clinics (Sao Paulo) 2012;67 Suppl 1:109-12. [PMID: 22584714 DOI: 10.6061/clinics/2012(sup01)18] [Cited by in Crossref: 30] [Cited by in F6Publishing: 16] [Article Influence: 3.8] [Reference Citation Analysis]
574 Czeczok TW, Stashek KM, Maxwell JE, O'Dorisio TM, Howe JR, Hornick JL, Bellizzi AM. Clusterin in Neuroendocrine Epithelial Neoplasms: Absence of Expression in a Well-differentiated Tumor Suggests a Jejunoileal Origin. Appl Immunohistochem Mol Morphol 2018;26:94-100. [PMID: 29420353 DOI: 10.1097/PAI.0000000000000563] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
575 Eghtesad B, Aucejo F. Liver transplantation for malignancies. J Gastrointest Cancer. 2014;45:353-362. [PMID: 24604263 DOI: 10.1007/s12029-014-9590-2] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
576 Cejas P, Drier Y, Dreijerink KMA, Brosens LAA, Deshpande V, Epstein CB, Conemans EB, Morsink FHM, Graham MK, Valk GD, Vriens MR, Castillo CF, Ferrone CR, Adar T, Bowden M, Whitton HJ, Da Silva A, Font-Tello A, Long HW, Gaskell E, Shoresh N, Heaphy CM, Sicinska E, Kulke MH, Chung DC, Bernstein BE, Shivdasani RA. Enhancer signatures stratify and predict outcomes of non-functional pancreatic neuroendocrine tumors. Nat Med 2019;25:1260-5. [PMID: 31263286 DOI: 10.1038/s41591-019-0493-4] [Cited by in Crossref: 52] [Cited by in F6Publishing: 49] [Article Influence: 26.0] [Reference Citation Analysis]
577 Tian FX, Cai YQ, Zhuang LP, Chen MF, Xiu ZB, Zhang Y, Liu H, Liu ZH, Liu GP, Zeng C, Lin FL, Liu J, Huang ST, Zhang LZ, Lin HY. Clinicopathological features and prognosis of patients with gastric neuroendocrine tumors: A population-based study. Cancer Med. 2018;7:5359-5369. [PMID: 30311450 DOI: 10.1002/cam4.1683] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
578 Liu P, Zhang X, Shang Y, Lu L, Cao F, Sun M, Tang Z, Vollmar B, Gong P. Lymph node ratio, but not the total number of examined lymph nodes or lymph node metastasis, is a predictor of overall survival for pancreatic neuroendocrine neoplasms after surgical resection.Oncotarget. 2017;8:89245-89255. [PMID: 29179516 DOI: 10.18632/oncotarget.19184] [Cited by in Crossref: 7] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
579 Geijer H, Breimer LH. Somatostatin receptor PET/CT in neuroendocrine tumours: update on systematic review and meta-analysis. Eur J Nucl Med Mol Imaging 2013;40:1770-80. [PMID: 23873003 DOI: 10.1007/s00259-013-2482-z] [Cited by in Crossref: 101] [Cited by in F6Publishing: 89] [Article Influence: 12.6] [Reference Citation Analysis]
580 Tierney JF, Poirier J, Chivukula S, Pappas SG, Hertl M, Schadde E, Keutgen X. Primary Tumor Site Affects Survival in Patients with Gastroenteropancreatic and Neuroendocrine Liver Metastases. Int J Endocrinol. 2019;2019:9871319. [PMID: 30992703 DOI: 10.1155/2019/9871319] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
581 Bongiovanni A, Liverani C, Recine F, Fausti V, Mercatali L, Vagheggini A, Spadazzi C, Miserocchi G, Cocchi C, Di Menna G, De Vita A, Severi S, Nicolini S, Ibrahim T. Phase-II Trials of Pazopanib in Metastatic Neuroendocrine Neoplasia (mNEN): A Systematic Review and Meta-Analysis. Front Oncol 2020;10:414. [PMID: 32318336 DOI: 10.3389/fonc.2020.00414] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
582 Swiha MM, Sutherland DEK, Sistani G, Khatami A, Abazid RM, Mujoomdar A, Wiseman DP, Romsa JG, Reid RH, Laidley DT. Survival predictors of 177Lu-Dotatate peptide receptor radionuclide therapy (PRRT) in patients with progressive well-differentiated neuroendocrine tumors (NETS). J Cancer Res Clin Oncol 2021. [PMID: 34110489 DOI: 10.1007/s00432-021-03672-w] [Reference Citation Analysis]
583 Montelius M, Spetz J, Jalnefjord O, Berger E, Nilsson O, Ljungberg M, Forssell-Aronsson E. Identification of Potential MR-Derived Biomarkers for Tumor Tissue Response to 177Lu-Octreotate Therapy in an Animal Model of Small Intestine Neuroendocrine Tumor. Transl Oncol 2018;11:193-204. [PMID: 29331677 DOI: 10.1016/j.tranon.2017.12.003] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
584 Bowen KA, Silva SR, Johnson JN, Doan HQ, Jackson LN, Gulhati P, Qiu S, Riall TS, Evers BM. An analysis of trends and growth factor receptor expression of GI carcinoid tumors. J Gastrointest Surg 2009;13:1773-80. [PMID: 19582519 DOI: 10.1007/s11605-009-0958-8] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
585 Werner RA, Weich A, Higuchi T, Schmid JS, Schirbel A, Lassmann M, Wild V, Rudelius M, Kudlich T, Herrmann K, Scheurlen M, Buck AK, Kropf S, Wester HJ, Lapa C. Imaging of Chemokine Receptor 4 Expression in Neuroendocrine Tumors - a Triple Tracer Comparative Approach. Theranostics 2017;7:1489-98. [PMID: 28529632 DOI: 10.7150/thno.18754] [Cited by in Crossref: 46] [Cited by in F6Publishing: 42] [Article Influence: 11.5] [Reference Citation Analysis]
586 Nadler A, Cukier M, Rowsell C, Kamali S, Feinberg Y, Singh S, Law CH. Ki-67 is a reliable pathological grading marker for neuroendocrine tumors. Virchows Arch 2013;462:501-5. [PMID: 23588555 DOI: 10.1007/s00428-013-1410-8] [Cited by in Crossref: 21] [Cited by in F6Publishing: 24] [Article Influence: 2.6] [Reference Citation Analysis]
587 Krug S, Boch M, Daniel H, Nimphius W, Müller D, Michl P, Rinke A, Gress TM. Streptozocin-Based Chemotherapy in Patients with Advanced Neuroendocrine Neoplasms--Predictive and Prognostic Markers for Treatment Stratification. PLoS One 2015;10:e0143822. [PMID: 26630134 DOI: 10.1371/journal.pone.0143822] [Cited by in Crossref: 40] [Cited by in F6Publishing: 33] [Article Influence: 6.7] [Reference Citation Analysis]
588 Izumi H, Yazawa N, Furukawa D, Masuoka Y, Yamada M, Mashiko T, Kawashima Y, Ogawa M, Kawaguchi Y, Mine T, Hirabayashi K, Nakagohri T. Laparoscopic splenopancreatectomy for an endocrine tumor with cystic changes: a case report. Clin Case Rep 2017;5:328-32. [PMID: 28265400 DOI: 10.1002/ccr3.844] [Reference Citation Analysis]
589 Tran CG, Sherman SK, Chandrasekharan C, Howe JR. Surgical Management of Neuroendocrine Tumor Liver Metastases. Surg Oncol Clin N Am 2021;30:39-55. [PMID: 33220808 DOI: 10.1016/j.soc.2020.08.001] [Reference Citation Analysis]
590 Elf AK, Johanson V, Marin I, Bergström A, Nilsson O, Svensson J, Wängberg B, Bernhardt P, Elias E. Evaluation of SSTR2 Expression in SI-NETs and Relation to Overall Survival after PRRT. Cancers (Basel) 2021;13:2035. [PMID: 33922482 DOI: 10.3390/cancers13092035] [Reference Citation Analysis]
591 Dasari A, Shen C, Halperin D, Zhao B, Zhou S, Xu Y, Shih T, Yao JC. Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States. JAMA Oncol 2017;3:1335-42. [PMID: 28448665 DOI: 10.1001/jamaoncol.2017.0589] [Cited by in Crossref: 967] [Cited by in F6Publishing: 894] [Article Influence: 241.8] [Reference Citation Analysis]
592 Wang X, Li Y, Duan J, Chen Y, Yuan B, Qi Z, Tan H. Capecitabine and Temozolomide as a Promising Therapy for Advanced Thymic Atypical Carcinoid. Oncologist 2019;24:798-802. [PMID: 30413666 DOI: 10.1634/theoncologist.2018-0291] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
593 Finotti M, Auricchio P, Vitale A, Gringeri E, Cillo U. Liver transplantation for rare liver diseases and rare indications for liver transplant. Transl Gastroenterol Hepatol 2021;6:27. [PMID: 33824931 DOI: 10.21037/tgh-19-282] [Reference Citation Analysis]
594 Son HJ, Sohn DK, Hong CW, Han KS, Kim BC, Park JW, Choi HS, Chang HJ, Oh JH. Factors associated with complete local excision of small rectal carcinoid tumor. Int J Colorectal Dis. 2013;28:57-61. [PMID: 22821140 DOI: 10.1007/s00384-012-1538-z] [Cited by in Crossref: 38] [Cited by in F6Publishing: 29] [Article Influence: 4.2] [Reference Citation Analysis]
595 Das S, Dasari A. Epidemiology, Incidence, and Prevalence of Neuroendocrine Neoplasms: Are There Global Differences? Curr Oncol Rep 2021;23:43. [PMID: 33719003 DOI: 10.1007/s11912-021-01029-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
596 金海林, 韩树堂, 肖君, 张其德, 孙仁虎. 内镜黏膜下剥离术治疗消化道神经内分泌肿瘤28例及文献回顾. 世界华人消化杂志 2015; 23(24): 3950-3954 [DOI: 10.11569/wcjd.v23.i24.3950] [Reference Citation Analysis]
597 Ribeiro S, De Maeyer F, De Man M, Carton S, Cuyle PJ, Verslype C, Borbath I, Demetter P, Van Damme N, Van Eycken L, Vandamme T, Hoorens A, Geboes K. Lessons learned about appendiceal neuroendocrine neoplasms from data analysis of the Belgian Cancer Registry 2010-2015. Acta Gastroenterol Belg 2021;84:458-66. [PMID: 34599571 DOI: 10.51821/84.3.011] [Reference Citation Analysis]
598 Stier MW, Chapman CG, Shamah S, Donboli K, Yassan L, Waxman I, Siddiqui UD. Endoscopic resection is more effective than biopsy or EUS to detect residual rectal neuroendocrine tumor. Endosc Int Open 2021;9:E4-8. [PMID: 33403229 DOI: 10.1055/a-1300-1017] [Reference Citation Analysis]
599 Egorov VI, Kharazov AF, Pavlovskaya AI, Petrov RV, Starostina NS, Kondratiev EV, Filippova EM. Extensive multiarterial resection attending total duodenopancreatectomy and adrenalectomy for MEN-1-associated neuroendocrine carcinomas. World J Gastrointest Surg 2012; 4(10): 238-245 [PMID: 23443490 DOI: 10.4240/wjgs.v4.i10.238] [Cited by in CrossRef: 2] [Article Influence: 0.2] [Reference Citation Analysis]
600 Scherübl H, Streller B, Stabenow R, Herbst H, Höpfner M, Schwertner C, Steinberg J, Eick J, Ring W, Tiwari K, Zappe SM. Clinically detected gastroenteropancreatic neuroendocrine tumors are on the rise: Epidemiological changes in Germany. World J Gastroenterol 2013; 19(47): 9012-9019 [PMID: 24379626 DOI: 10.3748/wjg.v19.i47.9012] [Cited by in CrossRef: 65] [Cited by in F6Publishing: 62] [Article Influence: 8.1] [Reference Citation Analysis]
601 Kos-Kudła B, Ćwikła J, Ruchała M, Hubalewska-Dydejczyk A, Jarzab B, Krajewska J, Kamiński G. Current treatment options for gastroenteropancreatic neuroendocrine tumors with a focus on the role of lanreotide. Contemp Oncol (Pozn) 2017;21:115-22. [PMID: 28947880 DOI: 10.5114/wo.2017.68619] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
602 Liu Q, Zang J, Sui H, Ren J, Guo H, Wang H, Wang R, Jacobson O, Zhang J, Cheng Y, Zhu Z, Chen X. Peptide Receptor Radionuclide Therapy of Late-Stage Neuroendocrine Tumor Patients with Multiple Cycles of 177Lu-DOTA-EB-TATE. J Nucl Med 2021;62:386-92. [PMID: 32826319 DOI: 10.2967/jnumed.120.248658] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
603 Nahmias A, Grozinsky-Glasberg S, Salmon A, Gross DJ. Pancreatic neuroendocrine tumors with transformation to insulinoma: an unusual presentation of a rare disease. Endocrinol Diabetes Metab Case Rep 2015;2015:150032. [PMID: 26113980 DOI: 10.1530/EDM-15-0032] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
604 Memeo R, Roselli S, Lupo L, Cherkaoui Z, Pessaux P. Laparoscopic management of neuroendocrine tumors: state-of-the-art. Transl Gastroenterol Hepatol. 2017;2:109. [PMID: 29354766 DOI: 10.21037/tgh.2017.11.19] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
605 Roohi S, Rizvi SK, Naqvi SAR. 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy: Indigenously Developed Freeze Dried Cold Kit and Biological Response in In-Vitro and In-Vivo Models. Dose Response 2021;19:1559325821990147. [PMID: 33628154 DOI: 10.1177/1559325821990147] [Reference Citation Analysis]
606 Zhu X, Yong H, Zhang L, Huang Y, Zheng J, Liu C, Xiu D, Zhang P. Pure alpha-fetoprotein-producing neuroendocrine carcinoma of the pancreas: a case report. BMC Gastroenterol 2015;15:16. [PMID: 25886790 DOI: 10.1186/s12876-015-0246-x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 2.2] [Reference Citation Analysis]
607 Chowdry RP, Bhimani C, Delgado MA, Lee DJ, Dayamani P, Sica GL, Owonikoko TK. Unusual suspects: pulmonary opportunistic infections masquerading as tumor metastasis in a patient with adrenocorticotropic hormone-producing pancreatic neuroendocrine cancer. Ther Adv Med Oncol 2012;4:295-300. [PMID: 23118805 DOI: 10.1177/1758834012456415] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
608 Kim M, Lee S, Lee J, Park SH, Park JO, Park YS, Kang WK, Kim ST. The Role of Plasma Chromogranin A as Assessment of Treatment Response in Non-functioning Gastroenteropancreatic Neuroendocrine Tumors. Cancer Res Treat 2016;48:153-61. [PMID: 25779359 DOI: 10.4143/crt.2014.183] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
609 Uccella S, La Rosa S, Volante M, Papotti M. Immunohistochemical Biomarkers of Gastrointestinal, Pancreatic, Pulmonary, and Thymic Neuroendocrine Neoplasms. Endocr Pathol. 2018;29:150-168. [PMID: 29520563 DOI: 10.1007/s12022-018-9522-y] [Cited by in Crossref: 43] [Cited by in F6Publishing: 34] [Article Influence: 14.3] [Reference Citation Analysis]
610 Chatani PD, Agarwal SK, Sadowski SM. Molecular Signatures and Their Clinical Utility in Pancreatic Neuroendocrine Tumors. Front Endocrinol (Lausanne) 2020;11:575620. [PMID: 33537001 DOI: 10.3389/fendo.2020.575620] [Reference Citation Analysis]
611 Belousova E, Karmazanovsky G, Kriger A, Kalinin D, Mannelli L, Glotov A, Karelskaya N, Paklina O, Kaldarov A. Contrast-enhanced MDCT in patients with pancreatic neuroendocrine tumours: correlation with histological findings and diagnostic performance in differentiation between tumour grades. Clin Radiol 2017;72:150-8. [PMID: 27890421 DOI: 10.1016/j.crad.2016.10.021] [Cited by in Crossref: 36] [Cited by in F6Publishing: 35] [Article Influence: 7.2] [Reference Citation Analysis]
612 Graham MM, Gu X, Ginader T, Breheny P, Sunderland JJ. 68Ga-DOTATOC Imaging of Neuroendocrine Tumors: A Systematic Review and Metaanalysis. J Nucl Med 2017;58:1452-8. [PMID: 28280220 DOI: 10.2967/jnumed.117.191197] [Cited by in Crossref: 50] [Cited by in F6Publishing: 46] [Article Influence: 12.5] [Reference Citation Analysis]
613 Kunz PL, Fisher GA. Advances in the treatment of gastroenteropancreatic neuroendocrine tumors. Clin Exp Gastroenterol 2010;3:79-86. [PMID: 21694850 DOI: 10.2147/ceg.s5928] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
614 Reeders J, Ashoka Menon V, Mani A, George M. Clinical Profiles and Survival Outcomes of Patients With Well-Differentiated Neuroendocrine Tumors at a Health Network in New South Wales, Australia: Retrospective Study. JMIR Cancer 2019;5:e12849. [PMID: 31746768 DOI: 10.2196/12849] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
615 Foubert F, Salimon M, Dumars C, Regenet N, Girot P, Venara A, Senellart H, Heymann MF, Matysiak-Budnik T, Touchefeu Y. Survival and prognostic factors analysis of 151 intestinal and pancreatic neuroendocrine tumors: a single center experience. J Gastrointest Oncol 2019;10:103-11. [PMID: 30788165 DOI: 10.21037/jgo.2018.09.13] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
616 Barnes J, Johnson SJ, French JJ. Correlation of Ki-67 indices from biopsy and resection specimens of neuroendocrine tumours. Ann R Coll Surg Engl 2017;99:193-7. [PMID: 27490982 DOI: 10.1308/rcsann.2016.0225] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
617 Kaur J, Mogulla S, Malik A, Garg S. Unusual Presentation of a Sphenoidal Sinus Neuroendocrine Tumor: A Case Report and Review of Literature. Cureus 2021;13:e13689. [PMID: 33833913 DOI: 10.7759/cureus.13689] [Reference Citation Analysis]
618 Lee L, Ito T, Jensen RT. Imaging of pancreatic neuroendocrine tumors: recent advances, current status, and controversies. Expert Rev Anticancer Ther 2018;18:837-60. [PMID: 29973077 DOI: 10.1080/14737140.2018.1496822] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 5.3] [Reference Citation Analysis]
619 Murray L, Haley C, Berry-Cabán CS, Toledo A. Duodenal neuroendocrine tumor and the onset of severe diabetes mellitus in a US veteran. SAGE Open Med Case Rep 2016;4:2050313X15624530. [PMID: 27489708 DOI: 10.1177/2050313X15624530] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
620 Fang C, Wang W, Zhang Y, Feng X, Sun J, Zeng Y, Chen Y, Li Y, Chen M, Zhou Z, Chen J. Clinicopathologic characteristics and prognosis of gastroenteropancreatic neuroendocrine neoplasms: a multicenter study in South China. Chin J Cancer 2017;36:51. [PMID: 28637502 DOI: 10.1186/s40880-017-0218-3] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 4.3] [Reference Citation Analysis]
621 Deng S, Fan Z, Xia H, Gong Y, Qian Y, Huang Q, Cheng H, Jin K, Xiao Z, Luo G, Yu X, Liu C. Fibrinogen/Albumin Ratio as a Promising Marker for Predicting Survival in Pancreatic Neuroendocrine Neoplasms. Cancer Manag Res 2021;13:107-15. [PMID: 33447083 DOI: 10.2147/CMAR.S275173] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
622 Nikou GC, Angelopoulos TP. Current concepts on gastric carcinoid tumors. Gastroenterol Res Pract. 2012;2012:287825. [PMID: 23316222 DOI: 10.1155/2012/287825] [Cited by in Crossref: 39] [Cited by in F6Publishing: 35] [Article Influence: 4.3] [Reference Citation Analysis]
623 Lewis MA, Hubbard J. Multimodal liver-directed management of neuroendocrine hepatic metastases. Int J Hepatol. 2011;2011:452343. [PMID: 22121491 DOI: 10.4061/2011/452343] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
624 Anlauf M, Sipos B, Boeck I, Baldus SE, Heikaus S, Krausch M, Knoefel WT, Begum N, Goretzki P, Schott M, Auernhammer CJ, Cremer B, Rinke A, Ezziddin S, Fottner C, Pöpperl G, Lahner H, Hörsch D, Gabbert HE, Komminoth P, Perren A, Klöppel G, Wiedenmann B, Pavel M, Pape U. [Neuroendocrine neoplasms of the distal jejunum and ileum]. Pathologe 2014;35:283-93; quiz 294. [PMID: 24671468 DOI: 10.1007/s00292-013-1888-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
625 Kim YI, Yoo C, Oh SJ, Lee SJ, Kang J, Hwang HS, Hong SM, Ryoo BY, Ryu JS. Tumour-to-liver ratio determined by [68Ga]Ga-DOTA-TOC PET/CT as a prognostic factor of lanreotide efficacy for patients with well-differentiated gastroenteropancreatic-neuroendocrine tumours. EJNMMI Res 2020;10:63. [PMID: 32542576 DOI: 10.1186/s13550-020-00651-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
626 Han X, Xu X, Jin D, Wang D, Ji Y, Lou W. Clinicopathological characteristics and prognosis-related factors of resectable pancreatic neuroendocrine tumors: a retrospective study of 104 cases in a single Chinese center. Pancreas. 2014;43:526-531. [PMID: 24658317 DOI: 10.1097/mpa.0000000000000065] [Cited by in Crossref: 32] [Cited by in F6Publishing: 17] [Article Influence: 4.6] [Reference Citation Analysis]
627 Ro C, Chai W, Yu VE, Yu R. Pancreatic neuroendocrine tumors: biology, diagnosis,and treatment. Chin J Cancer. 2013;32:312-324. [PMID: 23237225 DOI: 10.5732/cjc.012.10295] [Cited by in Crossref: 66] [Cited by in F6Publishing: 55] [Article Influence: 7.3] [Reference Citation Analysis]
628 Kim HK, Ha SY, Lee J, Park SH, Park JO, Lim HY, Kang WK, Park YS, Kim ST. The impact of pathologic differentiation (well/poorly) and the degree of Ki-67 index in patients with metastatic WHO grade 3 GEP-NECs. Oncotarget 2017;8:73974-80. [PMID: 29088761 DOI: 10.18632/oncotarget.18168] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
629 Schraml C, Schwenzer NF, Sperling O, Aschoff P, Lichy MP, Müller M, Brendle C, Werner MK, Claussen CD, Pfannenberg C. Staging of neuroendocrine tumours: comparison of [68Ga]DOTATOC multiphase PET/CT and whole-body MRI. Cancer Imaging. 2013;13:63-72. [PMID: 23466785 DOI: 10.1102/1470-7330.2013.0007] [Cited by in Crossref: 60] [Cited by in F6Publishing: 48] [Article Influence: 7.5] [Reference Citation Analysis]
630 Liberini V, Huellner MW, Grimaldi S, Finessi M, Thuillier P, Muni A, Pellerito RE, Papotti MG, Piovesan A, Arvat E, Deandreis D. The Challenge of Evaluating Response to Peptide Receptor Radionuclide Therapy in Gastroenteropancreatic Neuroendocrine Tumors: The Present and the Future. Diagnostics (Basel) 2020;10:E1083. [PMID: 33322819 DOI: 10.3390/diagnostics10121083] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
631 Mafficini A, Scarpa A. Genomic landscape of pancreatic neuroendocrine tumours: the International Cancer Genome Consortium. J Endocrinol 2018;236:R161-7. [PMID: 29321190 DOI: 10.1530/JOE-17-0560] [Cited by in Crossref: 34] [Cited by in F6Publishing: 21] [Article Influence: 11.3] [Reference Citation Analysis]
632 洪娜, 王进. 直肠神经内分泌肿瘤的临床病理特征及预后. 世界华人消化杂志 2016; 24(33): 4526-4530 [DOI: 10.11569/wcjd.v24.i33.4526] [Reference Citation Analysis]
633 García-Carbonero R, Vilardell F, Jiménez-Fonseca P, González-Campora R, González E, Cuatrecasas M, Capdevila J, Aranda I, Barriuso J, Matías-Guiu X; Spanish Society of Pathology., Spanish Society of Medical Oncology. Guidelines for biomarker testing in gastroenteropancreatic neuroendocrine neoplasms: a national consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology. Clin Transl Oncol 2014;16:243-56. [PMID: 23749327 DOI: 10.1007/s12094-013-1062-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
634 Oberstein PE, Saif MW. Safety and efficacy of everolimus in adult patients with neuroendocrine tumors. Clin Med Insights Oncol 2012;6:41-51. [PMID: 22253554 DOI: 10.4137/CMO.S7319] [Cited by in Crossref: 13] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
635 Dixon RK, Britt EJ, Netzer GA, Afshar M, Burke A, Liu S, Jean J, Shah NG. Ten-year Single Center Experience of Pulmonary Carcinoid Tumors and Diagnostic Yield of Bronchoscopic Biopsy. Lung 2016;194:905-10. [PMID: 27544227 DOI: 10.1007/s00408-016-9932-x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
636 Bellizzi AM. Pathologic Considerations in Gastroenteropancreatic Neuroendocrine Tumors. Surg Oncol Clin N Am 2020;29:185-208. [PMID: 32151355 DOI: 10.1016/j.soc.2019.11.003] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
637 Filosso PL, Falcoz PE, Solidoro P, Pellicano D, Passani S, Guerrera F, Ruffini E; ESTS Lung Neuroendocrine Working-Group Participating Centers*. The European Society of Thoracic Surgeons (ESTS) lung neuroendocrine tumors (NETs) database. J Thorac Dis 2018;10:S3528-32. [PMID: 30510790 DOI: 10.21037/jtd.2018.04.104] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
638 Alshammari TF, Hakami RA, Alali MN, AlShammari S, Zayed MA, AlSohaibani MO, Bin Traiki T. A Perforated Colonic Neuroendocrine Tumor with Liver Metastasis: A Case Report and Literature Review. Am J Case Rep 2019;20:920-5. [PMID: 31249283 DOI: 10.12659/AJCR.916288] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
639 Dayan A, Ricci C, Campana D, Santini D, Fughelli P, Minni F, Nardo B. Siblings Diagnosed With Primary Neuroendocrine Tumor of the Left Hepatic Duct. ACG Case Rep J 2019;6:e00104. [PMID: 31620513 DOI: 10.14309/crj.0000000000000104] [Reference Citation Analysis]
640 Saif MW, Parikh R, Ray D, Kaye JA, Kurosky SK, Thomas K, Ramirez RA, Halfdanarson TR, Beveridge TJR, Mirakhur B, Nagar SP, Soares HP. Medical record review of transition to lanreotide following octreotide for neuroendocrine tumors. J Gastrointest Oncol 2019;10:674-87. [PMID: 31392048 DOI: 10.21037/jgo.2019.03.11] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
641 Buzzoni R, Carnaghi C, Strosberg J, Fazio N, Singh S, Herbst F, Ridolfi A, Pavel ME, Wolin EM, Valle JW, Oh DY, Yao JC, Pommier R. Impact of prior therapies on everolimus activity: an exploratory analysis of RADIANT-4. Onco Targets Ther 2017;10:5013-30. [PMID: 29081664 DOI: 10.2147/OTT.S142087] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
642 Zhou B, Zhan C, Wu J, Liu J, Zhou J, Zheng S. Prognostic Significance of Preoperative Neutrophil-to-Lymphocyte Ratio in Surgically Resectable Pancreatic Neuroendocrine Tumors. Med Sci Monit 2017;23:5574-88. [PMID: 29168979 DOI: 10.12659/msm.907182] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]
643 Chablaney S, Zator ZA, Kumta NA. Diagnosis and Management of Rectal Neuroendocrine Tumors. Clin Endosc. 2017;50:530-536. [PMID: 29207857 DOI: 10.5946/ce.2017.134] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
644 Filice A, Fraternali A, Frasoldati A, Asti M, Grassi E, Massi L, Sollini M, Froio A, Erba PA, Versari A. Radiolabeled somatostatin analogues therapy in advanced neuroendocrine tumors: a single centre experience. J Oncol 2012;2012:320198. [PMID: 22934111 DOI: 10.1155/2012/320198] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 2.6] [Reference Citation Analysis]
645 Chu H, Zhang C, Shi Y, Wu W, Hu Z, Zhang J, Huang D. Gallbladder neuroendocrine carcinoma: A single center experience. Medicine (Baltimore) 2020;99:e21912. [PMID: 32899024 DOI: 10.1097/MD.0000000000021912] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
646 Tan H. Advances in the diagnosis and treatment of gastric neuroendocrine neoplasms. Transl Gastroenterol Hepatol 2016;1:87. [PMID: 28138652 DOI: 10.21037/tgh.2016.11.03] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
647 García-Carbonero R, Salazar R, Sevilla I, Isla D. SEOM clinical guidelines for the diagnosis and treatment of gastroenteropancreatic neuroendocrine tumours (GEP NETS). Clin Transl Oncol 2011;13:545-51. [PMID: 21821488 DOI: 10.1007/s12094-011-0695-9] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
648 Perkins J, Boland P, Cohen SJ, Olszanski AJ, Zhou Y, Engstrom P, Astsaturov I. Successful imatinib therapy for neuroendocrine carcinoma with activating Kit mutation: a case study. J Natl Compr Canc Netw 2014;12:847-52. [PMID: 24925195 DOI: 10.6004/jnccn.2014.0079] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
649 Kıvrak Salim D, Bayram S, Gömceli İ, Çekin AH, Karaca M, Koçer M, Yıldız M. Palliative resection of primary site in advanced gastroenteropancreatic neuroendocrine tumors improves survivals. Turk J Gastroenterol 2019;30:910-6. [PMID: 31625933 DOI: 10.5152/tjg.2019.19168] [Reference Citation Analysis]
650 Büyükaşık K, Arı A, Tatar C, Akçe B, Sevinç MM, Sarı S, Paşaoğlu E, Bektaş H. Clinicopathological features of gastroenteropancreatic neuroendocrine tumors: A retrospective evaluation of 42 cases. Turk J Surg 2017;33:279-83. [PMID: 29260133 DOI: 10.5152/UCD.2017.3685] [Reference Citation Analysis]
651 Katsuta E, Kudo A, Akashi T, Mitsunori Y, Matsumura S, Aihara A, Ban D, Ochiai T, Tanaka S, Eishi Y, Tanabe M. Macroscopic morphology for estimation of malignant potential in pancreatic neuroendocrine neoplasm. J Cancer Res Clin Oncol 2016;142:1299-306. [PMID: 26885661 DOI: 10.1007/s00432-016-2128-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
652 Aly RG, Rekhtman N, Li X, Takahashi Y, Eguchi T, Tan KS, Rudin CM, Adusumilli PS, Travis WD. Spread Through Air Spaces (STAS) Is Prognostic in Atypical Carcinoid, Large Cell Neuroendocrine Carcinoma, and Small Cell Carcinoma of the Lung. J Thorac Oncol 2019;14:1583-93. [PMID: 31121325 DOI: 10.1016/j.jtho.2019.05.009] [Cited by in Crossref: 19] [Cited by in F6Publishing: 24] [Article Influence: 9.5] [Reference Citation Analysis]
653 Jiang X, Cao Y, Li F, Su Y, Li Y, Peng Y, Cheng Y, Zhang C, Wang W, Ning G. Targeting β-catenin signaling for therapeutic intervention in MEN1-deficient pancreatic neuroendocrine tumours. Nat Commun. 2014;5:5809. [PMID: 25517963 DOI: 10.1038/ncomms6809] [Cited by in Crossref: 51] [Cited by in F6Publishing: 43] [Article Influence: 7.3] [Reference Citation Analysis]
654 Kawaguchi Y, Maruno A, Kawashima Y, Ito H, Ogawa M, Mine T. Amenorrhea as a rare drug-related adverse event associated with everolimus for pancreatic neuroendocrine tumors. World J Gastroenterol 2014; 20(42): 15920-15924 [PMID: 25400479 DOI: 10.3748/wjg.v20.i42.15920] [Cited by in CrossRef: 2] [Article Influence: 0.3] [Reference Citation Analysis]
655 You Y, Jang JY, Kim SC, Yoon YS, Park JS, Cho CK, Park SJ, Yang JD, Lee WJ, Hong TH, Ahn KS, Jeong CY, Lee HK, Lee SE, Roh YH, Kim HJ, Kim H, Han IW. Validation of the 8th AJCC Cancer Staging System for Pancreas Neuroendocrine Tumors Using Korean Nationwide Surgery Database. Cancer Res Treat. 2019;51:1639-1652. [PMID: 30999719 DOI: 10.4143/crt.2019.023] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
656 Shen C, Dasari A, Chu Y, Halperin DM, Zhou S, Xu Y, Shih YT, Yao JC. Clinical, pathological, and demographic factors associated with development of recurrences after surgical resection in elderly patients with neuroendocrine tumors. Ann Oncol 2017;28:1582-9. [PMID: 28444105 DOI: 10.1093/annonc/mdx164] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
657 Mei S, Gibbs J, Economos K, Lee YC, Kanis MJ. Clinical comparison between neuroendocrine and endometrioid type carcinoma of the uterine corpus. J Gynecol Oncol 2019;30:e58. [PMID: 31074241 DOI: 10.3802/jgo.2019.30.e58] [Reference Citation Analysis]
658 Attarian S, Libutti SK, Chuy J. ACTH-Producing Pancreatic Neuroendocrine Tumor Presenting with Severe Hypokalemic Alkalosis: A Case Report. J Gastrointest Cancer 2016;47:217-20. [PMID: 26073616 DOI: 10.1007/s12029-015-9740-1] [Reference Citation Analysis]
659 Zhang P, Wang W, Lu M, Zeng C, Chen J, Li E, Tan H, Yu X, Tang Q, Zhao J, Shen L, Li J. Clinicopathological features and outcome for neuroendocrine neoplasms of gastroesophageal junction: A population-based study. Cancer Med. 2018;7:4361-4370. [PMID: 30062861 DOI: 10.1002/cam4.1702] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
660 Imamura M. Recent standardization of treatment strategy for pancreatic neuroendocrine tumors. World J Gastroenterol 2010; 16(36): 4519-4525 [PMID: 20857521 DOI: 10.3748/wjg.v16.i36.4519] [Cited by in CrossRef: 33] [Cited by in F6Publishing: 31] [Article Influence: 3.0] [Reference Citation Analysis]
661 Ramirez RA, Beyer DT, Chauhan A, Boudreaux JP, Wang YZ, Woltering EA. The Role of Capecitabine/Temozolomide in Metastatic Neuroendocrine Tumors. Oncologist. 2016;21:671-675. [PMID: 27226359 DOI: 10.1634/theoncologist.2015-0470] [Cited by in Crossref: 47] [Cited by in F6Publishing: 44] [Article Influence: 9.4] [Reference Citation Analysis]
662 Maxwell JE, O'Dorisio TM, Howe JR. Biochemical Diagnosis and Preoperative Imaging of Gastroenteropancreatic Neuroendocrine Tumors. Surg Oncol Clin N Am 2016;25:171-94. [PMID: 26610781 DOI: 10.1016/j.soc.2015.08.008] [Cited by in Crossref: 18] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
663 Komaç Ö, Bengi G, Sağol Ö, Akarsu M. C-reactive protein may be a prognostic factor for the whole gastroenteropancreatic neuroendocrine tumor group. World J Gastrointest Oncol 2019; 11(2): 139-152 [PMID: 30788040 DOI: 10.4251/wjgo.v11.i2.139] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
664 Shaheen M, Hassanain M, Aljiffry M, Cabrera T, Chaudhury P, Simoneau E, Kongkaewpaisarn N, Salman A, Rivera J, Jamal M. Predictors of response to radio-embolization (TheraSphere®) treatment of neuroendocrine liver metastasis. HPB (Oxford). 2012;14:60-66. [PMID: 22151453 DOI: 10.1111/j.1477-2574.2011.00405.x] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 2.6] [Reference Citation Analysis]
665 Salaria S, Means A, Revetta F, Idrees K, Liu E, Shi C. Expression of CD24, a Stem Cell Marker, in Pancreatic and Small Intestinal Neuroendocrine Tumors. Am J Clin Pathol. 2015;144:642-648. [PMID: 26386086 DOI: 10.1309/AJCPMZY5P9TWNJJV] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
666 Chauhan A, El-Khouli R, Waits T, Agrawal R, Siddiqui F, Tarter Z, Horn M, Weiss H, Oates E, Evers BM, Anthony L. Post FDA approval analysis of 200 gallium-68 DOTATATE imaging: A retrospective analysis in neuroendocrine tumor patients. Oncotarget 2020;11:3061-8. [PMID: 32850010 DOI: 10.18632/oncotarget.27695] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
667 Woodhouse B, Pattison S, Segelov E, Singh S, Parker K, Kong G, Macdonald W, Wyld D, Meyer-Rochow G, Pavlakis N, Conroy S, Gordon V, Koea J, Kramer N, Michael M, Wakelin K, Asif T, Lo D, Price T, Lawrence B; Commonwealth Neuroendocrine Tumour Collaboration (CommNETs). Consensus-Derived Quality Performance Indicators for Neuroendocrine Tumour Care. J Clin Med 2019;8:E1455. [PMID: 31547431 DOI: 10.3390/jcm8091455] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
668 Dou D, Shi YF, Liu Q, Luo J, Liu JX, Liu M, Liu YY, Li YL, Qiu XD, Tan HY. Hsa-miR-202-3p, up-regulated in type 1 gastric neuroendocrine neoplasms, may target DUSP1World J Gastroenterol 2018; 24(5): 573-582 [PMID: 29434446 DOI: 10.3748/wjg.v24.i5.573] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
669 Kidd M, Modlin I, Öberg K. Towards a new classification of gastroenteropancreatic neuroendocrine neoplasms. Nat Rev Clin Oncol 2016;13:691-705. [PMID: 27273044 DOI: 10.1038/nrclinonc.2016.85] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 4.4] [Reference Citation Analysis]
670 Nishio M, Hirasawa K, Ozeki Y, Sawada A, Ikeda R, Fukuchi T, Kobayashi R, Makazu M, Sato C, Maeda S. Short- and long-term outcomes of endoscopic submucosal dissection for non-ampullary duodenal neuroendocrine tumors. Ann Gastroenterol 2020;33:265-71. [PMID: 32382229 DOI: 10.20524/aog.2020.0477] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
671 Mulholland N, Chakravartty R, Devlin L, Kalogianni E, Corcoran B, Vivian G. Long-term outcomes of (131)Iodine mIBG therapy in metastatic gastrointestinal pancreatic neuroendocrine tumours: single administration predicts non-responders. Eur J Nucl Med Mol Imaging 2015;42:2002-12. [PMID: 26142730 DOI: 10.1007/s00259-015-3116-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
672 Del Arco CD, Sastre J, Peinado P, Díaz Á, Medina LO, Fernández Aceñero MJ. Neuroendocrine Neoplasms in Rare Locations: Clinicopathological Features and Review of the Literature. Indian J Endocrinol Metab 2018;22:308-15. [PMID: 30090720 DOI: 10.4103/ijem.IJEM_446_17] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
673 Lee JE, Hong SH, Jung HI, Son MW, Ahn TS, Han SW, Cho JH. Small-cell neuroendocrine carcinoma of the ileum: case report and literature review. BMC Surg 2019;19:135. [PMID: 31510991 DOI: 10.1186/s12893-019-0591-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
674 Berardi R, Morgese F, Torniai M, Savini A, Partelli S, Rinaldi S, Caramanti M, Ferrini C, Falconi M, Cascinu S. Medical treatment for gastro-entero-pancreatic neuroendocrine tumours. World J Gastrointest Oncol 2016; 8(4): 389-401 [PMID: 27096034 DOI: 10.4251/wjgo.v8.i4.389] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.6] [Reference Citation Analysis]
675 Leeds JS, Nayar MK, Bekkali NLH, Wilson CH, Johnson SJ, Haugk B, Darne A, Oppong KW. Endoscopic ultrasound-guided fine-needle biopsy is superior to fine-needle aspiration in assessing pancreatic neuroendocrine tumors. Endosc Int Open 2019;7:E1281-7. [PMID: 31579710 DOI: 10.1055/a-0990-9611] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
676 Childs A, Vesely C, Ensell L, Lowe H, Luong TV, Caplin ME, Toumpanakis C, Thirlwell C, Hartley JA, Meyer T. Expression of somatostatin receptors 2 and 5 in circulating tumour cells from patients with neuroendocrine tumours. Br J Cancer. 2016;115:1540-1547. [PMID: 27875519 DOI: 10.1038/bjc.2016.377] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 3.6] [Reference Citation Analysis]
677 Bai J, Na H, Hua X, Wei Y, Ye T, Zhang Y, Jian G, Zeng W, Yan L, Tang Q. A retrospective study of NENs and miR-224 promotes apoptosis of BON-1 cells by targeting PCSK9 inhibition. Oncotarget 2017;8:6929-39. [PMID: 28036293 DOI: 10.18632/oncotarget.14322] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 5.3] [Reference Citation Analysis]
678 Feng T, Lv W, Yuan M, Shi Z, Zhong H, Ling S. Surgical resection of the primary tumor leads to prolonged survival in metastatic pancreatic neuroendocrine carcinoma. World J Surg Oncol 2019;17:54. [PMID: 30898132 DOI: 10.1186/s12957-019-1597-5] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
679 Shi H, Jiang C, Zhang Q, Qi C, Yao H, Lin R. Clinicopathological heterogeneity between primary and metastatic sites of gastroenteropancreatic neuroendocrine neoplasm. Diagn Pathol 2020;15:108. [PMID: 32917216 DOI: 10.1186/s13000-020-01030-x] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
680 Mori R, Yamashita SI, Midorikawa K, Abe S, Inada K, Yoneda S, Okabayashi K, Nabeshima K. CDX2 Expression and Prognostic Factors of Resectable Pulmonary Large Cell Neuroendocrine Carcinoma. Clin Med Insights Oncol 2020;14:1179554920967319. [PMID: 33293882 DOI: 10.1177/1179554920967319] [Reference Citation Analysis]
681 Liu EH, Solorzano CC, Katznelson L, Vinik AI, Wong R, Randolph G. AACE/ACE disease state clinical review: diagnosis and management of midgut carcinoids. Endocr Pract. 2015;21:534-545. [PMID: 25962092 DOI: 10.4158/ep14464.dsc] [Cited by in Crossref: 16] [Cited by in F6Publishing: 7] [Article Influence: 3.2] [Reference Citation Analysis]
682 Kurita Y, Hara K, Kuwahara T, Mizuno N, Okuno N, Haba S, Okuno M, Natsume S, Senda Y, Kubota K, Nakajima A, Niwa Y, Shimizu Y. Comparison of prognosis between observation and surgical resection groups with small sporadic non-functional pancreatic neuroendocrine neoplasms without distant metastasis. J Gastroenterol 2020;55:543-52. [PMID: 31858231 DOI: 10.1007/s00535-019-01655-w] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
683 Bongiovanni A, Liverani C, Pusceddu S, Leo S, Di Meglio G, Tamberi S, Santini D, Gelsomino F, Pucci F, Berardi R, Lolli I, Bergamo F, Ricci S, Foca F, Severi S, Ibrahim T; SENECA Study Team Investigators. Randomised phase II trial of CAPTEM or FOLFIRI as SEcond-line therapy in NEuroendocrine CArcinomas and exploratory analysis of predictive role of PET/CT imaging and biological markers (SENECA trial): a study protocol. BMJ Open 2020;10:e034393. [PMID: 32690499 DOI: 10.1136/bmjopen-2019-034393] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
684 Kocha W, Maroun J, Kennecke H, Law C, Metrakos P, Ouellet JF, Reid R, Rowsell C, Shah A, Singh S, Van Uum S, Wong R. Consensus recommendations for the diagnosis and management of well-differentiated gastroenterohepatic neuroendocrine tumours: a revised statement from a Canadian National Expert Group. Curr Oncol 2010;17:49-64. [PMID: 20567626 DOI: 10.3747/co.v17i3.484] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 2.9] [Reference Citation Analysis]
685 Sharma P, Singh H, Bal C, Kumar R. PET/CT imaging of neuroendocrine tumors with (68)Gallium-labeled somatostatin analogues: An overview and single institutional experience from India. Indian J Nucl Med. 2014;29:2-12. [PMID: 24591775 DOI: 10.4103/0972-3919.125760] [Cited by in Crossref: 32] [Cited by in F6Publishing: 22] [Article Influence: 4.6] [Reference Citation Analysis]
686 Martin JA, Warner RR, Wisnivesky JP, Kim MK. Improving survival prognostication of gastroenteropancreatic neuroendocrine neoplasms: Revised staging criteria. Eur J Cancer. 2017;76:197-204. [PMID: 28334622 DOI: 10.1016/j.ejca.2017.02.008] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
687 Yim KL. Everolimus and mTOR inhibition in pancreatic neuroendocrine tumors. Cancer Manag Res 2012;4:207-14. [PMID: 22904642 DOI: 10.2147/CMAR.S25979] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
688 Kooyker AI, Verbeek WH, van den Berg JG, Tesselaar ME, van Leerdam ME. Change in incidence, characteristics and management of colorectal neuroendocrine tumours in the Netherlands in the last decade. United European Gastroenterol J 2020;8:59-67. [PMID: 32213058 DOI: 10.1177/2050640619865113] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
689 Haugvik SP, Marangos IP, Røsok BI, Pomianowska E, Gladhaug IP, Mathisen O, Edwin B. Long-term outcome of laparoscopic surgery for pancreatic neuroendocrine tumors. World J Surg. 2013;37:582-590. [PMID: 23263686 DOI: 10.1007/s00268-012-1893-5] [Cited by in Crossref: 37] [Cited by in F6Publishing: 37] [Article Influence: 4.6] [Reference Citation Analysis]
690 Yun SP, Shin N, Seo HI. Clinical outcomes of small cell neuroendocrine carcinoma and adenocarcinoma of the gallbladder. World J Gastroenterol 2015; 21(1): 269-275 [PMID: 25574101 DOI: 10.3748/wjg.v21.i1.269] [Cited by in CrossRef: 20] [Cited by in F6Publishing: 18] [Article Influence: 3.3] [